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19|Introduction
InTROduCTIOn
Familial Hypercholesterolemia (FH) (OMIM #143890) is the most common metabolic 
disorder with a prevalence estimated between in 1:244 and 1:600 (1-3). FH is associated 
with premature cardiovascular disease (CVD) (4). 
FH can be diagnosed by clinical criteria (table 1) and genetically by identification of 
a pathogenic mutation in the LDLR gene, APOB gene or PCSK9 gene (5-8). Currently 
over 1200 different mutations are known, most often found in the LDLR gene (www.
jojogenetics.nl). Severity can differ depending on the type of mutation. In general apoB 
mutations are considered to cause a milder phenotype than LDLR or PCSK9 mutations. 
Within LDLR mutation, null-mutations, mutations which lead to no residual function of 
the LDL-receptor, are associated with a more severe phenotype with higher high low-
density lipoprotein cholesterol (LDL-C) levels compared to LDLR defective mutations 
with residual LDL-receptor function (9). 
The increased LDL-C levels are the driving force of the increased cardiovascular risk in 
FH patients. To lower CVD risk in FH patients cholesterol lowering agents, mainly statins, 
are used. The impact of statins on the life expectancy of FH patients can hardly be 
overestimated. Before the statin era half of men with FH and 12% of women with FH 
suffered from a myocardial infarction before the age of fifty years (10). 
However, despite statin therapy some FH patients still develop CVD (11). The classical 
risk factors: age, male sex, body mass index (BMI), hypertension, diabetes mellitus, 
smoking and reduces high-density lipoprotein (HDL) levels all clearly contribute to CVD 
risk in FH patients (12-14). But even in the absence of these classical risk factors some FH 
patients will develop cardiovascular events.
Since every patient who is diagnosed with FH immediately starts on statin treatment, 
more studies were necessary to determine CVD risk in these treated patients. The aim 
of this thesis was to identify which of these statin treated FH patients were at a higher 
risk of developing CVD. To investigate this risk I used different approaches as elaborated 
below.
1
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Table 1 | Dutch Lipid Clinic Network diagnostic criteria for Familial Hypercholesterolemia(15)
Criteria Points
Family History
First-degree relative with known premature coronary and vascular disease, OR 
First-degree relative with known LDL-C level above the 95th percentile*
1
First-degree relative with tendinous xanthomata and/or arcus cornealis, OR
Children aged less than 18 years with LDL-C level above the 95th percentile
2
Clinical History
Patient with premature coronary artery disease* 2
Patient with premature cerebral or peripheral vascular disease1* 1
Physical examination
Tendinous xanthomata 6
Arcus cornealis prior to age 45 years 4
Cholesterol levels mg/dl (mmol/liter)
LDL-C >= 330 mg/dL ( ≥8.5) 8
LDL-C 250 – 329 mg/dL (6.5–8.4) 5
LDL-C 190 – 249 mg/dL (5.0–6.4) 3
LDL-C 155 – 189 mg/dL (4.0–4.9) 1
dnA analysis
Functional mutation in the LDLR, apo B or PCSK9 gene 8
diagnosis (diagnosis is based on the total number of points obtained)
Definite Familial Hypercholesterolemia >8
Probable Familial Hypercholesterolemia 6-8
Possible Familial Hypercholesterolemia 3-5
Unlikely Familial Hypercholesterolemia <3
1* Premature = < 55 years in men; < 60 years in women
LDL-C = low density lipoprotein cholesterol
FH, familial hypercholesterolemia
LDLR = low density lipoprotein receptor 
Apo B = apolipoprotein B 
PCSK9 = Proprotein convertase subtilisin/kexin type 9
Cardiovascular imaging
One approach is to detect subclinical atherosclerosis in asymptomatic persons with FH. 
Advanced atherosclerosis on cardiovascular imaging might identify FH patients, who 
are at exceptional risk of developing cardiovascular events. 
Atherosclerotic lesions can be visualized by numerous imaging modalities. Among 
the commonly used methods are carotid ultrasonography and computed tomography 
coronary angiography (CTCA).
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Carotid ultrasonography
Carotid ultrasonography can be used to measure subclinical atherosclerosis depicted 
as the presence of carotid plaques or increased carotid intima-media thickness. Both of 
these outcomes have been associated with CVD risk in the general population (16-18). 
However, data lacks about the association between carotid ultrasonography outcomes 
and CVD in FH patients. Moreover, statin-treatment influences the ultrasonography 
outcomes. Both in FH as in non-FH patients it was shown that statins decrease C-IMT. 
However, whether carotid ultrasonography outcomes during statin-treatment are still 
useful for risk prediction has not been established.
Coronary imaging
CTCA is mainly used in symptomatic patients, who present with thoracic chest pain 
suspected to derive from atherosclerotic disease of the heart. One of the outcomes 
of the CTCA is the Agatston calcium score, which is calculated based on the intensity, 
volume and quantity of the calcific (white) signal on the CTCA-scans (19). This score is 
associated with cardiovascular events, and can improve risk prediction in the general 
population (20-24). In 2011, we performed a study in 101 asymptomatic FH patients 
to determine subclinical coronary atherosclerosis showing a wide variety of coronary 
artery calcification score (CAC-score), and CAC was more abundant in long-term, 
aggressively statin-treated FH patients than in untreated controls (25). The diversity of 
CAC scores in FH patients has been party explained by the higher CAC score in those FH 
patients with LDLR null-mutations compared to LDLR-defective mutations.(26).
Aortic valve calcification
Aortic valve calcification (AoVC) has an estimated prevalence of >50% in the elderly 
(>75 years) and is associated with 50% higher risk of CVD events (27,28). In homozygous 
FH, AoVC has a prevalence of 100%, and many of these patients need surgical 
intervention of functional valvular disease (29,30). Heterozygous FH is associated 
with less aortic valve dysfunction on echocardiography than homozygous FH (31-34). 
However, the prevalence and extent of aortic valve calcification (AoVC) is unknown in 
long-term, statin-treated heterozygous FH patients. Statins seem to have little effect on 
the progression of AOVC in the general population (35-37). Therefore this group is of 
particular interest, since statin therapy is the main reason for the prolonged survival in 
these patients (38). In this thesis, I present the first comparison between the prevalence 
of AOVC in heterozygous FH and non-FH patients.
1
11|Introduction
Carotid ultrasonography
Carotid ultrasonography can be used to measure subclinical atherosclerosis depicted 
as the presence of carotid plaques or increased carotid intima-media thickness. Both of 
these outcomes have been associated with CVD risk in the general population (16-18). 
However, data lacks about the association between carotid ultrasonography outcomes 
and CVD in FH patients. Moreover, statin-treatment influences the ultrasonography 
outcomes. Both in FH as in non-FH patients it was shown that statins decrease C-IMT. 
However, whether carotid ultrasonography outcomes during statin-treatment are still 
useful for risk prediction has not been established.
Coronary imaging
CTCA is mainly used in symptomatic patients, who present with thoracic chest pain 
suspected to derive from atherosclerotic disease of the heart. One of the outcomes 
of the CTCA is the Agatston calcium score, which is calculated based on the intensity, 
volume and quantity of the calcific (white) signal on the CTCA-scans (19). This score is 
associated with cardiovascular events, and can improve risk prediction in the general 
population (20-24). In 2011, we performed a study in 101 asymptomatic FH patients 
to determine subclinical coronary atherosclerosis showing a wide variety of coronary 
artery calcification score (CAC-score), and CAC was more abundant in long-term, 
aggressively statin-treated FH patients than in untreated controls (25). The diversity of 
CAC scores in FH patients has been party explained by the higher CAC score in those FH 
patients with LDLR null-mutations compared to LDLR-defective mutations.(26).
Aortic valve calcification
Aortic valve calcification (AoVC) has an estimated prevalence of >50% in the elderly 
(>75 years) and is associated with 50% higher risk of CVD events (27,28). In homozygous 
FH, AoVC has a prevalence of 100%, and many of these patients need surgical 
intervention of functional valvular disease (29,30). Heterozygous FH is associated 
with less aortic valve dysfunction on echocardiography than homozygous FH (31-34). 
However, the prevalence and extent of aortic valve calcification (AoVC) is unknown in 
long-term, statin-treated heterozygous FH patients. Statins seem to have little effect on 
the progression of AOVC in the general population (35-37). Therefore this group is of 
particular interest, since statin therapy is the main reason for the prolonged survival in 
these patients (38). In this thesis, I present the first comparison between the prevalence 
of AOVC in heterozygous FH and non-FH patients.
        
12 |      Chapter 1
Non-traditional risk factors
CVD risk prediction might be improved by measuring non-traditional risk factors. Among 
these is lipoprotein (a), or Lp(a). Lp(a) was discovered in 1963 by Kare Berg and is a LDL-
like protein with an apo(a) moiety. Lp(a) levels are predominantly genetically determined 
(39), and inversely correlated with the length of the apo(a) moiety. The length of apo(a) 
is mainly determined by kringle IV type 2 repeats (figure 1). Lp(a) concentration and 
kringle IV type 2 repeat number are independent risk factors for CVD in the general 
population, and FH (12,40). In FH, women clearly have a lower CVD burden than men 
(41-43). but female FH patients, whose Lp(a) levels are elevated, might be susceptible of 
premature CVD (44). The relationship between Lp(a) and CVD risk may be effected true 
the binding of oxidized phospholipids which may cause instability of atherosclerotic 
plaques through increased inflammation (45). Other pathophysiological mechanisms 
in which Lp(a) could play a role are wound healing and fibrinolysis pathways, however 
how these pathways play a role in the atherosclerosis pathophysiology is unknown 
(39,46). Unfortunately, there is a poor Lp(a) lowering responds to statins and other lipid 
lowering medication. Novel therapeutic agents are currently being developed who are 
aimed to specifically lower Lp(a) levels but to date no therapy is registered that can 
exclusively lower Lp(a) levels. 
Figure 1 | Schematical structure of Lipoprotein (a).
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Another approach of finding novel risk factors is using proteomics techniques. 
Proteomics aims to find difference in quantity in proteins of different samples, and has 
been used to identify novel biomarkers in several disease states, including coronary 
artery disease (47,48). In this thesis I aimed to identify novel markers of cardiovascular 
disease in long-term statin treated FH patients by applying the proteomic technique 
to samples of different risk groups of these FH patients. Risk in these patients was 
identified using coronary angiography with which we investigated a low risk group, an 
intermediate risk group, and a group with manifested cardiovascular disease.
Cardiovascular imaging and Lp(a)
Lp(a) levels in the general population are associated with AoVC (49), but the relation 
between AoVC and Lp(a) in FH is unknown as is the relationship between Lp(a) plasma 
levels and cardiovascular imaging outcomes. In this thesis I investigated whether 
Lp(a) was associated with the cardiovascular imaging modalities, carotid calcification, 
coronary calcification and aortic valve calcification.  
GeneRAl OuTlIne OF THe THeSIS
In Chapter 2, I validated our carotid ultrasonography device for use in the studies of Chapter 
3 and Chapter 6. In Chapter 3, I investigated whether carotid ultrasonography outcomes 
were different between statin-treated FH patients and healthy controls, and whether these 
ultrasonography outcomes correlated with coronary atherosclerosis measured by CTCA. In 
Chapter 4, I continued to study the CTCA data and investigated whether long-term, statin-
treated FH patients had a higher prevalence and extend of AoVC than healthy controls. The 
association between AoVC and Lp(a) in heterozygous FH patients is shown in Chapter 5. This 
association is known in the general population but has not been previously investigated 
in FH patients. Chapter 6 focusses on the association between carotid ultrasonography 
outcomes and Lp(a) in statin-treated FH patients to investigate whether the residual risk 
of high Lp(a) levels can be depicted by this non-invasive imaging technique. In Chapter 
7, the possible therapeutic possibilities in lowering Lp(a) are described, including novel 
agents which are currently still in development. The iTRAQ proteomics approach was used 
in Chapter 8 to explore novel proteins associated with coronary atherosclerosis and CVD 
endpoint in treated heterozygous FH patients. The summary and discussion of the thesis is 
presented in English (Chapter 9) and Dutch (Chapter 10).   
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ABSTRACT 
Introduction
Ultrasonography is the most commonly used imaging modality for assessing subclinical 
atherosclerosis by measuring carotid intima media thickness (C-IMT) and plaques. C-IMT 
can be reliably measured using automated software, which is present on the portable 
Panasonic CardioHealth station (CHS). The aim of this study was to determine whether 
the CHS provides reliable and reproducible data in comparison with another automated 
software package present on the previously validated Philips iU22 (PiU).
Methods and Results
Carotid ultrasonography was performed by two experienced observers in 85 subjects. 
C-IMT was measured bilaterally from two different angles, and plaque scans were 
performed bilaterally. 
The intra-class correlation (ICC) of the C-IMT measurements was 0.98 (95% CI: 0.94-0.99) 
and 0,96 (95% CI: 0.89-0.99) for Observer X and Y, respectively. The ICC of the C-IMT 
between the two observers was 0.98 (95% CI: 0.95-0.99), and the limitsof agreement 
(LOA) were 0.007±0.040 mm (p=0.31). The ICC between both systems was 0.89 (95% CI: 
0.81-0.93), and the LOA were 0.015±0.052 mm (p=0.03). Inter-observer agreement for 
the assessment of plaque was high on the CHS (kappa: 0.9±0.1, p=<0.001), and between 
systems (kappa: 1.0±0.0, p=<0.001).
Conclusion
The CHS has an excellent agreement with the validated PiU. The acquisition time of the 
CHS is shorter than that of the PiU. We conclude that the CHS is a rapid, reliable and 
precise method for assessing C-IMT and plaques, making it highly suitable for high-
throughput screening and clinical use.
Keywords
• Carotid Intima Media Thickness
• Intra-observer Variability
• Inter-observer Variability
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InTROduCTIOn
Cardiovascular disease (CVD) is one of the main causes of death worldwide(1). CVD 
risk can be identified with imaging techniques, like ultrasonography, by detecting 
subclinical atherosclerosis. Ultrasound is the most commonly used imaging modality 
to assess carotid intima media thickness (C-IMT) and atherosclerotic plaques (2-5). 
C-IMT can be measured manually, or with automated software. Automated C-IMT 
measurements have been shown to produce more reliable, reproducible and faster 
results than manual measurements(6). The Panasonic CardioHealth Station (CHS) is 
a portable system capable of measuring the C-IMT automatically (figure 1), but has 
hitherto not been tested against another validated automated C-IMT measurement 
system, such as the widely used Philips iU-22 (PiU) ultrasound system(7). We therefore 
compared the performances of these systems to evaluate whether the CHS produces 
reliable and reproducible data in C-IMT measurements and in the detection of carotid 
plaques.
MATeRIAlS And MeTHOdS
Study population
Seventy dyslipidaemic patients were recruited between March 2014 and March 2015 
from the outpatient clinic for cardiovascular genetics at the Erasmus MC. 
Healthy controls were recruited through advertisements. All subjects were over 18 
years old, written informed consent was obtained, and the study was approved by the 
local ethical committee (MEC-2012-309; MEC-2013-556).
All subjects underwent carotid ultrasound imaging twice, on either the CHS (intra-
observer variability and inter-observer variability), or on both systems (inter-system 
variability).
Measurements were performed by two experienced observers (Observer X and 
Observer Y).  
Equipment:
The CHS (Panasonic, Yokohama, Japan) is a portable system capable of automated C-IMT 
measurements. The CHS is equipped with a broadband 9 MHz linear-array transducer. 
As a reference, we used the previously validated semi-automated PiU (Philips Medical 
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Systems, Bothell, USA(7)), equipped with an L9-3 transducer, which used the automated 
QLAB IMT plugin for C-IMT measurements. 
Carotid ultrasound acquisition
All images were acquired based on the ‘American Society of Echocardiography 
consensus statement’ protocol (8). In short, subjects were examined lying on an even 
surface with their head positioned in an angle of approximately 45 degrees facing 
left when measuring the right side, and vice versa, while performing the ultrasound 
acquisition. 
Carotid ultrasound analysis
The mean C-IMT was measured over a length of 1 cm, at least 0.5 cm proximal of the 
bifurcation in the common carotid artery. Both sides were measured from two angles: 
anterior (170°-190°), and lateral (right: 120°-145°; left: 210°-235°). 
A plaque scan was performed by placing the transducer transversally in the neck, 
visualizing the internal, external and common carotid artery. A plaque was marked as 
present only if the local IMT was more than 50% of the surrounding IMT, or if the C-IMT 
was above 1.5 mm (9). 
Intra-observer and inter-observer variability
For the intra-observer variability the result section of the CHS monitor was covered so 
that the results were not visible for the observer. After the first procedure the patient 
was asked to stand up, was then repositioned, and finally re-measured.  
The inter-observer variability was assessed by measuring patients twice in succession. 
First, one of the observers measured the subject whilst the other observer was in the 
next room. After the first observer finished the procedure the other observer was 
summoned and subsequently performed the second measurement. From the acquired 
data we used the individual measurements at the four scan positions, as well as the 
C-IMT per patient.
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Table 2.1 | Inter-observer variability in the Panasonic CHS of all patients. 1*
Results per scan 
position
Results of the mean  
C-IMT per subject
C-IMT:
Mean C-IMT (±SD) 0.611 ± 0.141 mm 0.610 ± 0.126 mm
Intra-class coefficient (95%CI) 0.91 (0.88-0.94) 0.98 (0.95-0.99)
Difference between both 
observers (LOA) (±SD)
0.008±0.081 mm (p=0.25) 0.007±0.040 mm (p=0.31)
Correlation of the C-IMT 
difference and the mean C-IMT
R= -0.09; (p= 0.26) R= -0.28; (p= 0.09)
Plaques:
Plaques found Obs X: 27 (34%)
Obs Y: 30 (38%)
Obs X: 17 (43%)
Obs Y: 17 (43%)
Agreement of plaque presence 
(Intraclass kappa) (±SD)
73 (0.81±0.1) (p<0.001) 38 (0.90±0.1) (p<0.001)
1* Patients were 51±15 years old, BMI was 25.8±3.8, and 50% were male.
Inter-system variability
Observer X started scanning the healthy subject with the PiU, and immediately 
thereafter the subject was repositioned and measured with the CHS. The output of both 
devices of a healthy subject with a plaque are shown in figure 2.
Figure 2.1a |  Image outcome of a plaques scan (same location) on the two different systems.
The lumen of the carotid artery are marked with stars, and the plaques pointed out with arrows.
CHS PiU
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Figure 2.1b | Image output of the C-IMT measurement of the two different systems.
Longitudinal view of the common carotid artery and bifurcation. On the left side of the images 
the widening of the artery suggest the bifurcation where the “arteria carotis communis” splits into 
the “arteria carotis inerna”, and the “arteria carotis externa”. CHS: Panasonic CardioHealthStation; 
PiU: Philips iU-22 ultrasound system.
Statistics
Binary variables were expressed as number (percentage), and continuous variables 
as mean ± standard deviation. For C-IMT, the intra-class coefficient (ICC) and Bland 
Altman analyses were used to determine the mean difference within and between the 
observers. The ICC was expressed as mean (95% CI). The results of the Bland-Altman 
analyses were expressed as the limits of agreement (LOA) as mean ± standard deviation. 
The LOA expresses the difference between the two measurements and a one sample 
t-test was used to test for statistical significance.  
The inter-observer variability was determined on the individual C-IMT measurements, 
and on the mean C-IMT of a subject. 
The association between the differences in C-IMT measurements and the mean C-IMT 
was determined by linear regression.
Agreement in plaque identification between observers and systems was expressed by 
the Kappa statistic. 
All statistical analyses were performed using SPSS version 21 (SPSS Inc., Chicago, IL, 
USA).
ReSulTS
In total 85 subjects were examined in this study. For determination of intra-observer 
variability, observer X scanned 15 patients and observer Y 15 other patients; 40 patients 
CHS PiU
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were scanned for the inter-observer variability; and 15 healthy subjects were scanned 
for the inter-system variability. Baseline values are presented in the footnote of the 
tables. 
Intra-observer variability
The LOA for C-IMT of Observer X were 0.005±0.035 mm (p=0.60), and the ICC was 0.98 
(95% CI: 0.94-0.99). Similarly, the LOA for C-IMT of Observer Y were 0.015±0.043 mm 
(p=0.21), and the ICC was 0.96 (95% CI: 0.89-0.99). Intra-observer variability of plaque 
presence was not determined, since measurements were made in quick succession and 
it is unlikely to forget the presence of a plaque in the first measurement.
Inter-observer variability 
Results of C-IMT measurements at all four scan positions, the mean C-IMT per patient, 
and plaque scans are depicted in table 1. The Bland Altman plot is shown in figure 3a. 
The LOA for C-IMT was not significantly different between the observers. The SD of the 
LOA was approximately 50% lower for the mean C-IMT of the four scans per subject. 
Similarly, the ICC improved by taking the mean C-IMT per patient. Plaque presence was 
similar between observers as indicated by the high intraclass kappa.
In linear regression analysis, the C-IMT difference between observers did not increase 
with C-IMT value, indicating that the inter-observer variability was independent of 
C-IMT values. 
Table 2.2 | Variability between the Panasonic CHS and the Philips PiU of the four scan positions 
in the healthy volunteers. 2*
CHS Piu Inter-system
Acquisition time (minutes) 2±1 4±1 (p<0.001)
C-IMT:
Mean C-IMT (±SD) 0.516±0.077 mm 0.531±0.087 mm
Difference between both C-IMT 
measurements (LOA) (±SD)
0.0154 ±0.0522 mm 
(p=0.03)
Intra-class coefficient (95%CI) 0.89 (0.81-0.93)
Correlation of the C-IMT differ-
ence and the mean C-IMT
R= -0.38; (p= 0.16)
Plaques:
Plaques found 1 1 1
2* Subjects were 38±14 years old, BMI was 23.2±2.3, and 47% were male.
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Inter-system variability
Image acquisition time, defined as time between acquiring the first and last image, of 
the CHS was significantly shorter (2±1 minutes) than the PiU (4±1 minutes; p=<0.001). 
Results of the C-IMT measurements, and plaque scans of the healthy volunteers are 
depicted in table 2, and the Bland Altman plot is shown in figure 3b. For C-IMT the LOA 
were significantly lower on the CHS than on the PiU. However, the ICC for the C-IMT was 
similar. One plaque was present in the healthy controls which was seen on both devices. 
Figure 2.2 | Bland Altman Plots 
a). Bland-Altman plot of the inter-observer variability. Outer-lines: +/- 1.96*SD.
b). Bland-Altman plot of the inter-system variability. Outer-lines: +/- 1.96*SD.
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dISCuSSIOn
This study shows that the portable CHS generated reliable and reproducible data that 
were in large agreement with the PiU measurements, irrespective of the observer 
acquiring the images. Interestingly, the ICC for the intra-observer variability was similar 
to that of the inter-observer variability suggesting a highly reliable measurement 
technique. High mean C-IMT values were not associated with high measurement 
variation suggesting that the measurements are reliable at both low and high C-IMT.
These results are in line with an earlier study showing that the fully automated C-IMT-
measurements of the CHS were comparable to manual C-IMT measurements(6). The 
use of manual C-IMT measurements has considerably decreased with the evolvement 
of automated C-IMT measurement software. However, differences between these 
automated systems might exist. In our study, the CHS measured the C-IMT significantly 
smaller than the PiU, although it is questionable whether the mean 0.015 mm 
difference is clinically relevant. Vanoli et al. also found smaller C-IMT values with the CHS 
(0.012mm) although in their study this was not statistically significant (6). These results 
do emphasise caution when comparing C-IMT results obtained with different systems. 
Carotid images on the PiU, a semiautomated system, must be stored before the C-IMT 
can be measured by the software. Storage enables retrospective evaluation, which is not 
possible on the CHS. The CHS on the other hand is a fully automated portable system 
that immediately generates the C-IMT value during image acquisition, these images are 
also stored but in less quality than those of the PiU. Notably, the acquisition time is 
shorter on the CHS than on the PiU. Moreover, Aldridge et al. showed that training of 
nonsonographers on 60 subjects with the CHS was sufficient to give results comparable 
to an expert sonographer(10). Taken together, the CHS has advantages compared to the 
PiU for performing carotid ultrasound imaging during outpatient visits and as a high-
throughput system in large studies. 
Whether C-IMT measurements are useful for individual risk assessment remains a 
matter of debate (11, 12). Recent population studies showed that C-IMT is associated 
with CVD(8), although C-IMT seems to have no additional value in cardiovascular 
risk prediction(11, 12). However, the current guidelines of the European Society of 
Cardiology states that C-IMT-measurements should be considered in asymptomatic 
adults at moderate risk(13). The discussion about the clinical usefulness of C-IMT is 
outside the scope of the current study. 
The presence of carotid plaques and especially plaque volume are strong predictors of 
2
27|Validation CHS and PiU
dISCuSSIOn
This study shows that the portable CHS generated reliable and reproducible data that 
were in large agreement with the PiU measurements, irrespective of the observer 
acquiring the images. Interestingly, the ICC for the intra-observer variability was similar 
to that of the inter-observer variability suggesting a highly reliable measurement 
technique. High mean C-IMT values were not associated with high measurement 
variation suggesting that the measurements are reliable at both low and high C-IMT.
These results are in line with an earlier study showing that the fully automated C-IMT-
measurements of the CHS were comparable to manual C-IMT measurements(6). The 
use of manual C-IMT measurements has considerably decreased with the evolvement 
of automated C-IMT measurement software. However, differences between these 
automated systems might exist. In our study, the CHS measured the C-IMT significantly 
smaller than the PiU, although it is questionable whether the mean 0.015 mm 
difference is clinically relevant. Vanoli et al. also found smaller C-IMT values with the CHS 
(0.012mm) although in their study this was not statistically significant (6). These results 
do emphasise caution when comparing C-IMT results obtained with different systems. 
Carotid images on the PiU, a semiautomated system, must be stored before the C-IMT 
can be measured by the software. Storage enables retrospective evaluation, which is not 
possible on the CHS. The CHS on the other hand is a fully automated portable system 
that immediately generates the C-IMT value during image acquisition, these images are 
also stored but in less quality than those of the PiU. Notably, the acquisition time is 
shorter on the CHS than on the PiU. Moreover, Aldridge et al. showed that training of 
nonsonographers on 60 subjects with the CHS was sufficient to give results comparable 
to an expert sonographer(10). Taken together, the CHS has advantages compared to the 
PiU for performing carotid ultrasound imaging during outpatient visits and as a high-
throughput system in large studies. 
Whether C-IMT measurements are useful for individual risk assessment remains a 
matter of debate (11, 12). Recent population studies showed that C-IMT is associated 
with CVD(8), although C-IMT seems to have no additional value in cardiovascular 
risk prediction(11, 12). However, the current guidelines of the European Society of 
Cardiology states that C-IMT-measurements should be considered in asymptomatic 
adults at moderate risk(13). The discussion about the clinical usefulness of C-IMT is 
outside the scope of the current study. 
The presence of carotid plaques and especially plaque volume are strong predictors of 
        
28 |      Chapter 2
cardiovascular events (14). However, plaque volume could not be scored on the systems 
we used since they were not able to obtain 3D ultrasound imaging.
Big inter-observer differences were not related to high C-IMT levels showing that the 
CHS is reliable at both low and high C-IMT. However, we measured the C-IMT between 
systems in healthy subjects with relatively low C-IMT values. Therefore, we cannot exclude 
that higher C-IMT values would expose differences between the systems. Furthermore, 
healthy volunteers are also less likely to have carotid plaques. Although plaque presence 
in the inter-observer variability group was not significantly different, there was not a 
complete agreement between the two experienced observers. This emphasizes caution 
in interpreting and combining results on plaque presence, especially those results from 
inexperienced sonographers. 
COnCluSIOn
The portable CHS provides precise measurements of C-IMT and reliably detects carotid 
plaques, with a shorter acquisition time than that of the PiU. We conclude that the CHS 
is a rapid,  reliable and precise method for assessing C-IMT and plaques, making it highly 
suitable for high-throughput screening and clinical use.
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ABSTRACT
Background and aims
Statins reduce subclinical atherosclerosis and premature atherosclerotic cardiovascular 
disease (ASCVD) in patients with familial hypercholesterolemia (FH).  However, some 
FH patients still develop ASCVD despite statin therapy. We compared subclinical 
atherosclerosis assessed by carotid plaque presence and intima media thickness 
(C-IMT), in long-term statin-treated FH patients to healthy controls. Furthermore we 
analysed whether carotid ultrasonography findings associated with subclinical coronary 
atherosclerosis.
Methods and results
We assessed the presence of carotid plaques and C-IMT in 221 asymptomatic 
heterozygous FH patients (48% men; 46±15 years) on long-term (10.0±7.8 years) statin 
treatment and 103 controls (32% men, 47±16 years). The frequency of carotid plaques 
and C-IMT did not differ significantly between the FH patients and controls (69 (31%) 
versus 24 (23%), p=0.1 and 0.58±0.13 versus 0.58±0.12 mm, p=0.9, respectively). In a 
subgroup of 49 FH patients who underwent cardiac computed tomography, coronary 
artery calcification correlated with carotid plaque presence (R=0.47; p=0.001), but not 
with C-IMT (R=0.20; p=0.2). 
Conclusions 
Carotid plaques and C-IMT did not differ between long-term statin-treated heterozygous 
FH patients and healthy controls. This shows that long-term statin treatment in these 
FH patients reduces carotid atherosclerosis to a degree of a healthy population. These 
findings strongly suggests that sonography of the carotid arteries during follow-up of 
statin-treated FH patients has limited value.
Keywords
• Carotid plaque presence 
• Carotid intima media thickness 
• Familial hypercholesterolemia 
• Residual risk
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InTROduCTIOn
Familial hypercholesterolemia (FH) is the most common genetic disorder associated 
with premature atherosclerotic cardiovascular disease (ASCVD), and is caused by 
pathogenic mutations in the LDLR,	 APOB or PCSK-9	 gene	 (1-3). The risk of premature 
ASCVD is increased due to high low-density lipoprotein cholesterol (LDL-C) levels (4), 
which can be lowered by statin treatment.  Statin therapy can reduce ASCVD risk in 
heterozygous FH patients to the same risk as in the general population (5).  However, 
there are still FH patients who develop ASCVD despite statin treatment (5). To identify 
these FH patients, imaging modalities that detect subclinical atherosclerosis may be 
useful.  Carotid ultrasonography can be used the detect plaques and estimate carotid 
intima media thickness (C-IMT). Increased C-IMT and the presence of carotid artery 
plaques in particular, are significant predictors of ASCVD in the general population(6-9). 
Previously it was shown that treatment with a high potency statin during 2 years 
inhibited progression of C-IMT in FH patients (10,11). Sivapalaratnam, et al. showed that 
the C-IMT of statin treated FH patients is comparable to that of their healthy spouses 
(12), suggesting a normalization of risk of ASCVD in the former group. However, C-IMT 
is not as strongly associated with ASCVD as the presence of carotid plaques (9,13,14), 
which was not investigated in the aforementioned study. Whether the prevalence of 
carotid plaques is normalized in FH patients by long-term statin treatment, and whether 
normalized carotid parameters indeed reflect subclinical coronary atherosclerosis, 
remains unknown. We therefore compared carotid plaque prevalence and C-IMT 
between FH patients and healthy controls. Moreover, in a subgroup of FH patients we 
correlated these parameters with coronary artery calcification. 
PATIenTS And MeTHOdS
Study Population
Between May 2012 and May 2015, asymptomatic heterozygous FH patients were 
recruited from the outpatient cardiogenetics clinic at the Erasmus Medical Centre in 
Rotterdam. FH was defined as a score ≥6 on ‘The Dutch Lipid Clinic Network criteria’ 
(addendum 1) (15). All patients were on statin treatment. All patients were screened for 
mutations in the LDLR, APOB and PCSK-9 genes. Patients with two mutations, compound 
heterozygous FH and homozygous FH, were excluded as were patients with symptoms 
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of ASCVD or a history of ASCVD.   
Controls were recruited through public advertisements, and were included between 
April 2014 and May 2015. Inclusion criteria for the controls were: no major illness, no 
statin or any other lipid-lowering medication use, and no history of ASCVD.
A total of 221 FH patients were included in our study. Expecting 15%±7% difference in 
carotid plaque presence (primary endpoint) between FH patients and controls, at least 
96 controls were required for a power of 80% and α of 5%. For C-IMT (secondary end 
point), we considered 0.05 mm to be a clinically significant difference and previously we 
observed standard deviation of  +-0.12 mm, to obtain a power of 80%, α of 5%, at least 
69 controls were required.
All subjects were over 18 years old. Written informed consent was obtained from all 
participants and healthy volunteers. This study was in accordance with the declaration 
of Helsinki and was approved by the local ethical committee (MEC-2012-309);( MEC-
2013-556).
Blood analyses
Fasting blood was collected in EDTA, processed the same day, and plasma samples were 
stored at -80oC. Lipid levels were measured using standard laboratory techniques.
Carotid ultrasonography
All carotid ultrasound scans and measurements were performed using a Panasonic 
CardioHealthStation (Yokohama, Japan) that uses a validated automated C-IMT 
capturing method (16). The scanning protocol is based on the ASE consensus (17), and 
has been previously published (18). In short, the plaque scans were performed bilaterally 
in the internal carotid artery, external carotid artery and common carotid artery. Plaques 
were defined as a local enlargement of the C-IMT of more than 50% of the surrounding 
C-IMT, or if the C-IMT was above 1.5 mm, and were scored as present or absent (19). 
C-IMT was measured over 1 cm length, at least 0.5 cm proximal of the bifurcation in the 
common carotid artery“, and measured in the end-diastolic phase which was identified 
by the vessel motion detector system based on the change in arterial diameter during 
the cardiac cycle (16). The C-IMT was measured twice on each side“, in a 45 degree angle 
determined by positioning the patients head against a 45 degree wedged pillow, and 
the mean of these four orientations was used in our study. 
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CT calcium imaging
A subgroup (n=49, 22%) of the asymptomatic FH patients in this cohort underwent a 
non-enhanced cardiac computed tomography (CT) scan (Somatom Definition, Siemens 
Medical Solutions, Forchheim, Germany) in the same period, to quantify the coronary 
calcium burden, not on indication but for another research study. The calcium score was 
measured as described previously (20), and expressed as the Agatson score (21). The 
FH patients who had their calcium score determined were divided in three subgroups. 
The first group were patients without detectable calcification [n=14). Patients with a 
positive calcium scan were split in two comparable sized groups (n=17; n=18) based on 
the calcium score, by using the median calcium score of the FH patients with coronary 
calcification (Agatston score cut-off of 136).
Statistical analyses
Data with a normal distribution were expressed as mean (±SD), and data with a skewed 
distribution as median (IQR). Differences between the groups at baseline were compared 
by a Chi-Square test for binary variables and by ANOVA for continuous variables. 
Factors associated with C-IMT and plaques were tested in linear and logistic regression 
analyses. The regression analyses were repeated separately in the FH patients and the 
controls to see if there were different predicting variables in the groups. 
To test the association of carotid plaques and C-IMT with coronary artery calcification, 
univariable ordinal regression analyses were performed. Finally, multiple ordinal 
regression analyses were performed to determine the predictive values of the carotid 
plaques presence and C-IMT for coronary calcification.  
The statistical analyses were performed using SPSS, version 20 (SPSS, Chicago, Illinois). 
ReSulTS
Clinical characteristics
Data were collected of 221 FH patients, and 103 healthy controls. DNA analysis 
confirmed FH in 170 patients (77%), with mutations in the LDLR and APOB gene in 151 
and 19 patients, respectively. PCSK-9 gene mutations were not present in our patients. 
Characteristics of FH patients and controls are depicted in table 1. FH patients were 
of similar age and had similar LDL-C levels as controls. All FH patients used statins on 
average for 10.0±7.8 years. At inclusion, 74% of patients used rosuvastatin or atorvastatin, 
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Table 3.1 | Characteristics of the FH patients and non-FH  controls.
Characteristics FH (n=221) control (n=103) p
Age (years) 46±15 47±16 0.57
Sex (male) 107 (48%) 33 (32%) 0.004
Body mass index (kg/m2) 26.3±4.8 25.2±4.6 0.05
Systolic blood pressure (mmHg) 129±14 136±21 0.001
Diastolic blood pressure (mmHg) 78±9 83±12 <0.001
Hypertension1 46 (21%) 16 (16%) 0.3
Diabetes mellitus2 6 (3%) 1 (1%) 0.3
Smoker (current, former) 72 (33%) 36 (35%) 0.4
LDL-R mutation 151 (68%) N/A
APOB mutation 19 (9%) N/A
No mutation detected 51 (23%) N/A
Total cholesterol levels pre-statin 
treatment (mmol/L)
8,5±2,1 N/A
Total Cholesterol (mmol/L) 5.1±1.2a 5.6±1.0 0.001
HDL-C (mmol/L) 1.4±0.4a 1.6±0.4 0.03
LDL-C (mmol/L) 3.3±1.0a 3.3±0.7 0.99
ApoB (mg/L) 1.1±0.3a 1.0±0.2 0.16
Triglyceride (mmol/L)b 1.1 (0.8)a 1.2 (0.8) 0.14
Cholesterol year scorec 358,1±153,6 288,5±115,6 <0.001
Years on statins 
≤ 1 year 32 (15%) N/A
1-2 years 15 (7%) N/A
2-5 years 27 (12%) N/A
>5 years 147 (67%) N/A
High intensity statin dosed 164 (74%) N/A
Atorvastatin 73 (33%) N/A
Fluvastatine 2 (1%) N/A
Pravastatine 6 (3%) N/A
Rosuvastatine 90 (41%) N/A
Simvastatine 50 (23%) N/A
1 Defined as being diagnosed by physician or taking antihypertensive drugs; 2 Defined as being diagnosed by 
physician or taking anti-diabetic drugs; a values of statin treated patients; b median (IQR); c cholesterol year 
score was calculated using the formula: Untreated total cholesterol x years without statin treatment + statin-
treated total cholesterol x years treated with statins; d Defined as atorvastatin ≥40mg, Rosuvastatin ≥20mg, 
and simvastatin ≥40mg; nd: not determined.
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score was calculated using the formula: Untreated total cholesterol x years without statin treatment + statin-
treated total cholesterol x years treated with statins; d Defined as atorvastatin ≥40mg, Rosuvastatin ≥20mg, 
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23% used simvastatin and the remainder used fluvastatin or pravastatin. The FH group 
contained more men than the healthy control group. The main differences between 
the groups were a higher BMI and lower blood pressure, total cholesterol and HDL 
cholesterol in the FH group.  
Carotid ultrasonography findings
The frequency of plaques in 69 FH patients out of 221 FH patients was not significantly 
different from 24 out of 103 controls (31% versus 23%; p= 0.09). The mean C-IMT was 
similar in the FH patients to the healthy controls (0.58±0.13mm and 0.58±0.12mm, 
respectively; p=0.90). Adjustment for age, male sex, body mass index, systolic and 
diastolic blood pressure, total cholesterol, and HDL-cholesterol did not materially 
change these results (data not shown).
In the FH group, plaque presence was associated with age, male sex, body mass 
index, systolic blood pressure, type 2 diabetes mellitus, hypertension, smoking, 
total cholesterol, LDL-cholesterol, triglyceride levels, years on statins, and CYS. In the 
multivariate logistic regression model, we used all the significant co-variables except 
years on statins and CYS. These two variables were excluded because of associations 
with other variables, which were used to calculate them. Notably, substituting these 
variables for age and highest cholesterol levels did not change the results. After adding 
the remaining significant variables from the univariate analyses, only age remained 
significantly associated with the presence of plaque (table 2a). Similarly, in the FH group, 
the mean C-IMT was positively associated with age, male sex, body mass index, systolic 
blood pressure, diastolic blood pressure, hypertension, smoking, total cholesterol, LDL-
cholesterol, triglyceride levels, years on statins, and CYS. In the multiple linear regression 
model the remaining associated variables were age and hypertension (table 2b). In the 
control group, results were similar to FH for plaques.
Coronary artery calcification findings
In the subgroup of 49 FH patients, the plaque presence significantly correlated with the 
coronary calcium-score (Spearman correlation coefficient R=0.47; p=0.001), but  C-IMT 
did not (R=0.20; p= 0.2). 
Of the FH patients, who underwent cardiac CT, 14 patients showed no coronary 
calcifications (Agatston-score: 0); 17 had  mild calcification (Agatston -score: 1-136); 
and 18 had more severe calcification (Agatston -score>136). In univariable ordinal 
regression analyses, only the presence of carotid plaques (proportional odds: 7.96, 95% 
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Table 3.2 | Multiple regression analyses
A: Multiple Logistic regression of predictors of the presence of carotid plaques in the FH 
patients, and controls.
FH R2 = 40% Controls R2 = 34%
OR 95% CI OR p OR 95% CI OR p
Age (Years) 1.11 1.07-1.15 <0.001 1.10 1.03-1.17 0.01
Sex (Male) 1.79 0.82-3.93 0.1 1.56 0.37-6.66 0.5
Body Mass Index (kg/m2) 0.99 0.90-1.08 0.8 1.13 0.99-1.29 0.1
Systolic Blood Pressure 
(mmHg)
1.02 0.99-1.05 0.3 0.99 0.96-1.02 1.0
Hypertension 1.14 0.44-2.93 0.8 2.75 0.66-
11.50
0.2
Smoker (Current, Former) 1.44 0.69-2.98 0.3 0.74 0.21-2.68 0.7
Total Cholesterol (mmol/L) 0.53 0.18-1.53 0.2 3.10 0.49-
19.61
0.2
LDL-C (mmol/L) 2.71 0.85-8.62 0.1 0.20 0.02-2.40 0.2
Triglycerides (mmol/L) 1.32 0.85-2.10 0.2 0.75 0.25-2.21 0.6
Bold entries in the table highlight a significant p level < 0.05
B: Multiple linear regression analyses of predictors of C-IMT in the FH patients, and controls.
FH R2 = 36% Controls R2 = 50%
OR 95% CI OR p OR 95% CI OR p
Age (Years) 1.00 1.00-1.00 <0.001 1.01 1.01-1.01 <0.001
Sex (Male) 0.98 0.95-1.01 0.1 1.00 0.95-1.04 0.6
Body Mass Index (kg/m2) 1.00 1.00-1.00 0.3 1.00 1.00-1.01 0.2
Systolic Blood Pressure 
(mmHg)
1.00 1.00-1.00 0.2 1.00 1.00-1.00 0.4
Hypertension 1.05 1.01-1.10 0.02 0.99 0.93-1.05 0.9
Smoker (Current, Former) 1.00 0.97-1.03 0.1 1.01 0.96-1.05 0.7
Total Cholesterol 
(mmol/L)
1.02 0.95-1.10 0.9 0.94 0.85-1.04 0.1
LDL-C (mmol/L) 0.99 0.92-1.07 0.5 1.01 0.89-1.14 0.1
Triglycerides (mmol/L) 0.99 0.96-1.02 0.9 1.00 0.94-1.05 0.3
Bold entries in the table highlight a significant p level < 0.05
CI 2.41-26.32; p=0.001) and age (proportional odds: 1.06, 95% CI 1.01-1.12; p 0.03) were 
significant predictors of coronary calcium category. C-IMT was not predictive of a higher 
calcium-score (proportional odds: 9.23, 95% CI 0.06-1511; p=0.4). In multiple ordinal 
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regression analyses, carotid plaque presence as a dichotomous variable was a strong 
predictor of calcium severity independently of age (proportional odds: 11.94 (95% CI 
3.26-43.69); p < 0.001) (table 3). 
Table 3.3 | Predictors of the extent of  coronary calcium 
Multiple ordinal regression in statin-treated FH patients (n=49)
Predictor variables Proportional Odds1 95 % CI p-Value
Plaque presence 11.94 3.26-43.69 0.0002
Age (Years) 1.09 1.03-1.16 0.005
1 The Proportional Odds was calculated with an ordinal logistic regression analysis, using three ranked 
categories of Agatston-score (AU = Agatston units): group 1 (AU=0, n=14), group 2 (0 <AU < 136; n = 17), 
group 3 (AU > 136; n = 18). This model predicts how much an increase in the explanatory variable leads to an 
increase of probability of being in the higher calcification group. 
R2 = Nagelkerke R square, CI = confidence interval
R2 = 42%
dISCuSSIOn
This study demonstrates that the prevalence of carotid plaques and C-IMT did not differ 
between long-term statin-treated FH patients and healthy controls. Moreover, carotid 
plaques but not C-IMT correlated with coronary calcium in a subgroup of FH patients 
who underwent cardiac CT.
In our cohort of FH patients with mean age of 46 years, we found that 31% showed carotid 
artery plaques , which was not significantly different from our controls. We observed a not 
significant 8% difference in plaque prevalence. It is unlikely that such a small difference 
contributes to a clinical relevant difference in risk of cardiovascular events in individual 
patients. However, at a population scale this still may point at incomplete normalisation of 
the risk. Some of our control subjects did exhibit ASCVD risk factors such as hypertension 
and smoking that could have led to an increase in carotid plaques or C-IMT. In contrast 
the prevalence of carotid plaques in our healthy volunteers (23%) in our study seems to 
be in line with previous studies in healthy volunteers. In a Swedish cohort with a mean 
age of 57 years,  plaques were present in 43% of the participants (22), and in an American 
multi-ethnic population with mean age 61 years, prevalence was 42% (9). The prevalence 
of plaques is higher in untreated newly diagnosed FH patients(17). In the pre-statin era, 
carotid plaques were present in 70% of FH patients all younger than 30 years, compared 
to only 12% in age-matched controls (23). This also suggests that initial differences in the 
3
39|Carotid ultrasonography in statin treated FH
regression analyses, carotid plaque presence as a dichotomous variable was a strong 
predictor of calcium severity independently of age (proportional odds: 11.94 (95% CI 
3.26-43.69); p < 0.001) (table 3). 
Table 3.3 | Predictors of the extent of  coronary calcium 
Multiple ordinal regression in statin-treated FH patients (n=49)
Predictor variables Proportional Odds1 95 % CI p-Value
Plaque presence 11.94 3.26-43.69 0.0002
Age (Years) 1.09 1.03-1.16 0.005
1 The Proportional Odds was calculated with an ordinal logistic regression analysis, using three ranked 
categories of Agatston-score (AU = Agatston units): group 1 (AU=0, n=14), group 2 (0 <AU < 136; n = 17), 
group 3 (AU > 136; n = 18). This model predicts how much an increase in the explanatory variable leads to an 
increase of probability of being in the higher calcification group. 
R2 = Nagelkerke R square, CI = confidence interval
R2 = 42%
dISCuSSIOn
This study demonstrates that the prevalence of carotid plaques and C-IMT did not differ 
between long-term statin-treated FH patients and healthy controls. Moreover, carotid 
plaques but not C-IMT correlated with coronary calcium in a subgroup of FH patients 
who underwent cardiac CT.
In our cohort of FH patients with mean age of 46 years, we found that 31% showed carotid 
artery plaques , which was not significantly different from our controls. We observed a not 
significant 8% difference in plaque prevalence. It is unlikely that such a small difference 
contributes to a clinical relevant difference in risk of cardiovascular events in individual 
patients. However, at a population scale this still may point at incomplete normalisation of 
the risk. Some of our control subjects did exhibit ASCVD risk factors such as hypertension 
and smoking that could have led to an increase in carotid plaques or C-IMT. In contrast 
the prevalence of carotid plaques in our healthy volunteers (23%) in our study seems to 
be in line with previous studies in healthy volunteers. In a Swedish cohort with a mean 
age of 57 years,  plaques were present in 43% of the participants (22), and in an American 
multi-ethnic population with mean age 61 years, prevalence was 42% (9). The prevalence 
of plaques is higher in untreated newly diagnosed FH patients(17). In the pre-statin era, 
carotid plaques were present in 70% of FH patients all younger than 30 years, compared 
to only 12% in age-matched controls (23). This also suggests that initial differences in the 
        
40 |      Chapter 3
presence of carotid plaque between the young untreated FH patients and controls have 
diminished later in life, owing to statin treatment of the FH patients.  It is possible that the 
small, not significant difference found in this study is mainly caused by those FH patients 
who did not start early with aggressive statin treatment.  Therefore, we cannot be sure that 
our results are applicable to all treated FH patients. It is possible that the control subjects 
with carotid plaque also have increased coronary artery calcification, but these data were 
not available. Further research is needed to determine whether carotid plaque presence 
predicts future cardiovascular events in statin-treated FH-patients.  
We observed no statistical differences in C-IMT between long-treated FH patients and 
healthy controls. These results are in line with a previous report using 40 FH patients 
treated for more than 5 years with statins (9). With 0.58 mm, the mean C-IMT values we 
measured are similar to several other studies on healthy subjects with approximately 
the same age, indicating that our control group does not have increased C-IMT values 
(9,22,24,25). Moreover the mean C-IMT value of our long-term statin treated FH patients 
are much lower than in the ASAP study population (10), and even lower than in the 
ENHANCE study population (26), or than in FH patients that have been treated for at 
least 5 years with statins (12). Characteristics of the ENHANCE population were similar 
to our cohort of FH patients, except that the treated LDL-C cholesterol in our patients 
(3.3±1.0 mmol/L) is lower than in statin + ezetimibe treated arm of the ENHANCE (3.7±1.4 
mmol/L; p<0.01). C-IMT values of the ENHANCE study (0.67±0.16 mm) were higher than 
in our study (0.58±0.13 mm; p<0.01) which might be explained by the combination of 
higher on-treatment LDL-C values, different measuring systems, or possibly, a longer 
period of statin treatment. 
We previously reported that subclinical coronary artery disease, as determined by 
coronary CT angiography, was increased in asymptomatic FH patients compared with 
statin-treated (3±4 years), non-anginal chest pain patients (27). In another study in the 
same patients, no differences in C-IMT were found (28), which is in line with our findings. 
In the current study we could not compare coronary CT angiography results between 
the FH patients and controls as calcium scoring was not performed because of the 
undesirable radiation exposure in the healthy controls.
In the present study, a subgroup of these FH patients (n=30) was included and 19 
FH patients were added, who only received non-enhanced cardiac CT scans. In these 
patients coronary artery calcification was strongly correlated with carotid plaque 
presence, but not with C-IMT. The lack of association of C-IMT and coronary artery 
calcification was also previously shown in non-statin treated FH patients (29,30). 
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The association of carotid plaque presence and C-IMT on ASCVD outcome has not 
been studied in statin-treated FH patients. Despite this lack of evidence many cohort 
and intervention studies have used C-IMT as a proxy of ASCVD outcome in statin-treated 
FH patients (18,26,31,32). Since in our study in statin-treated FH patients C-IMT did not 
associate with coronary calcification, C-IMT  might not be useful as a marker for ASCVD 
risk in these patients.
The case-control design of our study limits the possibility to observe changes in plaque 
presence and C-IMT over time. Since no prospective ultrasound data is available for our 
patients, we cannot assess whether ultrasonographic changes over time are associated 
with cardiovascular risk. Clinical characteristics differed slightly between patients and 
controls. The controls were of similar age, but more often women. Therefore, it is unlikely 
that better gender-matched controls will unmask a hidden burden in our treated FH 
cohort. Since the results were similar in both groups and the C-IMT values were similar 
to other healthy populations (9,22,24,25), and adjustment for these differences had no 
influence, it is unlikely that these differences have affected the outcome of our study. 
We did not include data of compound heterozygous FH patients and homozygous FH 
patients, because their baseline and treated LDL-C as well as their ASCVD risk is not 
comparable to heterozygous FH patients.
Carotid plaques were only scored as present or absent whilst plaque volume 
measurements may be a better way to score cardiovascular risk (14,33). However, this 
can only be done with 3D ultrasonography which was not available on our ultrasound 
system. Therefore, we cannot exclude that other ultrasonographic techniques or 
locations may yield different results. 
COnCluSIOn
Carotid plaques and C-IMT did not differ between long-term statin-treated heterozygous-
FH patients and healthy controls. This shows that long-term statin treatment in these 
FH patients reduces carotid atherosclerosis to a degree of a healthy population. These 
findings strongly suggests that sonography of the carotid arteries during follow-up of 
statin-treated FH patients has limited value.
Conflicts of interest
There was no relationship with industry that could cause a conflict of interest.
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ABSTRACT
Background
Familial hypercholesterolemia is typically caused by LDL receptor (LDLR) mutations that 
result in elevated levels of LDL cholesterol (LDL-C). In homozygous FH, the prevalence of 
aortic valve calcification (AoVC) reaches 100% and is often symptomatic. 
Objectives
The objective of this study was to investigate the prevalence, extent and risk-modifiers 
of AoVC in heterozygous FH (he-FH) that are presently unknown. 
Methods and results
145 asymptomatic patients with he-FH (93 men; mean age 52, ±8 years) and 131 non-
familial hypercholesterolemia controls (78 men; mean age 56, ±9 years) underwent CT 
computed tomography calcium scoring. AoVC was defined as the presence of calcium 
at the aortic valve leaflets. The extent of AoVC was expressed in Agatston units, as the 
AoVC-score. We compared the prevalence and extent of AoVC between cases and 
controls. In addition, we investigated risk modifiers of AoVC, including the presence 
of LDLR mutations without residual function (LDLR-negative mutations), maximum 
untreated LDL-cholesterol (maxLDL), LDL-C, blood pressure, and coronary artery 
calcification (CAC).
Prevalence (%) and AoVC-score (median, IQR) were higher in he-FH patients than in 
controls: 41%, 51(9-117); and 21%, 21(3-49) (p<0.001 and p=0.007). Age, untreated 
maxLDL, CAC and diastolic blood pressure were independently associated with AoVC. 
LDLR-negative mutational he-FH was the strongest predictor of the AoVC-score (OR: 
4.81; 95% CI: 2.22-10.40; p = <0.001). 
Conclusion
Compared to controls, he-FH is associated with a high prevalence and a large extent of 
subclinical AoVC, especially in patients with LDLR-negative mutations, highlighting the 
critical role of LDL-C metabolism in AoVC etiology.
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InTROduCTIOn 
Aortic valve calcification (AoVC) has an estimated prevalence of more than 50% in 
the elderly (> 75 years), and is associated with an elevated risk of coronary (72%) and 
cardiovascular events (50%) (1,2). In addition, the degree of AoVC correlates with stenosis 
severity, disease progression and the development of coronary and cardiovascular 
events (3-5). 
In the general population AoVC is associated with age, male gender, smoking, 
hypertension, diabetes, obesity and hypercholesterolemia (6,7). Patients with familial 
hypercholesterolemia (FH) have extremely high levels of low-density lipoprotein 
cholesterol (LDL-C) and may be at high risk of developing AoVC. FH is an autosomal 
inherited disorder caused by mutations in the LDL receptor (LDLR) gene, the 
apolipoprotein B (APOB) gene, or the proprotein convertase subtilisin/kexin type 
9 (PCSK9) gene (8). LDLR mutations can be classified as mutations with residual 
LDLR function (LDLR-defective mutations) or without LDLR function (LDLR-negative 
mutations) (9).
In patients who are homozygous for FH, the prevalence of AoVC reaches 100% and 
surgical intervention of functional valvular disease is often needed (10,11). Compared 
to homozygous FH, heterozygous FH (he-FH) is associated with less aortic valve 
dysfunction on echocardiography (12-15). However, the prevalence of AoVC in he-FH 
is unknown. 
The purpose of this single-centre study was to determine the prevalence and extent 
of AoVC in asymptomatic statin-treated patients, heterozygous for FH. In addition, we 
evaluated which variables were associated with the presence and extent of AoVC. In the 
molecular context of the patients, we compared AoVC between he-FH patients with 
and without LDLR-negative mutations.
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MeTHOdS
Study population
Between February 2008 and June 2011 we included 145 consecutive patients with 
he-FH. Additionally, between November 2006 and January 2011 we included 131 
consecutive patients with non-anginal chest pain (NACP) as a control group. Patients 
with NACP were used as a substitute for asymptomatic patients without he-FH because 
the radiation exposure limits the choice of controls to patients with an indication for 
cardiac computed tomography (CT). 
NACP patients were referred by their general practitioner for the evaluation of chest 
pain and underwent stress testing and cardiac CT. They did not have a history of coronary 
artery disease (CAD). NACP was defined as chest pain or discomfort that was not 1) 
provoked by exertion or emotional stress, or 2) relieved by rest or nitroglycerin(16).
He-FH patients were recruited from our tertiary outpatient lipid clinic. He-FH was 
determined either by the presence of a confirmed LDLR or APO-B gene mutation (the 
patients did not have PCSK-9 mutations), or clinically as having a untreated LDL-C 
above the 95th percentile for gender and age in combination with at least one of the 
following: the presence of typical tendon xanthomas in the patient or a first degree 
relative; an LDL-cholesterol level above the 95th percentile for gender and age in a first 
degree relative; proven CAD in a first degree relative under the age of 60 (17). 
DNA samples were taken of all patients with a clinical suspicion of he-FH and were 
sent to a central laboratory for mutational screening (18). A complete overview of the 
mutations found and clinical characteristics of both LDLR-negative and LDLR-defective 
he-FH has been previously published (19). Plasma lipid levels were measured on fasting 
blood samples at time of inclusion. Cholesterol levels before statin treatment were 
obtained from patient medical records, and used as the variable maximum untreated 
total cholesterol, and untreated maximum LDL cholesterol (maxLDL).
Exclusion criteria were: symptoms of CAD, history of CAD, rheumatic fever or known 
aortic valve pathology, although cardiac ultrasounds were not routinely performed prior 
to inclusion. Patients with a secondary cause of hypercholesterolemia such as renal, 
liver or thyroid disease were also excluded from the study. Further exclusion criteria 
were renal insufficiency (serum creatinine > 120 unmold/L), known contrast allergy and 
irregular heart rhythm (atrial fibrillation). In asymptomatic he-FH patients, the inclusion 
age was 40-70 years for men. Women were included after childbearing age (45-70 years) 
because of potential radiation-induced harm to the fetus or ovaries. 
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This study complies with the Declaration of Helsinki, the institution’s human research 
committee approved the study protocol and all patients gave written informed consent. 
CT calcium score
To quantify the AoVC, as well as the coronary calcium score, a cardiac CT scan without 
contrast medium was performed, which enabled calcium scoring at high accuracy and 
reproducibility (20,21). All CT scans were performed on a dual source CT scanner (first 
232 scans: Somatom Definition, last 44 scans: Somatom Definition FLASH, Siemens 
Medical Solutions, Forchheim, Germany), with application of a prospectively ECG-
triggered scan protocol with a tube current of 76 mAs at 70% of the RR-interval. Images 
were reconstructed with a slice thickness of 3 mm and an increment of 1.5 mm using a 
medium convolution kernel (B35f ). 
Lesions were classified as AoVC if located within the aortic valve leaflets, exclusive 
of the aortic annulus or coronary arteries, and contained 3 or more contiguous pixels 
with an attenuation value of more than 130 Houndsfield units (2,21). The AoVC-score 
was defined as the quantity of AoVC expressed in Agatston units, by the same lesion 
definition as for coronary artery calcium quantification (CAC), using dedicated software 
(MMWP, Siemens Medical Solutions, Forchheim, Germany) (22). The CT reading was 
performed blinded with regard to patient characteristics. The absence of AoVC was 
assigned a score of 0. Additional information about the scan protocol, including the 
quantification of coronary artery calcium (CAC) has been previously published (23).
Contrast-enhanced scans were consulted if the exact location of calcified lesions, in 
the valve or aortic root, were unclear.
Statistical analysis
Categorical variables were expressed as numbers (percent). Normally distributed 
continuous variables were shown as mean (± SD) and skewed variables as median (IQR). 
To determine the differences between he-FH patients and NACP patients we used a 
Pearson Chi-Square test to compare binary variables. Continuous variables with a 
normal distribution were tested with a T-test, and skewed variables were tested with a 
Mann-Whitney-U test. Statistical significance was considered at a two-sided P-value of 
< 0.05.
We compared the prevalence of AoVC and the AoVC-scores between he-FH and NACP 
patients, in relationship to age. Age categories were chosen on the basis of equal patient 
numbers in all groups (N = 92, N = 92 and N = 92). 
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To evaluate which variables were associated with AoVC we used a univariable ordinal 
logistic regression model. Subsequently, we divided the AoVC-score (Agatston units) 
into three groups based on equal distribution of patients in whom AoVC was present: 
1) AoVC-score = 0 (N = 190), 2) AoVC-score of > 0 – 37 (N = 43), and 3) AoVC-score > 
37 (N = 43). Variables associated with AoVC where analyzed in the entire cohort with a 
multivariable ordinal logistic regression model to identify a set of predictors of AoVC. We 
have chosen an ordinal regression model over a linear regression model to investigate 
a dose response relationship between the highly skewed AoVC variable and other 
variables. Correcting skewness by logistically transforming would have been possible 
as well, but we did not like to change the data into an artificial score in 190 persons 
whose Agatston score was 0.  
In addition, the association between the presence of CAC and AoVC was examined for 
he-FH patients and controls. The differences in distributions of AoVC in the presence and 
absence of CAC were analyzed with a Pearson Chi-Square test, and differences between 
the AoVC-score in the presence and absence of CAC with the Mann-Whitney-U test.
Finally, we compared the influence of LDLR-negative, and LDLR-defective mutational 
he-FH on AoVC. Data were analyzed using SPSS (version 22, SPSS, Chicago, USA).
ReSulTS
Baseline characteristics of he-FH patients and controls
Age, systolic blood pressure, and the prevalence of hypertension and diabetes were 
higher in control patients, than in the he-FH group (table 1). He-FH patients had higher 
untreated maxLDL levels, more frequently used statins, and more often reported a 
positive family history for CAD compared to the controls. Gender, body mass index and 
treated cholesterol levels were similar in both groups. 
AoVC in he-FH patients and controls 
AoVC was compared between he-FH patients and controls (table 2). AoVC was more 
prevalent in he-FH patients (41%, N = 59) than in controls (21%, N = 27, P < 0.001), 
irrespective of the age category. Limiting the analysis to patients with AoVC present, the 
AoVC-score (median, IQR) was higher in he-FH patients than in controls: 51 (9 - 117) and 
21 (3 - 49), respectively (P = 0.007). 
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Table 4.1 |  Clinical characteristics
He-FH
(n = 145)
Control
(n = 131)
p-value
General
• Age (years) 52 ± 8 56 ± 9 < 0.001
• Gender (male) 93 (64) 78 (60) 0.432
• Body mass index (kg / m²) 27 ± 4 27 ± 5 0.309
• Smoking (current / former) 41 (28) 45 (35) 0.277
• Hypertension1* 38 (26) 59 (45) 0.001
• Systolic blood pressure (mmHg) 129 ± 7 141 ± 20 < 0.001
• Diastolic blood pressure (mmHg) 80 ± 10 81 ± 12 0.282
• Diabetes Mellitus 6 (4) 17 (13) 0.008
• Positive family history of premature 
coronary artery disease 2*
102 (70) 65 (50) < 0.001
lipids
• Maximum untreated total cholesterol (mmol / L) 9.8 ± 2.3 5.5 ± 1.2 < 0.001
• Maximum untreated LDL cholesterol (mmol / L) 7.1 ± 2.2 3.7 ± 1.1 < 0.001
• Statin use 142 (98) 44 (34) < 0.001
• Total cholesterol (mmol / L) 5.5 ± 1.4 5.3 ± 1.2 0.264
• HDL (mmol / L) 1.4 ± 0.4 1.4 ± 0.4 0.388
• LDL (mmol / L) 3.5 ± 1.3 3.5 ± 1.1 0.980
• Triglyceride (mmol / L)  1.09 (0.80 - 1.65) 1.32 (0.87 - 1.79) 0.107
Values are mean  SD, n (%), or median (interquartile range). 1*Blood pressure >140/90 mm Hg and/or 
antihypertensive treatment. 2*Proven coronary artery disease in first-degree relative aged <60 years.
Control = patients with nonanginal chest pain; HDL = high density lipoprotein; he-FH = heterozygous familial 
hypercholesterolemia; LDL = low-density lipoprotein; LDL-C = low-density lipoprotein cholesterol.
Table 4.2 | Calcification of the aortic valve leaflets
He-FH
(n = 145)
Control
(n = 131)
p-value
AoVC present
AoVC present, per age category: 59 (41%) 27 (21%) < 0.001
• 40 - 50 years 16 (26%) 0 (0%) 0.002
• 51 - 58 years 21 (48%) 8 (17%) 0.001
• 59 - 70 years 22 (56%) 19 (36%) 0.005
AoVC-score 51 (9 - 117) 21 (3 - 49) 0.007
AoVC-score per category: < 0.001
• Agatston = 0 86 (59) 104 (79) -
• Agatston > 0 – 37 24 (17) 19 (15) -
• Agatston > 37 35 (24) 8 (6) -
Continuous data are expressed as median (IQR), dichotomous data as N (%), age categories chosen on the 
basis of equal patient numbers in all groups (N = 92).
He-FH = heterozygous familial hypercholesterolemia, control = patients with non-anginal chest pain. AoVC 
= aortic valve calcification, AoVC-score categories chosen on the basis of equal distribution of patients with 
AoVC (N = 43).
4
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Risk factors for AoVC
Risk factors for AoVC are shown in table 3. The AoVC burden by Agatston score was 
associated with age, untreated maxLDL, LDLR-negative mutational he-FH, CAC and 
diastolic blood pressure. Gender, smoking, hypertension, diabetes mellitus and obesity 
were not associated with the extent of AoVC. 
In the multivariable ordinal regression model, all variables explained 27% of the 
variance of AoVC and all remained significantly associated with AoVC. Among the 
variables, LDLR-negative mutation carrier status was a strong predictor of the extent of 
AoVC (OR: 4.81; 95% CI: 2.22-10.40; p= <0.001). Analyses restricted to the he-FH patients, 
LDLR-defective, and LDLR-negative had similar results (data not shown).
Association between coronary and aortic valve calcification  
The presence of CAC was associated with a higher prevalence of AoVC, both in he-FH 
and control patients (table 4). Of the patients without CAC, no more than 4% showed 
AoVC. However, in the absence of AoVC, still more than 39% of patients exhibited CAC. 
Aortic valve calcification and LDL receptor mutational status
Out of 145 he-FH patients, fifty-nine patients (41%) had an LDLR-negative mutation. 
Compared to he-FH patients with LDLR-defective mutations, LDLR-negative mutational 
he-FH was associated with: higher total cholesterol (5.8 ± 1.6 and 5.3 ± 1.3 mmol/L, 
p=0.026), LDL-C (3.9 ± 1.4 and 3.2 ±1.1 mmol/L, p=0.002) and untreated maxLDL (8.0 
± 2.5 and 6.6 ± 1.7 mmol/L, p= <0.001). In addition, he-FH patients with LDLR-negative 
mutations were younger (51 ± 7 and 53 ± 8 years, p=0.040), started using statins at 
younger age (40 ± 9.8 and 46 ± 9.4 years, p=<0.001), and used statins for a longer period 
of time (10. ± 7 and 7 ± 7 years, p=0.010). All other variables from table 1 were not 
statistically different between groups. 
He-FH patients with LDLR-negative mutations had higher prevalence of AoVC (31 
(53%)) as compared to LDLR-defective mutations (28 (33%); p< 0.001) and controls 
(27 (21%); p = 0.016). The difference in AoVC prevalence between LDLR-defective 
mutational he-FH and the controls was also significant (p = 0.048). Additionally, AoVC-
scores increase faster with age in LDLR-negative he-FH than in LDLR-defective he-FH 
(data not shown). 
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Table 4.3 |  Predictive value of risk factors for AoVC-score.
n = 276 univariable ordinal regression 
in the entire cohort
Multivariable ordinal regression 
in the entie cohort†
 Proportional 
Odds §
95 % CI  p-Value Proportional 
Odds §
95 % CI  p-Value
LDLR-negative 
mutation
3.87 2.19-6.84 < 0.001 4.81 2.22-10.40 < 0.001
Age (Years) 1.07 1.04-1.11 < 0.001 1.12 1.08-1.16 < 0.001
Sex (Male) 1.40 0.83-2.37 0.212     
BMI 1.05 0.99-1.11 0.106     
Smoking (Current/ 
Former)
1.24 0.73-2.11 0.433     
Hypertension ‡ 0.84 0.58-3.32 0.518     
Diabetes Mellitus 0.72 0.30-1.70 0.452     
Maximum Untreat-
ed Cholesterol
1.33 1.21-1.46 < 0.001     
Maximum Untreat-
ed LDL Cholesterol
1.26 1.13-1.39 < 0.001 1.18 1.03-1.34  0.01
Treated Total Cho-
lesterol
1.09 0.90-1.31 0.373     
HDL 1.02 0.54-1.95 0.943     
LDL 1.10 0.90-1.36 0.349     
TG 0.98 0.81-1.19 0.842     
Systolic Blood 
Pressure
1.01 0.99-1.03 0.065     
Diastolic Blood 
Pressure
1.03 1.00-1.05 0.031 1.04 1.01-1.07  0.01
CAC (per 100 
Agatston Units 
Increase)
1.26 1.16-1.36 < 0.001     
CAC (Present) 6.97 3.18-15.29 < 0.001     
Agatston units: group 1 (AoVC score ¼ 0), group 2 (AoVC score >0 to 37), and group 3 (AoVC score >37). †= No 
significant interaction between the presence of AoVC and other risk factors. § = Because 3 ranked categories 
(3 AoVC groups) are being analyzed, the proportional odds variable is a relative risk that is calculated with 
an ordinal logistic regression analysis. This model predicts how much an increase in the explanatory variable 
leads to an increase of probability in the higher AoVC group. 
‡ = Blood pressure >140/90 mm Hg and/or antihypertensive treatment. BMI = body mass index; CAC = 
coronary artery calcification (Agatston units); CI = confidence interval; LDLR = low-density lipoprotein 
receptor; other abbreviations as in Tables 1 and 2.
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Table 4.4 | Association between the presence of CAC and AoVC for FH patients and controls.
CAC present CAC absent p-value
He-FH (n = 145)
• AoVC present 56 (39%) 3 (2%) < 0.001
• AoVC absent 61 (42%) 25 (17%)
• AoVC-score 55 (13 - 125) 3 (0 - 3) 0.019
Control (n = 131)
• AoVC present 22 (17%) 5 (4%) 0.002
• AoVC absent 51 (39%) 53 (40%)
• AoVC-score * 15 (2 - 44) 24 (10 - 98) 0.257
∗ Median AoVC-score of patients with AoVC present in Agatston units.
Continuous data are expressed as median (interquartile range), AoVC = aortic valve calcification, 
CAC = coronary artery calcification (Agatston units), FH = familial hypercholesterolemia. He- FH 
= heterozygous familial hypercholesterolemia, control = patient with non-anginal chest pain. 
dISCuSSIOn
The main findings of this study can be summarized as: 1) the prevalence and extent of 
AoVC was higher in he-FH patients than in the non-familial hypercholesterolemia; 2) 
age, untreated maxLDL, LDLR-negative mutational he-FH and diastolic blood pressure 
were positively associated with AoVC; 3) the level of treated LDL-C was not predictive 
of the prevalence and extent of AoVC; and 4) the absence of CAC was associated with a 
low prevalence of AoVC.
In a recent study by Smith et al., using Mendelian randomization, it has been shown 
that a genetic predisposition to elevated LDL-C was associated with the presence of 
AoVC and the incidence of functional aortic stenosis in large community based cohorts 
(24). The authors concluded that their results provided evidence supportive of a causal 
association between LDL-C and aortic valve disease. We also performed a Mendelian 
randomization approach, which is a combination of 1): An association of the genetic 
background (the LDL-receptor mutation), with the intermediate trait (untreated maxLDL) 
and the outcome parameter (AoVC); and 2): An association between the intermediate 
trait (untreated maxLDL) and outcome parameter (AoVC), corrected for confounding by 
multiple regression analysis. This Mendelian randomization approach mimics a RCT on 
a genetic level, and suggests a causal role of LDL-C in beginning aortic-valve pathology. 
In our study, he-FH patients were exposed to extremely high levels of LDL prior to 
statin treatment, especially those with LDLR-negative mutational he-FH. This could have 
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caused the higher prevalence and quantity of AoVC that we found in he-FH patients, and 
particularly those with LDLR-negative mutations. Since the moment of being diagnosed 
with hypercholesterolemia patients have been treated with statins, which dramatically 
lowered LDL-C levels, and thereby reduced the predictive value  of LDL-C towards AoVC. 
This could explain why untreated maxLDL and LDLR-negative mutational he-FH were, 
and the level of statin treated LDL-C was not predictive of AoVC in our study. 
Diastolic blood pressure was mildly but significantly associated with AoVC in our 
overall normotensive subjects. One might speculate that the increased diastolic blood 
pressure promotes stress on the aortic side of the valve leaflets, which is where aortic 
valve lesions are most commonly found (25). This increased stress on the aortic valve 
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In this study, 145 asymptomatic patients with heterozygous familial hypercholesterolemia (he-FH) and 131 nonfamilial hypercholesterolemia control
subjects underwent computed tomography calcium scoring of the aortic valve. Severity of aortic valve calci cation (AoVC) per group is shown in the
pie charts, and the bar graph illustrates the untreated low-density lipoprotein (LDL-C) levels for the groups. LDLR ¼ low-density lipoprotein receptor;
MaxLDL ¼ untreated maximum low-density lipoprotein cholesterol.
 LDLR-Defective Control
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can lead to tissue remodelling and promote inflammation, leading to calcification, 
stenosis, and ultimately valve failure (26).
Messika-Zeitoun et al. investigated determinants and progression of AoVC in a 
population based follow-up study, using electron-beam-CT. De novo AoVC was found 
to be associated with elevated LDL-C levels, whereas established AoVC progressed 
independently of atherosclerotic risk factors and faster with increasing initial extent of 
AoVC (27). This led to the hypothesis that elevated levels of LDL-C have their atherogenic 
effect during the early phase of AoVC, before the start of statin treatment. 
As shown in the results section, patients with LDLR-negative mutational he-FH started 
using statins at younger age and used statins for a longer period of time. However, 
despite their more intense statin treatment, these patients showed a higher prevalence 
of AoVC, which more rapidly increased with age. To investigate the effect of statin 
treatment on AoVC in our cohort of he-FH patients of whom we knew were exposed to 
high levels of LDL-C early in life, we included “duration of statin use” in a multivariable 
ordinal regression model. Duration of statin use was however not associated with 
AoVC after correction for age, untreated maxLDL, LDLR-negative mutational he-FH and 
diastolic blood pressure. All other variables remained statistically significant (data not 
shown). 
In addition, three major prospective randomized trials could not demonstrate any 
impact of lipid lowering therapy on the rate of progression of AoVC (28-30). However, 
macrophage and osteoclast infiltration of the AoVC were reduced by atorvastatin in 
cholesterol fed mice (31). Apparently, other pathogenic risk mechanisms prevail once 
AoVC has been established. It is known that during the later stages of calcific aortic 
stenosis, a process of osteoblastic activity prevails over the initial atherosclerotic process, 
resulting in progressive calcification of the valve that seems unrelated to LDL-C levels or 
statin treatment and fits the observed independence of AoVC from lipid profile or statin 
treatment. The extensive AoVC in our young study population suggest that statins have 
their main effect in preventing aortic valve pathology prior to the development of aortic 
valve stenosis. The three prospective randomized trials were restricted to patients with 
beginning aortic valve pathology in whom statins could not exert a preventive effect 
anymore. Even though the exact role of serum lipids in the pathogenesis of aortic valve 
disease is unknown, it is evident that lipid depositions are found within and in proximity 
to aortic valve lesion which is not the case in healthy valve leaflets (25). This suggests a 
critical role for lipids in the early onset of aortic valve pathology. 
The concept of two different phases in the development of AoVC progression is not 
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only essential in comprehending the effect of statin treatment, but could also explain 
the discordant association between AoVC and CAC. As shown in table 4, the absence of 
CAC was associated with very low prevalence of AoVC. However, the absence of AoVC 
was not predictive of the absence of CAC. Perhaps, during the early phase of AoVC, 
risk factors for CAC are preconditions for the development of AoVC. However, if AoVC 
develops after the initial atherosclerotic phase, its progression seems to be regulated by 
risk factors that differ from those causing CAC (27,33). 
We found that the prevalence and extent of subclinical AoVC is clearly increased in 
he-FH patients, especially in patients carrying LDLR-negative mutations. It should be 
emphasized that AoVC is generally without symptoms, and only a fraction of patients 
with AoVC ultimately develop clinical aortic stenosis. The reported prevalence of 
hemodynamically significant aortic valve stenosis on echocardiography is low in he-FH 
(15). Since statin therapy became available, the risk of cardiovascular disease mortality 
has been substantially reduced in he-FH patients (35). 
Detection and treatment of he-FH patients at young age may not only slow 
progression of CAD but also could be effective to prevent or slow the development 
of AoVC during the early phase of disease. This underlines the clinical importance of 
studies on the effectiveness of statin use for the primary prevention of AoVC, especially 
in patients with LDLR-negative mutational he-FH. 
Study limitations
This study is a cross-sectional observation of AoVC in patients aged between 40 and 
70 years, without clinical outcome data, and without functional assessment of stenosis 
with echocardiography. The cross-sectional design of our study did not allow for proper 
evaluation of the effects of statins on AoVC, which would require a prospective study 
and sequential imaging. Additionally, we do not have sufficient follow-up in our cohort 
to assess the clinical consequences of the observed AoVC, which a limitation of the 
observational design of the present study.
 Only asymptomatic patients were selected and it remains to be seen if patients with 
AoVC will eventually develop clinical aortic valve disease, since the majority of AoVC will 
not lead to aortic stenosis (36).  
The current selection of he-FH patients, who were referred to our university lipid clinic, 
may have more severe AoVC as compared to he-FH patients in the general population. 
This single center study from a tertiary hospital could have resulted in overestimation of 
the total prevalence and extent of AoVC. However, this potential selection bias should 
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equally hold for LDLR-negative and LDLR-defective mutations.  
We have analyzed patients with a major locus effect in the cholesterol metabolism, 
but we cannot exclude contributions from variants of other genes, like NOTCH1 (37,38). 
Especially calcified bicuspid aortic valves have very high heritability. Bicuspid aortic 
valves have an estimated prevalence of 1-2%. The linkage peaks of aortic stenosis and 
the NOTCH1 gene have not been found on chromosome 19 on which the LDL receptor 
is located (19p13.2). Without co-segregation with the mutations in the LDL receptor, it is 
unlikely that our cohort was enriched with variants of these other genes.
Recent studies on coronary atherosclerosis showed that the calcified plaque 
component increased after long-term statin therapy (39,40). In our study, patients with 
he-FH and particularly patients with LDLR-negative mutations, received higher dosages 
of statins for longer periods of time and statin use could therefore be a more complex 
confounder in our analyses. However, in our multivariable ordinal regression model, the 
time of statin treatment was not significantly associated with AoVC in he-FH patients. 
As compared to the general population, we did not find male gender to be a risk 
modifier of AoVC. This is likely caused by the relatively small size of our study as 
compared to the large population based Heinz Nixdorf Recall Study or the Multi-Ethnic 
Study of Atherosclerosis (2,5,27). 
COnCluSIOn
We found that: he-FH is associated with a high prevalence and a large extent of 
subclinical AoVC; age, diastolic blood pressure, untreated maxLDL, and LDLR-negative 
mutations were associated with the extent of AoVC; the difference between LDLR-
negative and defective mutations provides important evidence for the critical role of 
LDL-C metabolism for the pathogenesis of AoVC and; the absence of CAC was associated 
with low prevalence of AoVC suggesting shared pathophysiological determinants. 
Worldwide, the majority of he-FH patients, who have been treated with statins for a 
substantial period of their life, are still too young to express valve diseases. However, 
due to the prolonging survival in these patients, because of statin treatment, our results 
suggest that aortic valve pathology will be a common problem in aging he-FH patients, 
especially in those with LDLR-negative mutations.
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PeRSPeCTIVeS
Clinical Competency:
This is the first study that shows a high prevalence and extent of aortic valve calcification 
in he-FH patients. With the prolonging survival in these patients due to statin treatment, 
and its lacking effect in halting the progression of AoVC, our study results suggest that 
aortic valve pathology will be a common problem in the aging he-FH patient. 
Translational Outlook:
The mechanism by which LDL-C initiates AoVC requires furthers investigation.
Translational Outlook 2:
Prospective imaging studies of aging he-FH patients are needed to elucidate the clinical 
outcome of aortic valve pathologies in these patients.    
4
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465|Rebuttal AoVC in FH
Calcific aortic valve disease (CAVD) is the most common indication worldwide for valve 
intervention. For years, the mechanism for this calcification was thought to be due to 
a passive degenerative process. However, in the 21st century, the National Heart, Lung, 
and Blood Institute of the National Institutes of Health recognized that CAVD is an active 
biologic osteogenic process (1). Initiation of osteogenesis in the aortic valve depends 
on risk factors similar to those known to promote coronary artery disease, which cause 
myofibroblasts to differentiate via an osteogenic gene activation that results in valve 
calcification (1,2).
In this issue of the Journal, a study from the Netherlands by ten Kate et al. (3) tested 
the prevalence, extent, and risk modifiers of CAVD in patients with heterozygous familial 
hypercholesterolemia (he-FH). Clinically, the he-FH phenotype is encountered more 
often than the homozygous phenotype due to rapid progression of coronary artery 
disease in the homozygous patient population. The investigators therefore sought to 
determine the prevalence of CAVD in patients with he-FH by measuring the amount of 
calcification burden via computed tomography measurements of the coronary artery 
and aortic valve, low-density lipoprotein receptor (LDLR) function, and lipid levels and 
assessing their association with CAVD.
LDL Receptor Density
The investigators discovered that the prevalence of aortic valve calcification (AoVC) and 
the AoVC score (median [interquartile range]) were both higher in patients with he-FH 
than in control subjects: 41% versus 21%, respectively (p < 0.001) and 51 (9 to 117) 
versus 21 (3 to 49) (p = 0.007) (3). LDLR-negative mutational he-FH was the strongest 
predictor of the AoVC score (odds ratio: 4.81; 95% confidence interval: 2.22 to 10.40; p < 
0.001). He-FH was associated with a high prevalence and a large extent of subclinical 
AoVC, especially in patients with LDLR-negative mutations, compared with the control 
subjects. Moreover, the AoVC scores increased faster with age in the LDLR-negative he-
FH patients than in the LDLR-defective he-FH patients.
Calcification Density
The LDLR-negative mutation carrier status was a strong predictor of the extent of 
AoVC (3). The association between coronary artery calcification and AoVC was associated 
with a higher prevalence of AoVC, both in patients with he-FH and in control subjects. 
The authors hypothesized that the high level of coronary artery calcification may be due 
to confounding variables such as differences in statin therapy in the he-FH population 
4
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versus the control population. The concept of 2 different phases of AoVC progression is 
not only essential but could explain the discordant findings. The National Heart, Lung, 
and Blood Institute Aortic Stenosis Working Group for CAVD (1) also emphasized this 
concept in early valve sclerosis versus late valve stenosis.
Lipid Density
Compared with he-FH patients with LDLR-defective mutations, patients with LDLR-
negative mutational he-FH had higher levels of total cholesterol and maximum untreated 
low-density lipoprotein cholesterol (3). In addition, he-FH patients with LDLR-negative 
mutations began statin treatment at a younger age and used statins for a longer period 
of time. Figure 1 illustrates the results of the study in patients with he-FH, including the 
effect of functional low-density lipoprotein (LDL) receptors and proportional increases 
in LDL with the degree of AoVC.
Figure 1 |  The LDL-Density-Gene Effect
(A) The control heart with the normal low-density lipoprotein receptor (LDLR). 
(B) Heterozygous familial hypercholesterolemia–defective receptor mutation and mild calcific aortic valve 
disease. 
(C) Heterozygous familial hypercholesterolemia–negative receptor mutation and severe calcific aortic 
valve disease. + = a semi-quantitative measurement of approximately 10% effect; AoVC = aortic valve 
calcification; density = concentration; CAC = coronary artery calcification; LDL = low-density lipoprotein.
To the best of our knowledge, this study by ten Kate et al. (3) is the first to correlate 
in patients the role of LDL and the effect of the LDL receptor genetic contribution in 
terms of phenotypic expression of calcification in the valve and in the coronary arteries. 
The LDL-density theories (4–6) provide a hemodynamic explanation for why abnormal 
calcification develops secondary to high LDL density concentration up-regulating 
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osteogenesis. The effect of fluid flow in the heart is responsible for the variable 
phenotype expression, depending on the radius of the specific anatomic location in the 
heart (i.e., artery vs. valve).
Fluid hemodynamics in the heart depends on multiple factors, as derived by the 
Bernoulli equation for fluid flow (7). Bernoulli described flow through a column as 
being directly proportional to the change in pressure across the column and indirectly 
proportional to the resistance. The formula for flow through the heart is similar to Ohm’s 
law for electricity, as shown in Equation 1.
Equation 1Q=ΔPR
The entire formula for resistance for steady-state flow through a circular tube is shown 
in Equation 2, where η = viscosity and r = radius of the tube.
Equation 2R=8ηLπr4
Equations 1 and 2 can be combined to provide the flow rate through a circular tube in 
terms of a pressure drop, which is described as Poiseuille’s law:
Equation 3Q=πr48ηLΔP
The differences in the rate of fluid flow depend on the radius of the anatomic structure, 
which is inversely proportional to the resistance. In addition, it is important to note the 
inverse r4dependence of the resistance to fluid flow. If the radius of the tube is halved, the 
pressure drop for a given flow rate and viscosity is increased by a factor of 16, because the 
flow rate is then proportional to the fourth power of the radius. The LDL-Density-Radius 
Theory (4) and the LDL-Density-Pressure Theory (5) provide the molecular hypothesis of 
the role of lipids in the differentiation of valve myofibroblasts into osteoblast-like cells 
responsible for the calcifying phenotype. Expression of the calcification in the coronary 
artery (8) occurs at a faster rate than the aortic valve secondary to the effect of the radius 
in these 2 anatomic locations in the heart.
The present study (3) measured the level of calcification, and the results correlate the 
LDL concentration, LDL receptor gene expression, and finally a Mendelian randomization 
analysis to suggest a causal role of LDL-C in beginning aortic valve pathology. The first 
case report to demonstrate by histology the presence of atherosclerosis in the aortic 
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valve is in a post-mortem analysis of a patient’s aortic valve who had the diagnosis of 
familial hypercholesterolemia (9).
If atherosclerosis is an initiating event in this patient population, would lipid-lowering 
strategies be effective for the slowing of disease progression? In the present study (3), 
patients with he-FH were exposed to extremely high levels of LDL before statin treatment, 
especially those with mutational he-FH. Since these patients were first diagnosed with 
hypercholesterolemia, they have been treated with statins; this approach dramatically 
lowered LDL-C levels and thereby reduced the predictive value of LDL-C toward 
AoVC. The authors (3) proposed that the benefits of the statins are for patients who 
received the statins early in the atherosclerotic process (9), before the development of 
calcification and eventually severe stenosis. Furthermore, they hypothesized that the 
results of randomized controlled trials (6) that tested the effect of statins in CAVD may 
be due to the initiation of treatment in patients with advanced calcific disease.
In conclusion, the present study (3) is the first to combine biochemical analysis with 
genetic LDL receptor function and the calcifying phenotype in the heart. The study 
further confirms the hypothesis regarding the possible modification and slowing of 
CAVD progression with the use of long-term lipid lowering if the therapy is initiated in 
the early stages of pre-clinical CAVD, the atherosclerotic phase (9).
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ABSTRACT
Objectives
Lipoprotein(a) [Lp(a)] is an independent risk factor for aortic valve stenosis and aortic 
valve calcification (AVC) in the general population. In this study, we determined 
the association between AVC and both plasma Lp(a) levels and apolipoprotein( a) 
[apo(a)] kringle IV repeat polymorphisms in asymptomatic statin-treated patients with 
heterozygous familial hypercholesterolaemia (FH).  
Methods
A total of 129 asymptomatic heterozygous FH patients (age 40–69 years) were included in 
this study. AVC was detected using computed tomography scanning. Lp(a) concentration 
and apo(a) kringle IV repeat number were measured using immunoturbidimetry and 
immunoblotting, respectively. Univariate and multivariate logistic regression were used 
to assess the association between Lp(a) concentration and the presence of AVC.  
Results
Aortic valve calcification was present in 38.2% of patients, including three with extensive 
AVC (>400 Agatston units). Lp(a) concentration was significantly correlated with gender, 
number of apo(a) kringle IV repeats and the presence and severity of AVC, but not with 
coronary artery calcification (CAC). AVC was significantly associated with plasma Lp(a) 
level, age, body mass index, blood pressure, duration of statin use, cholesterolyear 
score and CAC score. After adjustment for all significant covariables, plasma Lp(a) 
concentration remained a significant predictor of AVC, with an odds ratio per 10-mg dL1 
increase in Lp(a) concentration of 1.11 (95% confidence interval 1.01– 1.20, P = 0.03).  
Conclusion
In asymptomatic statin-treated FH patients, plasma Lp(a) concentration is an 
independent risk indicator for AVC.  
Keywords
• aortic valve calcification, asymptomatic
• coronary artery calcification
• familial hypercholesterolaemia
• lipoprotein(a)
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InTROduCTIOn
Aortic valve calcification (AVC), characterized by calcium deposition and thickening of 
the aortic valve, is a significant risk factor for aortic valve stenosis and cardiovascular 
disease (CVD). AVC prevalence in the elderly population (> 75 years old) is approximately 
50% and 25% of them develop aortic valve stenosis [1]. AVC prevalence and severity 
are associated with coronary artery disease (CAD) [2], all-cause mortality [3] and 
aortic stenosis [4]. AVC shares several risk factors with atherosclerosis including age, 
male gender, dyslipidemia, smoking, hypertension, diabetes and obesity [5]. In 
heterozygous familial hypercholesterolemia (FH) patients, the onset and progression 
of valvular calcification are not completely explained by the above-mentioned risk 
factors, particularly not in statin-treated FH patients, whose low density lipoprotein 
(LDL)-cholesterol levels are markedly reduced, compared to the untreated condition. 
Additional risk factors for valvular calcification in these patients remain to be identified.
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MATeRIAlS And MeTHOdS
Study population
Between February 2008 and June 2011, 145 patients with a diagnosis of FH were 
recruited from the outpatient clinic, Erasmus Medical Center, Rotterdam, The 
Netherlands. As previously described [17], the inclusion criteria for FH were: either 
patients with a documented LDL receptor mutation or patients with LDL-cholesterol > 
95th percentile for gender and age in combination with either 1) the presence of typical 
tendon xanthomas in the patient or in a 1st degree relative or 2) LDL-cholesterol > 
95th percentile for gender and age in a 1st degree relative or 3) proven coronary artery 
disease in a 1st degree relative under age of 60. Patients with previous symptomatic 
CVD or with symptoms suggestive of ischemic heart disease at the time of inclusion 
were excluded from the study. All participants provided written informed consent prior 
to inclusion (Reference number MEC 2007-183). Of 129 FH patients, plasma samples 
were available for Lp(a) measurement; these patients were included in this study.
Computed tomographic scanning and calcification score measurement
All computed tomographic (CT) scannings were performed using a dual-source CT 
scanner (Somatom Definition, Siemens Medical Solutions, Forchheim, Germany). AVC 
and coronary artery calcification (CAC) were determined as previously described [17]. 
The calcium scores were calculated and expressed as Agatston Units (AU) as previously 
described [18]. An AU score of more than 400 was regarded as an extensive calcification 
[19]. 
Lp(a) measurement 
Venous blood samples were collected after an overnight fast. After centrifugation, 
plasma samples and buffy coats were collected and stored at -80oC until analysis. 
Lipid parameters were measured by standard laboratory techniques. Plasma Lp(a) 
concentrations were measured using a  particle enhanced immunoturbidimetric assay, 
independently of apo(a) KIV repeats (Diagnostic System #171399910930) [20]. In the 
samples with low Lp(a) concentration, Lp(a) levels were determined using an enzyme-
linked immunosorbent assay (ELISA) [21] that has a markedly lower detection limit.
Detection of apolipoprotein(a) KIV repeats
The number of apo(a) KIV repeats was determined by immunoblotting, using a volume 
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of plasma containing 30 ng apo(a) protein. Plasma samples were mixed with SDS gel-
loading buffer and heated at 98oC for 5 minutes. Gel electrophoresis was performed 
under a reducing condition with SDS and a 1.75% agarose gel. Proteins were then 
transferred to a PVDF membrane (Millipore) using a semi-dry blotting system (Millipore 
Graphite Electroblotter II) at 13 V for 1 hour. The membrane was subsequently incubated 
with blocking buffer containing 1% Bovine Serum Albumin (BSA) for 1 hour at 38oC 
to reduce non-specific binding. Primary antibody incubation was performed using 
monoclonal antibody 1A2 against apo(a) KIV [22], followed by incubation with goat 
anti-mouse IgG antibody coupled to Horseradish peroxidase (HRP) (Pierce, 1:3000). 
Enhanced chemiluminescence (ECL) and visualization on film were used for detection. 
A mixture of human plasma samples with 5 isoforms of known number of apo(a) KIV 
repeats was used as reference material. 
Statistical analysis
Data are presented as mean + standard deviation or median (Interquartile range, IQR) for 
continuous variables and as number (%) for categorical variables. Mann-Whitney U and 
Fisher’s exact tests were performed to analyze the differences between 2 continuous 
and categorical parameters, respectively. The presence of AVC or CAC was defined as 
AVC or CAC score of more than 0 AU. The severity of AVC or CAC was expressed by the AU 
score as continuous variables. Apo(a) phenotypes were categorized into 2 groups: low 
molecular weight (LMW) apo(a) (KIV < 22 repeats) and high molecular weight (HMW) 
apo(a) (KIV > 22 repeats). When 2 apo(a) isoforms were detected in the immunoblot, 
the smaller isoform was used for categorization as discussed recently [6]. Hypertension 
was defined as a systolic blood pressure (SBP) above 140 mm Hg or a diastolic blood 
pressure (DBP) above 90 mm Hg or those who were receiving antihypertensive therapy 
at the time of inclusion. Cholesterol-year score, a measurement of life-long cholesterol 
burden, was calculated using the formula (untreated total cholesterol x years without 
statins) + (statin-treated total cholesterol x years with statins) [23]. Correlations between 
Lp(a) concentrations and other variables were determined using Spearman correlation 
test. In order to account for different levels of CAC score, regression models were fitted on 
Lp(a) concentration, the presence and the severity of AVC separately, using CAC score as 
an independent variable. Subsequently, the residuals were used to calculate Spearman 
correlation coefficient (r).  Significant predictors for the presence of AVC (AVC score > 
0) were identified using univariate logistic regression analysis. The variables entered to 
the model were classical risk factors for CVD or parameters previously suggested [24]. 
5
75|Lp(a) and AoVC in FH
of plasma containing 30 ng apo(a) protein. Plasma samples were mixed with SDS gel-
loading buffer and heated at 98oC for 5 minutes. Gel electrophoresis was performed 
under a reducing condition with SDS and a 1.75% agarose gel. Proteins were then 
transferred to a PVDF membrane (Millipore) using a semi-dry blotting system (Millipore 
Graphite Electroblotter II) at 13 V for 1 hour. The membrane was subsequently incubated 
with blocking buffer containing 1% Bovine Serum Albumin (BSA) for 1 hour at 38oC 
to reduce non-specific binding. Primary antibody incubation was performed using 
monoclonal antibody 1A2 against apo(a) KIV [22], followed by incubation with goat 
anti-mouse IgG antibody coupled to Horseradish peroxidase (HRP) (Pierce, 1:3000). 
Enhanced chemiluminescence (ECL) and visualization on film were used for detection. 
A mixture of human plasma samples with 5 isoforms of known number of apo(a) KIV 
repeats was used as reference material. 
Statistical analysis
Data are presented as mean + standard deviation or median (Interquartile range, IQR) for 
continuous variables and as number (%) for categorical variables. Mann-Whitney U and 
Fisher’s exact tests were performed to analyze the differences between 2 continuous 
and categorical parameters, respectively. The presence of AVC or CAC was defined as 
AVC or CAC score of more than 0 AU. The severity of AVC or CAC was expressed by the AU 
score as continuous variables. Apo(a) phenotypes were categorized into 2 groups: low 
molecular weight (LMW) apo(a) (KIV < 22 repeats) and high molecular weight (HMW) 
apo(a) (KIV > 22 repeats). When 2 apo(a) isoforms were detected in the immunoblot, 
the smaller isoform was used for categorization as discussed recently [6]. Hypertension 
was defined as a systolic blood pressure (SBP) above 140 mm Hg or a diastolic blood 
pressure (DBP) above 90 mm Hg or those who were receiving antihypertensive therapy 
at the time of inclusion. Cholesterol-year score, a measurement of life-long cholesterol 
burden, was calculated using the formula (untreated total cholesterol x years without 
statins) + (statin-treated total cholesterol x years with statins) [23]. Correlations between 
Lp(a) concentrations and other variables were determined using Spearman correlation 
test. In order to account for different levels of CAC score, regression models were fitted on 
Lp(a) concentration, the presence and the severity of AVC separately, using CAC score as 
an independent variable. Subsequently, the residuals were used to calculate Spearman 
correlation coefficient (r).  Significant predictors for the presence of AVC (AVC score > 
0) were identified using univariate logistic regression analysis. The variables entered to 
the model were classical risk factors for CVD or parameters previously suggested [24]. 
        
76 |      Chapter 5
The independent association of Lp(a) concentrations with AVC was further investigated 
using multivariate logistic regression analysis with increasing numbers of significant 
AVC predictors from the univariate analysis. All data were analyzed using IBM SPSS v 
21.0 software. Results were considered statistically significant at p < 0.05.
ReSulTS
Characteristics of study population
The general characteristics of the study population are presented in table 1. The 
population consisted of 81 men and 48 women. The median age was 51 years (IQR = 46-
59) (range from 40-69 years). The majority of patients (97.7%) was treated with statins. 
The median duration of statin-use was 7 years (IQR = 2-14) (range from 0-30 year). Data 
on calcification scores were available for all participants. A total of 50 patients (39.8%) 
had developed AVC, of which 3 (2.3%) patients had extensive calcification of more than 
400 AU. Prevalence of CAC was 79.1% with 28 patients having developed extensive CAC. 
No bicuspid aortic valves were identified.
Plasma Lp(a) concentration and apo(a) KIV isoforms 
The median plasma Lp(a) concentration was 26.7 mg/dL, ranging from 0.5 to 419.8 mg/
dL (IQR = 8.1-63.9 ). Plasma Lp(a) levels were significantly higher in patients with AVC 
than in those without (43.4(10.6-105.0) vs. 24.5(5.5-49.1) mg/dL, p = 0.02). Thirty six 
(27.9%) patients had one or two isoforms of LMW apo(a) and 90 (69.8%) patients had 
only HMW apo(a) isoforms. We were unable to measure the apo(a) KIV repeat number 
of the other 3 patients. Therefore, the frequency of the LMW apo(a) phenotypes in the 
population was 0.29. The frequency of LMW apo(a) phenotypes was not significantly 
different between patients with and without AVC (31% vs. 27%, p = 0.68). As expected, 
patients with LMW apo(a) phenotypes had higher plasma Lp(a) concentrations than 
those with HMW apo(a) (91.5(26.6-129.8) vs. 18.0(4.2-41.2) mg/dL, p < 0.001). In addition, 
the number of apo(a) KIV repeats was inversely correlated with Lp(a) concentrations (r = 
-0.57, p < 0.001). Lp(a) concentrations positively correlated with both the presence (r = 
0.21, p = 0.02) and the severity (r = 0.19, p = 0.04) of AVC.
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Table 5.1 | General characteristics of the study population
n 129
Male (n, %) 81 (62.8%)
Age (y) 51 (46-59)
Systolic blood pressure (mmHg) 129+12
Diastolic blood pressure (mmHg) 80+8
BMI (kg/m2) 26.3+3.7
Total cholesterol (mmol/L) 5.47+1.41
LDL-cholesterol (mmol/L) 3.49+1.24
HDL-cholesterol (mmol/L) 1.38+0.37
Triglyceride (mmol/L) 1.05 (0.78-1.55)
Fasting blood sugar (mmol/L) 5.31+0.69
Lipoprotein(a) (mg/dL) 26.7 (8.1-63.9)
Statin medication (n, %) 126 (97.7%)
Duration of statin use (y) 7 (2-14)
Previous and current smoker (n, %) 33 (25.6%)
Hypertension (n, %)* 34 (26.4%)
Bicuspid aortic valve (n, %) 0 (0%)
Aortic valve calcium (n, %)
     0 AU 79 (61.2%)
     > 0 – 100 AU 38 (29.5%)
     > 100 – 400 AU 9 (7.0%)
     > 400 AU 3 (2.3%)
Coronary artery calcium (n, %)
     0 AU 27 (20.9%)
     > 0 – 100 AU 45 (34.9%)
     > 100 – 400 AU 29 (22.5%)
     > 400 AU 28 (21.7%)
* Hypertension: SBP >140mmHg and/or DBP > 90 mmHg or the use of antihypertensive medication.
Association between Lp(a) and CVD-related parameters
Lp(a) concentrations were positively correlated with gender (r = 0.20, p = 0.02), as 
female FH patients had higher Lp(a) concentrations than male patients (35.5(11.7-74.8) 
vs. 19.7(4.3-50.5) mg/dL, p = 0.02). In contrast, no significant associations were found 
between Lp(a) concentrations and the presence (r = 0.05, p = 0.56) or severity (r = 0.09, 
p = 0.32) of CAC. After adjustment for CAC, Lp(a) concentrations remained positively 
correlated with the presence of AVC (r = 0.19, p = 0.03) but not with the severity of AVC (r 
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= -0.02, p = 0.82). No significant correlations were found between Lp(a) concentrations 
and age, BMI, blood pressure, smoking or other lipid parameters.
Association of AVC with Lp(a) and other CVD parameters
Next we analyzed the significant predictors for the presence of AVC using logistic 
regression analysis (table 2). In a univariate model, age, BMI, blood pressure, duration 
of statin use, CYS, CAC and Lp(a) concentrations were found to be significant predictors 
for AVC. 
Table 5.2 | Univariate logistic regression analysis of the presence of aortic valve calcification 
(AVC) in patients with familial hypercholesterolemia (FH).
 Odds ratio 95%CI p
Age (year) 1.10 1.04-1.16 <0.001
Gender (male) 1.67 0.79-3.55 0.18
BMI (kg/m2) 1.11 1.01-1.23 0.04
Systolic blood pressure (mmHg) 1.06 1.02-1.10 0.001
Diastolic blood pressure (mmHg) 1.05 1.01-1.11 0.03
Total cholesterol (mmol/l) 1.15 0.89-1.49 0.28
LDL-cholesterol  (mmol/l) 1.34 0.98-1.85 0.07
HDL-cholesterol (mmol/l) 0.90 0.35-2.32 0.82
Triglyceride (mmol/l) 1.04 0.69-1.56 0.86
Fasting blood glucose (mmol/l) 1.26 0.76-2.10 0.37
Lipoprotein(a) (per 10 mg/dL) 1.12 1.04-1.20 0.004
LMW apo(a) phenotype 1.23 0.56-2.72 0.60
Duration of statin use (year) 1.08 1.02-1.13 0.004
Previous and current smoker 0.87 0.38-1.97 0.73
Hypertension 1.35 0.61-3.00 0.46
CYS 1.006 1.003-1.01 <0.001
CAC score (AU) 1.004 1.004-1.005 <0.001
* Hypertension: SBP >140mmHg and/or DBP > 90 mmHg or the use of antihypertensive medication; CYS: 
cholesterol-year score, was calculated using the formula: Untreated total cholesterol x years without statin 
treatment + statintreated total cholesterol x years treated with statins; CAC: coronary artery calcification For 
each continuous parameter, odds ratio was calculated per 1 unit increase, except for Lipoprotein(a).
The independent association of Lp(a) concentration with AVC was analyzed using multiple 
logistic regression analysis with increasing number of parameters for adjustment (table 
3). As age, CYS and duration of statin-use were highly mutually correlated, CYS was used 
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as a representative of the 3 parameters. The association between Lp(a) concentration 
and AVC was not influenced by CYS and/or CAC adjustment. Moreover, after adjustment 
for all significant determinants of AVC from the univariate model (age, BMI, SBP, DBP, 
duration of statin use, CYS and CAC score), Lp(a) concentrations remained a significant 
predictor for AVC. A 10 mg/dL-increase in Lp(a) concentration was associated with an 
11% increased risk of developing AVC (95%CI = 1.01-1.20, p = 0.03). 
Table 5.3 | Adjusted association of Lp(a) concentration with aortic valve calcification (AVC) in 
patients with familial hypercholesterolemia (FH).
Adjusted for Odds ratio5* 95%CI p
CYS 1.10 1.02-1.20 0.02
CAC score 1.14 1.05-1.23 0.002
CYS and CAC score 1.13 1.04-1.22 0.005
Age, BMI, SBP, DBP, Duration of statin use, CYS 
and CAC score       
1.11 1.01-1.20 0.03
Odds ratios were calculated per 10 mg/dL increase of Lp(a) concentration, CYS: cholesterol-year score, CAC: 
coronary artery calcification, SBP: systolic blood pressure, DBP: diastolic blood pressure
In clinic, Lp(a) cutoff values of 30 or 50 mg/dL are used. Plasma Lp(a) concentrations over 
30 mg/dL were not significantly associated with an increased risk of AVC (OR(95%CI) = 
1.80(0.88-3.70), p = 0.11). Plasma Lp(a) concentrations above 50 mg/dL were associated 
with a 2.57-fold increased risk of AVC (95%CI = 1.20-5.52, p = 0.02). However, after 
adjustment for parameters selected from the univariate analysis, the association no 
longer reached statistical significance (OR(95%CI) = 2.03 (0.80-5.18), p = 0.14).
dISCuSSIOn
Little is known about the development of valvular calcification in patients with 
heterozygous FH. The exposure to classical risk factors is not a sufficient explanation 
for the development of AVC in these statin-treated patients. In the present study, we 
report, for the first time, a significant association of plasma Lp(a) concentrations with 
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patients. Our results are in line with previous findings showing that Lp(a) concentrations 
might have a casual role in AVC development [13], which may result in symptomatic 
end-stage aortic valve disease [12, 15, 25, 26]. 
Statin treatment has substantially improved the prognosis of patients with 
heterozygous FH [27]. Nonetheless, we observed impressive CAD in asymptomatic, 
long-term statin-treated FH patients [28]. It might be that additional risk factors that are 
independent of LDL levels determine the residual CVD risk in treated FH. In the Jupiter 
trial, statin negligibly influenced the average Lp(a) concentrations, whereas Lp(a) levels 
determined the residual risk [29]. In our treated FH patients, we found that Lp(a) levels 
were associated with AVC but not with CAC. It is, therefore, tempting to speculate that 
Lp(a) contributed to the residual CVD risk of treated FH through AVC and subsequent 
aortic valve stenosis.
It is well-established that plasma Lp(a) concentrations are largely genetically 
determined by the variation in the number of KIV repeats that are based on genetic 
variants at the LPA locus. However, we cannot exclude that Lp(a) is solely an associated 
factor for AVC in the present study. In the future, a large genetic study, i.e. a Mendelian 
randomization approach, is required to investigate the causality. Interestingly, LMW 
apo(a) phenotypes were not significantly associated with AVC, despite the strong 
correlation between apo(a) phenotypes and Lp(a) concentration. Moreover, the 
frequency of LMW apo(a) is similar in patients with and without AVC. We cannot exclude 
that this is a chance finding, because 14 of the 29 patients who expressed an LMW 
isoform also expressed an HMW isoform. The large group of mixed isoforms reduces 
the power for detecting an association between the specific LMW isoform and AVC. To 
study this association in FH a larger cohort is required. Alternatively, the LMW apo(a) 
phenotype was previously found to be a strong predictor for CVD outcomes [8, 30, 31], 
apo(a) KIV repeat number was not significantly associated with aortic valve stenosis in 
the general population [12]. 
As CAC and AVC have several pathological similarities and share risk factors [32-34], 
and CAC had a strong predictive value towards AVC [35, 36], we tested whether Lp(a) 
concentration was generally associated with calcification or specifically associated with 
calcification at the aortic valve. Interestingly, Lp(a) was associated only with AVC but not 
CAC in our patients. Moreover, the association between Lp(a) concentration and AVC 
was not influenced by the adjustment for CAC. These results suggest that high Lp(a) 
levels might point at FH patients specifically at risk for AVC. How Lp(a) is involved in the 
mechanism of AVC development remains to be established.
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Limitation
The capability of the CT scan to detect small calcified plaques is limited [37], therefore the 
presence of AVC might be underestimated. Moreover, we included only middle-aged, 
asymptomatic statin-treated FH patients. The results may be different in symptomatic, 
elderly or untreated patients. Replication in a larger group of FH patients is required to 
confirm and extend our findings.
Clinical implication
AVC and aortic valve stenosis are a major risk factor for CVD. However, no efficient 
treatment other than aortic valve replacement is available. With this study, we provide 
evidence that plasma Lp(a) concentrations may be a clinically useful risk factor of AVC 
and subsequent residual CVD risk assessment in heterozygous FH patients. Although 
statin treatment has been found to reduce AVC in vitro and in vivo [38, 39], it does 
not affect the clinical outcome of AVC [40, 41], and we speculated that this might 
be explained by the fact that statins do not reduce Lp(a) concentrations [29, 42]. In 
contrast, the progression of CAC is attenuated by statins, which is mainly the result of 
the cholesterol-lowering effect of statins [43, 44]. As the association between Lp(a) and 
AVC found in this study was independent of cholesterol-year score (CYS), therapeutic 
strategies to lower plasma Lp(a) concentration may be a potential treatment for AVC 
in FH patients. Notably, the commonly used Lp(a) cut-off points of 30 and 50 mg/dL 
(80th percentile) were not independently associated with AVC. These cut-off values 
were suggested based on the association between Lp(a) and myocardial infarction [45, 
46]. However, data to support a clear Lp(a) cut-off point associated with increased AVC 
are not available and need further investigation. In addition, FH patients have higher 
plasma Lp(a) levels than the general population [47, 48]. Therefore, thresholds have to 
be validated in this particular high risk group to be discriminative. In our population, 
an Lp(a) higher than the 80th percentile (~80 mg/dL) was independently associated 
with an increased risk of AVC presence (data not shown). On the other hand, based on 
our results, lowering Lp(a) concentration is expected to have a limited effect on the 
development of CAC in asymptomatic FH patients.
In conclusion, we report a significant association between plasma Lp(a) concentration 
and AVC in asymptomatic statin-treated FH patients, independently of age and other 
CVD-related risk factors. Although AVC and CAC were strongly mutually associated, 
Lp(a) concentration was not correlated with CAC, suggesting a specific role of Lp(a) in 
AVC in these patients. 
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ABSTRACT
Background
Lipoprotein (a), also called Lp(a), is a cardiovascular disease (CVD) risk factor. Statins 
do not lower Lp(a), this may at least partly explain residual CVD risk in statin-treated 
patients with familial hypercholesterolemia (FH). We investigated the association of 
Lp(a) levels with atherosclerosis in these patients.
Methods and results
We performed ultrasonography in 191 statin-treated FH patients (50% men; 48±15 
years) to detect carotid plaques and determine carotid intima-media thickness (C-IMT). 
Patients with high versus low Lp(a) levels (≤ 0.3 g/L) had similar plaque prevalence (36 
and 31%, p=0.4) and C-IMT (0.59±0.12 and 0.59±0.13 mm, p=0.8). Patients with and 
without plaques had similar Lp(a) levels (median 0.35 (IQR: 0.57) and 0.24 (0.64) g/L, 
respectively, p = 0.4).
Conclusions 
The Lp(a) levels were not associated with atherosclerosis in the carotid arteries of 
statin-treated FH patients. This suggests that adequate statin treatment delays carotid 
atherosclerosis in FH independently of Lp(a) levels.
Keywords:
•	Carotid plaque presence 
•	Carotid intima media thickness 
•	Lipoprotein (a)
•	Familial hypercholesterolemia 
•	Residual risk
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InTROduCTIOn
Familial hypercholesterolemia (FH) is the most common genetic disorder associated 
with premature cardiovascular disease (CVD). FH is caused by mutations in the LDLR, 
APOB or PCSK-9 gene [2-4]. FH patients have raised low-density lipoprotein (LDL)-
cholesterol levels, which strongly increases the risk of premature CVD [5]. To reduce CVD 
risk, preventive statin therapy is indicated, but despite statin treatment some FH patients 
still develop CVD [6-8]. This residual risk might be partly explained by alternative risk 
factors like lipoprotein (a), also called Lp(a). 
Lp(a) is a LDL-like protein with an apo(a) moiety, and Lp(a) levels are predominantly 
genetically determined [9]. High Lp(a) levels have been shown to explain residual CVD 
risk in FH patients as well as in the general population[10, 11], and are unaffected by 
statin therapy[12].
Atherosclerosis can be visualized by carotid ultrasonography as the presence of 
plaques and the intima media thickness (C-IMT), which are both associated with 
CVD[13-16]. Previous studies have shown an association between Lp(a) levels and C-IMT 
in subjects in the general population and in those with severe hypercholesterolemia 
[17, 18]. However, it is unknown whether Lp(a) levels are associated with carotid plaque 
presence and C-IMT in statin-treated patients. 
The aim of this study is to assess whether Lp(a) levels are related to atherosclerosis 
depicted by carotid ultrasonography in statin-treated FH patients.
MeTHOdS
Study Population
Between May 2012 and October 2014, FH patients were included from the outpatient 
cardio-genetics clinic at the Erasmus Medical Center in Rotterdam. FH was defined as 
a score ≥6 on ‘The Dutch Lipid Clinic Network criteria’ [19].  All patients were screened 
for mutations in the LDLR, APOB and PCSK-9 genes. Patients with homozygous and 
compound heterozygous FH were excluded. Written informed consent for blood 
storage and the use of clinical data was obtained and approved by the local ethical 
committee (MEC-2012-309).
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Blood analyses
Fasting blood was collected, processed the same day and EDTA plasma samples were 
stored at -80oC. Within 30 months Lp(a) levels were determined in once thawed samples 
using an apo(a)-size independent immunoturbidimetric assay (Lp(a) 21 FS, DiaSys, 
Holzheim, Germany). Other lipid levels were measured according to the standard 
laboratory techniques.
Carotid ultrasonography
All carotid ultrasound measurements were performed on the Panasonic 
CardioHealthStation (Yokohama, Japan), with a validated automated C-IMT capturing 
method [20] (figure 1). Subjects were examined in supine position with their head 
positioned in an angle of approximately 45 degrees. A plaque scan was performed by 
placing the transducer transversally, visualizing the common, internal, and external 
carotid artery. Plaques were defined as a local enlargement of the C-IMT of more than 
50% of the surrounding C-IMT, or if the C-IMT was above 1.5 mm, and were scored as 
present or absent. The mean C-IMT was measured over 1 cm length, at least 0.5 cm 
proximal of the bifurcation in the common carotid artery. Both sides were measured 
in two angles: anterior (170°-190°), and lateral (right: 120°-145°; left: 210°-235°), as 
indicated in real time by the device (Figure 1). In the present study, the C-IMT indicates 
the mean of the left and right mean C-IMT.
Statistical analysis:
Data with a normal distribution were expressed as mean (±SD), and data with a skewed 
distribution as median (IQR). Groups were compared a Chi-Square test or ANOVA. 
Skewed data was logistically transformed.
High baseline Lp(a) was defined as > 0.3 g/L and low as ≤ 0.3 g/L. This level has been 
reported to be the approximate median Lp(a) level in the general population [21, 22]. 
The associations between Lp(a) and the presence of carotid plaques and C-IMT were 
examined by logistic and linear regression methods, respectively. Additionally, these 
analyses were repeated in a subgroup of those with an LCL-C above 4mmol/L. Finally, 
associations between other variables and the presence of carotid plaques and C-IMT 
were assessed. 
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ReSulTS
Data were collected from 191 FH patients. FH was genetically confirmed in 149 patients 
(78%), with mutations in the LDLR and APOB gene in 130 and 19 patients, respectively. 
PCSK-9 gene mutations were not found. The patients were 48±15 years old, and 50% 
were men (Table 1). Plaques in the carotid arteries were present in 64 (33.5%) patients, 
and the C-IMT was 0.59±0.13 mm. The coronary calcium score, measured in a subgroup 
of 33 asymptomatic patients was 49 (344) Agatston units, and was not associated with 
carotid plaques (p=0.8), and C-IMT (p=0.737).
The Lp(a) levels ranged from 0.002 to 3.732 g/L with a median of 0.258 (0.620)g/L. 
We compared the patients with high and low Lp(a) levels (>0.3 g/L versus ≤ 0.3 g/L) 
Figure 6.1 | Example of a C-IMT measurement of the Panasonic CardioHealthStation.
Output of the Panasonic CardioHealthStation showing one C-IMT measurement from the 
right common carotid artery from a lateral (135°) angle, over 1 cm. In the centre left side of the 
image results were displayed. The mean value displayed was combined with the other three 
measurements, and the mean of these four variables where used for analyses. 
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Table 6.1 | Baseline Characteristics
lp(a) >0.3g/l 
(n=91)
lp(a) ≤0.3g/l 
(n=100)
p
Age (years) 50±16 46±15 0.072
Sex (male) 45 (49%) 51 (51%) 0.472
Body mass index (kg/m2) 26.1±4.0 26.6±5.1 0.457
Systolic blood pressure (mmHg) 128±13 129±13 0.452
Diastolic blood pressure (mmHg) 78±8 78±9 0.842
Hypertension1 26 (28%) 28 (25%) 0.529
Diabetes mellitus2 4 (4%) 4 (4%) 0.586
Smoker (current and former) 35 (38%) 41 (41%) 0.469
Stigmata 3 20 (22%) 21 (21%) 0.554
Alcohol abuse 4 5 (5%) 9 (9%) 0.275
Inactivity 5 29 (32%) 23 (23%) 0.087
  
Maximal intensity statin 6 68 (75%) 69 (69%) 0.423
Years of statin treatment 10±8 10±7 0.815
Ezetimibe 36 (40%) 37 (37%) 0.415
  
LDL-R mutation 57 (63%) 73 (73%) 0.084
APOB mutation 11 (12%) 8 (8%) 0.242
No genetic confirmation 23 (25%) 19 (19%) 0.192
Positive family history 7 61 (67%) 67 (67%) 0.446
Premature CVD 8 18 (20%) 12 (12%) 0.106
Any CVD 18 (20%) 14 (14%) 0.191
Coronary calcium score (Agatston Units)9 50 (228)
(n=20)
40 (436)
(n=13)
0.882
Total Cholesterol (mmol/L) 5.00±0.94 5.09±1.15 0.567
HDL (mmol/L) 1.47±0.43 1.41±0.47 0.398
LDL (mmol/L) 3.20±0.85 3.23±1.02 0.794
Triglyceride (mmol/L)9 0.99 (0.64) 1.09 (0.94) 0.056
1  Defined as being diagnosed by physician or taking antihypertensive drugs;
2  Defined as being diagnosed by physician or taking anti-diabetic drugs;
3  Presence of Xanthoma/Xanthalasmata/arcus lipoides;
4   >2U alcohol/day ;
5  <30min of physical activity/day;  
6  The use of Atorvastatin ≥ 40mg or Rosuvastatin ≥ 20mg or Sinvastatin 80mg;
7  Any CVD in a first or second degree relative;
8  CVD <55 years (men) or < 60 (woman);
9  Mean (IQR).
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and we did not find significant differences in the baseline characteristics between these 
groups (Table 1). Plaque prevalence was similar in both groups:  33 (36%) vs 31 (31%) 
(p=0.4). There were no differences in C-IMT between the high Lp(a) group and the low 
Lp(a) group; 0.59±0.13 mm and 0.59±0.13mm (p=0.8). Qualitatively similar results were 
obtained when restricting the analyses to the mutation confirmed FH patients, or when 
other cut-off values of Lp(a) (0.5g/L and 1.0g/L, data not shown) were used. In the 
regression analyses, there were no statistically significant associations between Lp(a) 
levels and plaque presence (p=0.5) and C-IMT (p=0.4).  These results did not change 
in the sub-analysis in those with a treated LDL-C above 4mmol/L. In addition, no other 
variable except age was associated with carotid plaques (p= <0.001), and C-IMT (p= 
<0.001). Finally, Lp(a) levels did not differ between patients with and without plaques 
present in the carotids: (0.349 (0.571) and 0.243 (0.641)) g/L, p = 0.4).
dISCuSSIOn
In our study, Lp(a) levels are not associated with presence of carotid plaque and C-IMT 
in statin-treated FH patients. This is unexpected since Lp(a) is a residual risk factor in 
treated FH patients[10, 11], and Lp(a) levels are associated with C-IMT [17, 18]. As our FH 
patients received aggressive long-term statin therapy, they may have effectively delayed 
carotid atherosclerosis and vessel wall thickening, such that the association with Lp(a) 
levels is no longer evident. In a previous study in a subgroup of our FH patients, Lp(a) 
is also not associated with subclinical coronary atherosclerosis, depicted by coronary 
calcium scoring [23]. 
An explanation for the lack of association between Lp(a) and carotid plaques is the 
relative young age of our FH patients. The prevalence of carotid plaques in our patients 
with mean age 48 years is 33.5%. Recent studies has shown a 43% prevalence in a 
Swedish population with a mean age 57 years [1], and a 42% prevalence in 61±10 year 
old healthy American multi-ethnic population [16]. In adverse plaques were increased in 
a group of young, newly diagnosed and mostly untreated, FH patients [24]. This suggest 
that our study group has a low prevalence of carotid plaques which might be due to the 
aggressive statin treatment.
The very low C-IMT did not associate with Lp(a). In healthy young men with mean age 
29 years, a C-IMT of 0.54 mm is observed [25]. Additionally, the healthy controls of the 
ARIC study with a mean age of 56 years have a C-IMT of 0.60 mm [17]. Therefore, the 
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C-IMT in our study of aggressively treated FH patients seems in the range of a healthy 
population. This is important since in young, newly diagnosed and mostly untreated, FH 
patients the C-IMT values were increased [24]. At our outpatient clinic, we perform an 
active screening among relatives of FH patients. Early identification, a subsequent early 
start of aggressive statin treatment and patient education improving lifestyle may have 
resulted in a C-IMT within the normal range. Additionally coronary artery calcification 
does not associate with carotid plaques and C-IMT, even though we do see severe 
coronary lesions in some patients, which questions the clinical applicability of carotid 
sonography in statin-treated FH patients. 
Lp(a) levels are not influenced by statins [12]. In line, we find large variations of the 
Lp(a) levels. Hence, statin treatment may compensate for the atherogenic effects of 
Lp(a) by either unknown mechanisms influencing of Lp(a) function or fully independent 
of Lp(a). 
Although Lp(a) is not associated with subclinical atherosclerosis determined by 
C-IMT, Lp(a) levels might still contribute to residual CVD risk in treated FH patients. 
The relationship between Lp(a) and CVD risk may be effected via pathophysiological 
mechanisms other than atherosclerosis. Proposed mechanisms are wound healing and 
fibrinolysis, in which Lp(a) also plays a role [9, 22].
Limitations
Our study has some limitations. First, this study is an association study and therefore, we 
cannot prove or dismiss that Lp(a) has a causal effect in the residual CVD risk with this 
data. In addition, prospective ultrasound data was not available in these patients, and 
we cannot exclude that changes in plaque presence of C-IMT are associated with Lp(a). 
Another limitation is that carotid plaques are only scored categorical (present/absent), 
whereas plaque volume would be a more precise measurement. However, the device 
we used is not able to obtain 3D ultrasound plaque volume. Therefore, we cannot 
exclude different results when this 3D technique would have been used. In addition, we 
only used carotid ultrasound and did not look at other arteries liable to atherosclerosis. 
Therefore we cannot exclude different results if other arterial bed were examined.
Finally the Lp(a) measurement used is, like most commercially available measurements, 
not a fully KIV-2 independent measurement, which leads to an overestimation of 
the low Lp(a) levels and a underestimation of high Lp(a) levels. However, since our 
primary analyses uses a cut-off value near the median Lp(a) level, it is unlikely that our 
measurement method reclassified patients into the other group. 
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COnCluSIOn
In statin-treated FH patients, we cannot prove that Lp(a) is a residual risk factor of CVD, 
since Lp(a) levels are not associated with the presence of carotid plaque presence and 
the C-IMT. This is most likely explained by the long-term adequate statin treatment 
resulting in a low C-IMT, and the relative low prevalence of plaques in the carotid arteries.
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ABSTRACT  
Purpose of review
Lipoprotein (a) (Lp(a)) is an independent risk factor for cardiovascular disease (CVD). 
The aim of this review is to provide an overview of treatment options for Lp(a) lowering. 
Recent Findings
Recent studies confirmed that lifestyle intervention and statins do not affect Lp(a) 
levels, whereas Lp(a) is lowered by estrogens, niacin, and lipoprotein apheresis. CETP 
inhibitors and PCSK9 antibodies, currently studied in phase 3 trials, also lower Lp(a) 
concentrations by 30-50%. However, all of these compounds have modifying effects on 
multiple lipoprotein classes. An antisense oligonucleotide directed to apolipoprotein 
(a) has recently been developed to specifically lower circulating Lp(a) levels. This 
compound inhibited Lp(a) mRNA up to 90%, and Lp(a) levels up to 82% in human 
volunteers independent of Lp(a) levels at baseline.
Summary
Multiple agents, including the next generation RNA based antisense therapeutics have 
Lp(a) lowering properties . However, it remains to be established whether lowering 
Lp(a) reduces CVD events with specific Lp(a) lowering therapies.
Keywords (3-5)
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•	Treatment
•	Cardiovascular disease 
•	Risk factor
100 |      Chapter 7
ABSTRACT  
Purpose of review
Lipoprotein (a) (Lp(a)) is an independent risk factor for cardiovascular disease (CVD). 
The aim of this review is to provide an overview of treatment options for Lp(a) lowering. 
Recent Findings
Recent studies confirmed that lifestyle intervention and statins do not affect Lp(a) 
levels, whereas Lp(a) is lowered by estrogens, niacin, and lipoprotein apheresis. CETP 
inhibitors and PCSK9 antibodies, currently studied in phase 3 trials, also lower Lp(a) 
concentrations by 30-50%. However, all of these compounds have modifying effects on 
multiple lipoprotein classes. An antisense oligonucleotide directed to apolipoprotein 
(a) has recently been developed to specifically lower circulating Lp(a) levels. This 
compound inhibited Lp(a) mRNA up to 90%, and Lp(a) levels up to 82% in human 
volunteers independent of Lp(a) levels at baseline.
Summary
Multiple agents, including the next generation RNA based antisense therapeutics have 
Lp(a) lowering properties . However, it remains to be established whether lowering 
Lp(a) reduces CVD events with specific Lp(a) lowering therapies.
Keywords (3-5)
•	Lipoprotein (a) 
•	Treatment
•	Cardiovascular disease 
•	Risk factor
        
7101|Latest developments in the treatment of lipoprotein (a)
InTROduCTIOn
Lipoprotein (a) (Lp(a)) is an low density lipoprotein (LDL) like particle  with an 
apolipoprotein (apo(a)) moiety attached to it (figure 1[1])[2]. Multiple isoforms of apo(a) 
exist because the length of this protein is genetically determined by variations in the 
number of Kringle IV type 2 repeats encoded by the LPA gene [3]. The size of the apo(a) 
is inversely related with plasma Lp(a) levels [3]. In addition elevated plasma Lp(a) levels 
are causally related to cardiovascular disease (CVD), and the development of aortic 
valve calcification and aortic valve stenosis [4-7]. However, it is not known if reducing 
Lp(a) levels will also reduce the risk of CVD, because the first specific Lp(a) lowering 
compound has only recently been developed and outcome data is not yet available. The 
aim of this review is to give an overview of the current knowledge of Lp(a) modifying 
agents and interventions.  
Figure 7.1 | Lipoprotein(a) particle. 
Adapted from J  E Roeters van Lennep and M T Mulder[1].
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Life style and diet
Healthy lifestyle and a prudent diet are cornerstones of  CVD prevention. Recently two 
studies have addressed the effect of lifestyle intervention on Lp(a) levels. Both showed 
that Lp(a) levels are not influenced by rigorous exercise[8, 9]. 
Studies on the influence of diet on Lp(a) have produced conflicting result for a long 
time, and it remains to be established if diet indeed modifies Lp(a) or not [9, 10]. The main 
shortcomings of most of these studies include the  small sample size, the use of firmly 
isoform dependent assays for measuring Lp(a), and improper use of statistics. Recently, 
the Copenhagen Heart study established that Lp(a)levels are not directly influenced by 
food intake: No difference in Lp(a) levels was observed between fasting and non-fasting 
blood samples [11]. In conclusion, these studies reinforce that the influence of exercise 
and food intake on Lp(a) levels is limited at best.
Drug Treatment
Next to life style, weight control and dietary hygiene, pharmacological treatment plays 
a crucial role in CVD prevention. The remainder of this review focusses on the effect of 
different compounds on circulating Lp(a) levels. 
Estrogens
Hormone replacement therapy containing estrogens favourably influences Lp(a), 
LDL-cholesterol (LDL-C), and high dense lipoprotein-cholesterol (HDL-C) levels in 
postmenopausal women. Recently, Howard et al. [12], provided an excellent overview 
of all cardiovascular effects of hormone replacement therapy, including Lp(a). These 
authors concluded that despite the Lp(a) lowering effect of estrogens, there is no 
place for hormone replacement therapy in CVD prevention because it did not lead to 
a decrease in CVD events. Reversely, Lp(a) levels increase when the action of estrogens 
is blocked [13]. A recent double blinded randomized controlled trial (RCT) investigated 
the effect of Letrozole (Novartis, Basel, Switzerland), an aromatase inhibitor which 
inhibits the conversion of testosterone to estrogens, on lipoprotein levels. After 60 
months of follow-up Lp(a) was measured in 103 postmenopausal women with breast 
cancer, showing that Lp(a) levels where 106% higher compared to baseline in those 
randomized to Letrozole treatment [13]. Although, the mechanism is uncertain Hoover-
Plow and Menggui Huang proposed influence of estrogen on the LPA promoter[14]. 
This is highly suggestive of an association between estrogens and Lp(a) levels. Given the 
outcome of the hormone replacement therapy trials on CVD endpoints it is unlikely that 
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estrogens will even be used as Lp(a) lowering medication.
Thyroid hormone analogues
Abnormal thyroid function has serious consequences for lipoprotein levels and body 
composition [15]. These effects can be explained by the interaction of thyroid hormone 
with the thyroid hormone receptor. This receptor has two major isoforms, the α and 
the β isoform. The α isoform is predominantly present in heart and bone, whereas 
the β isoform is predominantly present in the liver. The thyroid hormone β-receptor 
analogue eprotirome (Karo Bio, Huddinge, Sweden) has been studied in two RCTs [15]. 
Eprotirome was found to lower Lp(a) levels by 43% from baseline, without any change 
in body weight, heart rate, blood pressure, or bone turnover [15]. This effect seems to 
be synergistic to either statins or ezetimibe because administration of eprotirome as 
monotherapy does not influence Lp(a) levels [16]. The proposed mechanism of Lp(a) 
lowering is that activation of the β isoform leads to a decreased apo-B synthesis. 
However, because of cartilage damage in toxicology studies in dogs and recent 
reports that elevation in liver function tests were observed in patients randomized to 
eprotirome, the trials were prematurely terminated [17]. To our knowledge there are no 
new thyroid analogues under development.
Statins
Statins are prescribed for over 20 years for treating dyslipidaemia to prevent CVD. 
Their effect is mainly due to lowering of LDL-C. Previous studies have reported either a 
lowering, no effect, or an increase in Lp(a) levels after statin treatment [18, 19]. It seems 
clear that Lp(a) cannot be cleared by the LDL-receptor. The mechanisms by which statins 
may affect Lp(a) levels, if they do,  remain to be clarified. Two recent studies evaluated 
the effect of statins on Lp(a) levels [20, 21]. In the first study patients who were receiving 
a standard statin dose were switched to the maximum dosage of rosuvastatin, i.e. 40mg 
[20]. In this study, optimizing statin dose led to a decrease of LDL-C (23%), but did not 
show an effect on Lp(a)[20]. In the second study the effect of morning and evening 
dosages of simvastatin were compared, in previously untreated patients [21]. In this 
study, the use of simvastatin led to a decrease in LDL-C (36-38%), but to no changes 
in Lp(a). In addition, there was no difference in morning or evening dosages on any 
lipoprotein[21]. In conclusion, the effect of statins on Lp(a) levels, if present, is most 
likely not clinically significant.
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Lipoprotein apheresis
Lipoprotein apheresis can lower LDL-C 60-70% by removal of lipoproteins from the 
circulation. It is used in patients with severe hypercholesterolemia such as homozygous 
familial hypercholesterolemia (FH) [22]. Another indication for lipoprotein apheresis 
is Lp(a)-hyperlipoproteinemia (Lp(a) > 0,6g/L) with progressive CVD [23]. In these 
patients, who are adequately treated with statins, lipoprotein apheresis reduces Lp(a) 
by 70% directly post-treatment [22, 23], this led to a decrease of major adverse coronary 
events by 78% [22]. However, it is uncertain whether the reduced event rate is due to 
Lp(a) lowering per se, because lipoprotein apheresis also lowers other lipoproteins, and 
may as well reduce other unknown risk factors. Disadvantages of lipoprotein apheresis 
include it’s time expenditure  and costs. Furthermore apheresis is not reimbursed in 
all countries. Despite the limited indication and availability, lipoprotein apheresis is a 
sound method to reduce CVD events in Lp(a)-hyperlipoproteinemia patients who have 
progressive CVD, although it is unknown if this effect is due to Lp(a) lowering per se.    
Niacin
Niacin (Vitamin B3 or nicotinic acid) has multiple effects on different lipoproteins; 
it lowers LDL-C and triglycerides (TG), and it increases HDL-C. Since 1990 it is being 
reported that niacin can also lower Lp(a) although the mechanism is unclear [24].  In the 
AIM-High (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High 
Triglycerides) trial patients were treated with high dose extended release niacin (1,5-2,0 
g/day) or placebo, on top of statins. Baseline Lp(a) and on-study Lp(a) predicted CVD 
events in both arms [25]. This suggest that Lp(a) still contributes to residual risk. In the 
extended release niacin group Lp(a) was 19% lower than in the placebo group. Despite 
this reduction in Lp(a), extended release niacin did not lead to a reduction in CVD events 
[25]. The criticism regards this trial include the fact  that patients were at low LDL-C levels 
(1.97 mmol/L), and critical differences in terms of LDL-C, HDL-C and TG levels were very 
small between treatment arms. The observed event rate was lower than expected, and 
the overall study was seriously underpowered [25, 26]. In addition, the recent HPS-2-
THRIVE (Heart Protection Study-2-Treatment of HDL to Reduce the Incidence of Vascular 
Events) trial also failed to show benefit on CVD outcome, despite an Lp(a) reduction of 
24% [27]. In this trial Tredaptive (niacin 2g/laropiprant 40mg, MSD, Whitehouse Station, 
NJ, USA)  was compared to placebo, on top of statin therapy. LDL-C , HDL-C and TG levels 
were optimal and it is questionable whether 2g of nicotinic acid is the correct therapy 
in that situation. It is also possible that the addition of lapopiprant, a prostaglandin D2 
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antagonist, had influence on outcome and safety. Neither the AIMHIGH or the HPS-
Thrive analysed whether the subgroup of patients with high Lp(a) at baseline did have 
a particular benefit of niacin therapy. In 2010 the European Atherosclerosis Society 
Consensus Panel recommended the use of niacin in high risk patients with elevated 
Lp(a) (>0,5g/L)[2]. However given the outcome of the recent RCT’s  it is questionable if 
this recommendation is correct [25, 28]. In conclusion, niacin can significantly reduce 
Lp(a) and effects on the lipoprotein profile are beneficial, but RCT’s have not shown a 
decrease in CVD outcome when added to statins, although specific subgroup analysis 
of patients with high Lp(a) has not been performed.
Ezetimibe
Previously it was shown that ezetimibe (MSD, Whitehouse Station, NJ, USA) does 
not influence Lp(a) levels, which is not surprising since the mechanism of inhibiting 
intestinal cholesterol uptake by blocking  Nieman-Pick C1-like protein, is not involved 
in Lp(a) metabolism as far as we know. In the recent PROBE (Prospective, Randomized, 
Open-label, Blinded Endpoint) study Lp(a) was not reduced in dyslipidaemic patients 
after addition of ezetimibe to statins [29]. 
Anti-sense Apo-B
Mipomersen (Carlsbad, CA, USA) is an antisense nucleotide that binds to the mRNA 
encoding the Apo-B protein and thereby inhibit its synthesis. Apo-B synthesis is 
essential for the formation of lipoprotein particles, and its inhibition reduces TG levels 
(25-33%), very low dense lipoprotein-cholesterol (VLDL-C) (33-37%),  LDL-C (28-37%) as 
well as Lp(a) (21-28%) [30, 31]. Although mipomersen reduces plasma levels of these 
atherogenic lipoproteins, no outcome study has been performed. Mipomersen is not 
very well tolerated. It was discontinued in 43% of patients after 26 weeks follow up, 
due to side effects such as injection site reactions (up to 92%), flu-like symptoms, and 
elevated liver enzymes [30, 31]. In January 2013, the FDA approved mipomersen for 
the treatment of homozygous FH. However the EMA did not follow, and mipomersen 
is therefore not approved in Europe [http://www.medscape.com/viewarticle/781317]. 
Due to the approval for an orphan disease, the Lp(a) lowering will merely be a beneficial 
side effect. It is improbable that mipomersen will be used specifically to lower Lp(a).
Microsomal triglyceride transport protein (MTP) inhibition
MTP is an enzyme that facilitates the transport of TG into VLDL-C in the liver, and the 
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secretion of chylomicrons from the intestine. Inhibiting the activity of this protein 
prevents the formation of chylomicrons and lipoproteins including Lp(a). The effect of 
the MTP inhibitor, Lomitapide (Aegerion Pharmaceuticals, Cambridge, Massachusetts, 
USA) in combination with a low-fat diet and maximum statin therapy, was studied 
in patients with homozygous FH. Following a 26 week open label study, a long-term 
extension study showed that 56 weeks of treatment led to a reduction of LDL-C (44%), 
and a reduction in Lp(a) of 19%. However, after 78 weeks Lp(a) had returned to baseline 
levels [32]. The most frequent encountered side effects were gastrointestinal complaints 
(93%), and elevated liver enzymes >3x upper limit normal (34%) and >5x upper limit 
normal (14%) [32]. In 2013, Lomotapide was approved by the FDA and EMA, for the 
treatment of homozygous FH patients. The safety profile makes it likely that lomitapide 
will remain solely registered for this indication. As with mipomersen, this implies that 
the decrease in Lp(a) will remain an additional beneficial effect for those homozygous 
FH patients who use the drug for LDL-C lowering. Furthermore,  the long-term extension 
study showed that the effect of lomitapide on Lp(a) is temporary so it is questionable 
whether this effect is clinically relevant. 
CETP inhibition
Cholesterol ester transfer protein (CETP) transfers cholesterol esters and TG between 
HDL-C and Apo-B containing lipoproteins. CETP inhibition decreases Apo-B containing 
lipoproteins and increases cholesterol enrichment in HDL-C. The first two CETP 
inhibitors were terminated  because of respectively safety concerns (ILLUMINATE 
(Investigation of Lipid Level Management to Understand its Impact in Atherosclerosis 
Events) with torcetrapib) and futility (dal-OUTCOMES  with dalcetrapib) [33]. Currently 
a third  CETP inhibitor, anacetrapib was investigated in two phase 3 safety trials. The 
DEFINE (Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib) 
showed a reduction in LDL-C (45%), TG (7%), an increase in HDL-C (169%), but no data 
on Lp(a) was available[34].  Furthermore, an CVD outcome trial with anacetrapib REVEAL 
(Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification)) 
is underway, results are expected in 2017. A phase 2 trial of anacetrapib in Japanese 
dyslipidaemic patients showed an increases in HDL-C of 160%, a decrease in LDL-C 
of 32%, and a decrease in Lp(a) cholesterol of 50% [33]., Furthermore a phase 3 trial 
in heterozygous FH patients (REALIZE (Study to Assess the Tolerability and Efficacy of 
Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial 
Hypercholesterolemia)) was completed in February 2014. However, the data have not 
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been published yet. Evacetrapib, (Eli Lilly, Indianapolis, Indiana, USA) , another CETP 
currently under investigation, reduces LDL-C (22%), increases HDL-C (136%) and TG 
(7%), but Lp(a) levels were not investigated[35]. Recently Dezima Pharma , announced 
a phase 1 trial to investigate the effect of their CETP inhibitor TA-8995 (Dezima Pharma, 
Naarden, The Netherlands) ) on Lp(a) levels [http://www.dezimapharma.com/dezima-
pharma-extends-clinical-development]. The mechanism of the Lp(a) lowering effect of 
the CETP inhibitors is not clear, and if CETP inhibition will prove to lower CVD risk it will 
be a challenge to determine to which extent Lp(a) will contribute to the reduction of 
CVD outcome, given its other beneficial effect on other lipoproteins. 
PCSK9-inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCKS-9) is secreted by the liver and 
regulates expression of the LDL-receptor by targeting it for lysosomal degradation 
[36]. To inhibit PCSK-9 activity, monoclonal antibodies have been developed that 
specifically target the PCSK-9 protein [36-38]. In recent phase 2 trials (AMGen: 
MENDEL (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients 
Currently Not Receiving Drug Therapy for Easing Lipid Levels) / LAPLACE-TIMI 57 
(LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin 
Therapy) / RUTHERFORD (Reduction of LDL-C With PCSK9 Inhibition in Heterozygous 
Familial Hypercholesterolaemia Disorder) /GAUSS (Goal Achievement After Utilizing an 
Anti-PCSK9 Antibody in Statin-Intolerant Subjects), ReGeneROn/SAnOFI: ODYSSEY 
(Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During 
Treatment With SAR236553) programs) the compounds of Amgen and Regeneron/
Sanofi showed that PCSK-9 inhibition on top of statin therapy reduces LDL-C by 55-65% 
, and Lp(a) by 30-40% [36-38]. This is also confirmed in a recently published phase III trial 
were after 52 weeks, there was a decrease in TG (4-23%), VLDL-C (20-79%), LDL-C (48-
61%), Lp(a) (23-33%), and in increase in HDL-C (4-11%)[39]. As with CETP inhibition the 
question how PCSK9 influences Lp(a) levels remains to be answered. It is hypothesized 
that PCSK-9 inhibition improves clearance either through an unknown receptor, directly 
from the circulation, or reduces synthesis by a decrease in substrate availability [37]. 
Although the phase 3 outcome trials are ongoing, PCSK-9 inhibition can be potentially 
important for Lp(a) reduction. However, because of the multiple actions of PCSK-
9 inhibition, the contribution of the direct effect of reduced Lp(a) on lowering CVD 
incidence will be a challenge to investigate. 
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Anti-sense apo-(a)
Recently, the results of a phase 1 study with an anti-sense compound was presented (ISIS 
APO(a)Rx, Gazelle Court Carlsbad, CA, USA) which acts specifically against the mRNA of 
apo(a), and lowers apo(a) mRNA by 90%, and Lp(a) levels up to 82% [40][ http://ir.isispharm.
com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1877550&highlight]. The phase 
I trials of ISIS APO(a)Rx have been completed, and a phase II trial will soon commence. 
This trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics 
of ISIS APO(a)Rx administered subcutaneously to patients with high Lipoprotein(a) 
levels (0,50-1,75 g/L)  and very high Lp(a) levels. (>1,75 g/L). It is the first agent which 
specifically targets Lp(a) and will cast the final verdict whether Lp(a) lowering will lower 
CVD event rates.
COnCluSIOn
Multiple agents have shown to have Lp(a) lowering properties. However statins, the 
most effective drugs in reducing CVD risk, do not modify Lp(a) to a clinical relevant 
degree. The drugs that do decrease Lp(a) have either no overall effect on CVD risk 
(estrogens and niacin), are currently investigated in phase 3 trials (CETP inhibitors and 
PCSK9 inhibitors) or are registered for an orphan population (homozygous FH patients 
for lomitapide and mipomersen). An overview of all drugs discussed in this study is 
shown in table 1. The mechanism by which Lp(a) is modified is mostly, as in case of 
niacin, CETP inhibitors and PCSK9 inhibition, unknown, which may be not surprising 
since insight into the metabolism of Lp(a) is limited. We created an overview of known 
and proposed mechanisms by which different drugs lower Lp(a) (figure 2). None of Lp(a) 
modifying agents which were reviewed, with the exception of antisense Lp(a), solely 
reduced Lp(a) without the modification of other lipoproteins. To establish whether Lp(a) 
reduction is a relevant target for CVD prevention this will be an essential piece of the 
puzzle to be determined in the future. 
ASO Apo-B, anti-sense oligonucleotide for apolipoprotein B (mipomersen); ASO 
apo(a), anti-sense oligonucleotide for apolipoprotein (a) (ISIS APO(a)Rx);  MTP-inhibitors, 
microsomal triglyceride transport protein inhibitor (Lomitapide); CETP, cholesterol ester 
transfer protein; PCSK-9, proprotein convertase subtilisin/kexin type 9; Lp(a), lipoprotein 
(a); TRβ, the β isoform of the thyroid hormone receptor.
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modifying agents which were reviewed, with the exception of antisense Lp(a), solely 
reduced Lp(a) without the modification of other lipoproteins. To establish whether Lp(a) 
reduction is a relevant target for CVD prevention this will be an essential piece of the 
puzzle to be determined in the future. 
ASO Apo-B, anti-sense oligonucleotide for apolipoprotein B (mipomersen); ASO 
apo(a), anti-sense oligonucleotide for apolipoprotein (a) (ISIS APO(a)Rx);  MTP-inhibitors, 
microsomal triglyceride transport protein inhibitor (Lomitapide); CETP, cholesterol ester 
transfer protein; PCSK-9, proprotein convertase subtilisin/kexin type 9; Lp(a), lipoprotein 
(a); TRβ, the β isoform of the thyroid hormone receptor.
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7113|Latest developments in the treatment of lipoprotein (a)
Because the length of the kringle IV repeat can interfere with Lp(a) measurements, it is 
difficult to compare studies using different assays for Lp(a) measurement, and this may 
explain some of the contradictory results between studies. For reliable reproducible 
studies a gold standard for measuring Lp(a) is needed as is recently discussed by 
Jacobson[41]. 
Presently the most evidence based strategy for CVD prevention in patients with 
increased Lp(a) levels is to lower LDL-C by statin therapy, and for patients with 
progressive CVD combined with Lp(a)-hyperlipoproteinemia lipoprotein apheresis has 
proven to reduce CVD events.
Key Points: (3-5 bullets in 1 sentence)
•	 Lp(a) is a risk factor of CVD.
•	 It is not clear if lowering Lp(a) lowers CVD risk.
•	 First line treatment of Lp(a)-hyperlipoproteinemia should be statin therapy to 
decrease CVD risk.
Figure 7.2 | Known and proposed mechanisms of compounds that lower Lp(a). 
ASO Apo-B, anti-sense oligonucleotide for apolipoprotein B (mipomersen); ASO apo(a), anti-sense 
oligonucleotide for apolipoprotein (a) (ISIS APO(a)Rx);  MTP-inhibitors, microsomal triglyceride transport 
protein inhibitor (Lomitapide); CETP, cholesterol ester transfer protein; PCSK-9, proprotein convertase 
subtilisin/kexin type 9; Lp(a), lipoprotein (a); TRβ, the β isoform of the thyroid hormone receptor.
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•	 Currently the only available Lp(a) lowering agents are estrogens, niacin, mipomersen, 
and lomitapide with either no effect on CVD outcome (estrogens, and niacin), or an 
unknown effect on CVD outcome (mipomersen, and lomitapide).
•	 New drugs (ISIS apo(a) Rx) are being developed that will be more commonly available 
and more specific for Lp(a) lowering.
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ABSTRACT
Background
Familial hypercholesterolaemia (FH) is the most common and serious monogenic 
disorder of lipid metabolism. The incidence of CAD varies among both treated and 
untreated FH patients. 
Objective: The aim of the study was to utilise proteomics to identify novel protein 
biomarkers that differentiate genetically confirmed FH patients at high CAD risk from 
low CAD risk. 
Methods
Sixty genetically confirmed FH patients were recruited and stratified into; (i) 
asymptomatic FH with low atherosclerotic burden (FH, n=20); (ii) asymptomatic FH 
with high atherosclerotic burden (FH + Ca, n=20); and (iii) FH with previously confirmed 
symptomatic CAD (FH + CAD, n=20). 
Results
Six new potential proteins were identified; leucine-rich alpha-2-glycoprotein 
(LRG1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), complement C4-B (C4B), 
complement C1q subcomponent subunit B (C1QB), monocyte differentiation antigen 
(CD14) and histidine-rich glycoprotein (HRG). There were significant associations 
between gender and C4B (Z=2.31, p=0.021), C1QB (Z=2.49, p=0.013), CD14 (Z=2.17, 
p=0.03) and HRG (Z=2.14, p=0.033). There were significant associations between 
smoking and LRG1 (χ2
2
=6.59, p=0.037), CB4 (χ2
2
=7.85, p=0.02) and HRG (χ2
2
=6.11, 
p=0.047). All the peptides were significantly associated with progression of CAD, 
independently of age and smoking. However, the absence of the proteins was the 
strongest marker. The most accurate predictor of CAD was HRG (AUROC=0.922), while 
LRG1, C4B and C1QB were excellent predictors of CAD (AUROC>0.9). For prediction of 
either coronary atherosclerosis or CAD; LRG1, C4B, C1QB and HRG were relatively good 
predictors.
Conclusions 
The present study has identified six novel protein biomarkers that are associated with 
atherosclerotic disease progression and subsequent coronary events in patients with 
FH.
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InTROduCTIOn 
Familial hypercholesterolemia (FH) is the most common and serious monogenic 
disorder of lipid metabolism1, 2 with a worldwide prevalence of at least 1 in 300.3 It is 
caused by mutations in the LDL receptor (LDLR) gene, the apolipoprotein B (APOB) gene, 
or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene.4-6 These mutations 
result in significantly elevated low-density lipoprotein (LDL) cholesterol levels that 
cause premature atherosclerotic coronary artery disease (CAD).7 
However, FH remains a frequently under diagnosed cause of CAD, and of those 
diagnosed, many are inadequately treated.8 In addition, the incidence of CAD and life 
expectancy varies among patients with both treated and untreated FH.9-11 Untreated, 
50% of male FH patients and 20% of female FH patients develop fatal coronary heart 
disease by 60 years of age. While treatment with statins more than halves the risk of 
coronary events in adults with FH,12 treated asymptomatic FH patients display significant 
variability in the extent of subclinical coronary atherosclerosis despite the use of 
aggressive statin therapy.9 Current known plasma biomarkers, in addition to classical 
risk factors, do not explain the residual CAD risk in people with FH. Indeed, the large 
variation in CAD incidence within the FH population suggests there are other factors, in 
addition to elevated cholesterol, that may play a role in development of atherosclerosis 
in FH. There is an urgent need for improved cardiovascular screening in asymptomatic 
individuals, however the development of novel markers to identify cardiovascular risk 
must add to the prognostic value provided by standard risk markers.13, 14
In the past decade, quantitative proteomic techniques including, isobaric tag for relative 
and absolute quantification (iTRAQ), have been used to identify novel biomarkers in 
several disease states, including CAD.15, 16 Using isotope labelled molecules, iTRAQ allows 
for the quantification of multiple proteins from various sources, in a single experiment.17 
Previous iTRAQ studies have shown differences in expected CAD associated proteins, 
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including those involved in inflammation, coagulation and lipid metabolism,15, 16 while 
other studies have identified novel predictors.15 To date, no such study has investigated 
the use of iTRAQ proteomics in predicting CAD risk in a FH population.
Therefore, the aim of the present study was to utilise proteomics to identify candidate 
protein biomarkers that may differentiate genetically confirmed FH patients at high 
CAD risk from those with low CAD risk.
MATeRIAlS & MeTHOdS
Study population
Sixty FH patients (40-70 yrs) from the Vascular Genetics Outpatient Clinic at the 
Erasmus MC were recruited. All participants had a genetically confirmed mutation 
in the LDLR-gene. The 60 patients were selected and stratified into 3 subgroups; (i) 
asymptomatic FH with a low atherosclerotic burden as defined a coronary diseased 
segment score of 0 (FH, n=20); (ii) asymptomatic FH with a high atherosclerotic burden 
as defined by a coronary diseased segment score >7 (FH + Ca, n=20); and (iii) FH with 
previously confirmed symptomatic CAD (myocardial infarction, percutaneous coronary 
intervention or coronary bypass surgery) (FH + CAD, n=20). Exclusion criteria included; 
a secondary cause of hypercholesterolaemia, and renal, liver and thyroid disease. Within 
the asymptomatic groups, additional exclusion criteria included; symptoms of CAD, 
history of CAD, renal insufficiency (serum creatinine >120 mmol/L), known contrast 
allergy and atrial fibrillation. The study was conducted in line with the Declaration 
of Helsinki. All patients gave a written informed consent and the study protocol was 
approved by the Erasmus MC Ethical Review Board.
Coronary CT Angiography (CCTA)
CCTA scan protocols and outcomes have previously been described.18 Briefly, all 
asymptomatic FH patients underwent CCTA to determine their atherosclerotic burden. 
Scans were performed on a dual source CT scanner (Somatom Definition, Siemens 
Medical Solutions) and analysed separately by two experienced readers blinded to the 
patient’s status. Coronary calcium was measured in Agatston units using dedicated 
software.19 In addition, using a modified 17 coronary segment model20 the percentage of 
maximum luminal diameter narrowing was visually estimated and graded as either; 0%, 
1-20%, 21-50%, 51-70% or >70%. Based on the narrowing per segment, 3 scores were 
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then used; (i) the diseased segment score (DSS), granting 1 point for each narrowing 
>20%; (ii) the CAD severity score, granting 1, 2 or 3 points per segment narrowing of 
21-50%, 51-70% and 70%, respectively; and (iii) the CAC extent score, granting 1, 2, 3 
or 4 points per segment narrowing of 1-20%, 21-50%, 51-70% and >70%, respectively. 
iTRAQ Proteomics
Isobaric tag for relative and absolute quantification (iTRAQ) was performed by 
Proteomics International (PI) on fasting EDTA plasma that had previously been stored at 
-80oC. The process involved an initial discovery phase followed by a validation phase. In 
the discovery phase the samples were depleted of the top 14 high abundance proteins, 
diafiltrated, reduced, alkylated and trypsin digested. The samples from each group were 
then labelled with iTRAQ reagents and combined to make a pooled sample (100 μL) for 
each individual group (FH, FH + Ca and FH + CAD) and an overall pooled sample (all 60 
samples). Samples were then desalted on a Strata-X 33 μm polymeric reversed phase 
column (Phenomenex) and dissolved in buffer (10 mM KH
2
PO
4
, pH3 in 10% acetonitrile) 
before separation by strong cation exchange liquid chromatography (SCX, Agilent 1100 
HPLC System) using a PolySulfoethyl column (4.6 x 100 mm, 5 μm, 300A). Peptides were 
eluted with a linear gradient of 0 – 400 mM KCl. Eight fractions containing the peptides 
were collected and desalted on Strata-X columns. The fractions were then analysed 
using electrospray ionisation mass spectrometry (Agilent 1260 Infinity HPLC system) 
coupled to an Agilent 1260 Chipcube Nanospray interface on an Agilent 6540 mass 
spectrometer, before being loaded onto a ProtlD-Chip-150 C18 column (Agilent) and 
separated with a linear gradient (water/acetonitrile/0.1% formic acid v/v).
In the validation phase, samples (20 μL) were again depleted of the top 14 high 
abundance proteins, diafiltrated, reduced, alkylated and trypsin digested. Samples were 
then desalted on a Strata-X 33 μm polymeric reversed phase column (Phenomenex) and 
analysed by electrospray ionisation mass spectrometry (LC/MS) using a Dionex UltiMate 
3000 nanoflow HPLC system coupled to a 4000 Q-TRAP mass spectrometer (AB Sciex). 
Duplicate runs were performed for all samples. A 1 μL volume containing 1:1 (v/v) ratio 
of tryptic unlabelled and 18O-labelled reference standard plasma peptides was then 
loaded onto an Agilent Zorbax 300SB-C18, 3.5 μm column and separated with a linear 
gradient of water/acetonitrile/0.1% formic acid (v/v) over 90 mins. A reference plasma 
sample was used as a control to determine the representative peptides of the new 
proteins and as an 18O-labelled reference standard for relative peptide quantification. 
MRM transitions for unlabelled and 18O-labelled peptides were created and searched for 
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in the mass spectrometer. Peptide peak area ratio analysis was performed using Skyline 
software.
Statistical analysis
Categorical variables were described using percentages. The distributional characteristics 
of continuous variables were examined using tests for skewness and kurtosis.21 Many 
were not normally distributed so all were described using the median and inter-quartile 
range (IQR). Univariable analysis of the association between the peptides and disease 
group was based upon the non-parametric Kruskal-Wallis test, and the Mann-Whitney 
test was used to examine dichotomous covariates. Correlation between continuous 
variables was assessed using the non-parametric Spearman rank-order correlation 
coefficient. Inflation of the critical significance level by multiple comparisons was 
addressed using the sequential rejection modification of the Bonferroni method 
developed independently by Holm and Simes.22, 23 Subsequent inferential analysis was 
based upon the underlying model of the disease process as a sequence of increasingly 
severe stages, which are irreversible, viz. normal, calcification, CAD. The appropriate 
statistical model is the continuation ratio regression model24 (OCR) which is a variation of 
the Cox proportional hazards model for discrete ordinal outcome data.25 The results are 
provided as hazard ratios (HR) with 95% confidence intervals (95% CI). Covariates that 
had the potential to confound the analysis were also examined using the OCR model. 
In order to preserve statistical power and in keeping with the development of methods 
for analysis of observational data, a proximity score was estimated for each peptide 
following the recommendations of Little and Rubin26 and Stuart.27 Estimation of covariate 
adjusted HRs used the proximity score as a single covariate. Analysis using the receiver 
operating characteristic (ROC) curve was used to estimate the predictive accuracy of 
proteins that showed an association with disease progression. The methods developed 
by Pepe28 were used to estimate the area under the ROC curve (AUROC) to compare 
the peptides with each other, and to examine alternative methods for combining the 
peptide results. Robust bootstrapped estimation of the standard errors was used to 
avoid overfitting. The same methods were used to estimate covariate adjusted AUROCs. 
It became apparent during the analysis that the association between the potential 
biomarkers and disease progression was negative and so an inverse transformation 
was used to prepare the ROC curves, resulting in axes which are reversed from the 
usual form. Because of the semi-continuous nature of the non-negative ‘clumping at 
zero’ measures of the proteins, analysis of the association between measures of CAD 
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severity and other disease characteristics with the proteins was conducted using a tobit 
regression model with truncation at zero.29 Statistical significance was determined by a 
p-value less than 0.05 for the multivariate models. All analysis was conducted using the 
Stata package (Version 13.1, StataCorp, College Station, Tx, USA).
ReSulTS
Patient characteristics
The patient characteristics are presented in Table 1. There was a significant difference 
in mean age between the groups in addition to a higher number of male patients. 
Approximately three quarters of the participants had a family history of CAD, while 
one third had known hypertension. There were no significant differences in fasting 
glucose levels between the groups (data not shown) and there were only 2 subjects 
with diabetes (both in the FH + Ca group). Thirty percent of the cohort were current or 
ex smokers and there were significantly more in the FH + CAD group (70% (46-86) vs. 
30% (13-54), p=0.004). As expected, the FH patients with low atherosclerotic burden 
(FH) had a significantly lower mean calcium score compared with the FH patients with 
high atherosclerotic burden (FH + Ca) (1.96 (1.18, 3.26) v 590.4 (408.8, 582,8), p=0.0001).
Table 8.1 | Patient characteristics
FH only FH + Ca FH + CAd Total p
n 20 19 20
Age (yrs) 46.1 (43.6, 48.6) 55.2 (51.4, 58.9) 57.3 (52.3, 62.3) 0.0005
Gender n (%) n (%) n (%)
• Male
• Female
11 (32.4)
9 (36.0)
14 (41.2)
5 (20.0)
9 (26.5)
11 (44.0)
34 (100)
25 (100)
0.186
Hypertension
• No
• Yes
19 (40.4)
1 (8.3)
12 (25.5)
7 (58.3)
16 (34.0)
4 (33.3)
47 (100)
12 (100)
0.047
Family History   
• No
• Yes
5 (33.3)
15 (34.1)
5 (33.3)
14 (31.8)
5 (33.3)
15 (34.1)
15 (100)
44 (100)
0.994
Smoker
• Never
• Former
• Current
11 (33.3)
6 (50.0)
3 (21.4)
16 (48.5)
3 (25.0)
0 (0)
6 (18.2)
3 (25.0)
11 (78.6)
33 (100)
12 (100)
14 (100)
0.001
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FH only FH + Ca FH + CAd Total p
n 20 19 20
Age (yrs) 46.1 (43.6, 48.6) 55.2 (51.4, 58.9) 57.3 (52.3, 62.3) 0.0005
Gender n (%) n (%) n (%)
• Male
• Female
11 (32.4)
9 (36.0)
14 (41.2)
5 (20.0)
9 (26.5)
11 (44.0)
34 (100)
25 (100)
0.186
Hypertension
• No
• Yes
19 (40.4)
1 (8.3)
12 (25.5)
7 (58.3)
16 (34.0)
4 (33.3)
47 (100)
12 (100)
0.047
Family History   
• No
• Yes
5 (33.3)
15 (34.1)
5 (33.3)
14 (31.8)
5 (33.3)
15 (34.1)
15 (100)
44 (100)
0.994
Smoker
• Never
• Former
• Current
11 (33.3)
6 (50.0)
3 (21.4)
16 (48.5)
3 (25.0)
0 (0)
6 (18.2)
3 (25.0)
11 (78.6)
33 (100)
12 (100)
14 (100)
0.001
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FH only FH + Ca FH + CAd Total p
BMI 24.9(23.7, 26.1) 27.2(25.1, 29.2) 26.3(24.9, 27.8) 0.17
lipids
• TC
• HDL
• TG
• LDL
5.39(4.92, 5.86)
1.45(1.31, 1.60)
1.02(0.84, 1.22)
3.36(2.89, 3.82)
5.38(4.87, 5.90)
1.22(1.07, 1.36)
1.20(0.92, 1.57)
3.62(3.16, 4.08)
4.91(4.46, 5.35)
1.23(1.09, 1.38)
0.96(0.80, 1.16)
3.25(2.89, 3.61)
0.39
0.043
0.51
0.57
years on statins 8.9 (5.80, 12.0) 10.8 (7.29, 14.4) 10.5 (7.79, 13.1) 0.48
Medication
• Oral antidiabetics
• Lipid lowering
• RR lowering
• Blood thinners
20 (100%)
20 (100%)
3 (15%)
0 (0%)
19 (100%)
18 (100%)
4 (22%)
3 (17%)
19 (95%)
20 (100%)
15 (75%)
20 (100%)
58 (98%)
58 (100%)
36 (62%)
23 (40%)
0.37
<0.001
<0.001
BMI, body mass index; CAD, coronary artery disease; FH, familial hypercholesterolemia; HDL, high-density 
lipoprotein; LDL, low-density lipoproteins; RR, relative risk; RR lowering, blood pressure–lowering drugs; TC, 
total cholesterol; TG, trigylcerides. 
Results presented as frequency (%) for categorical and mean (95% confidence interval) for continuous 
variables, respectively. Differences between the groups were assessed using analysis of variance with Holm-
Simes post-hoc comparisons.
Identification of potential protein biomarkers
In the initial discovery phase, 164 proteins were detected from a total of 47,708 
spectra. In the subsequent validation phase, all differentially expressed proteins were 
shortlisted and a list of common differentially expressed proteins was extrapolated. Of 
the 17 proteins identified, 9 were already available as existing PI assays. The remaining 
8 new proteins were assessed in silico and representative peptides and transitions were 
determined for 4 of them, while representative peptides could not be determined for 
the remaining 4 proteins. The final list of 13 proteins was represented by 20 peptides 
and 106 transitions and from this a final 6 proteins were selected as potential biomarker 
candidates. These proteins were; leucine-rich alpha-2-glycoprotein (LRG1), inter-
alpha-trypsin inhibitor heavy chain H3 (ITIH3), complement C4-B (C4B), complement 
C1q subcomponent subunit B (C1QB), monocyte differentiation antigen (CD14) and 
histidine-rich glycoprotein (HRG). 
Distribution and associations of protein biomarkers 
All of the 6 proteins displayed a bi-modal distribution and Figure 1 shows the median, 
inter-quartile range and range for each one. One sample in the FH + Ca group could not 
be analysed. There was significant rank-order correlation between the protein biomarkers, 
Table 8.1 | Continued
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with the exception of CD14. Not all proteins could be detected in a substantial proportion 
of participants; in particular, monocyte differentiation antigen (CD14) was not detected in 
more than 75% of the participants, including none of the FH + CAD patients. 
Within the whole cohort, there were significant associations between gender and 
C4B (Mann-Whitney Z=2.31, p=0.021), C1QB (Z=2.49, p=0.013), CD14 (Z=2.17, p=0.03) 
and HRG (Z=2.14, p=0.033). There were also significant associations between smoking 
and LRG1 (Kruskal-Wallis χ2
2
=6.59, p=0.037), CB4 (χ2
2
=7.85, p=0.02) and HRG (χ2
2
=6.11, 
p=0.047). There were no significant associations between any of the protein biomarkers 
and age or lipid levels. 
Figure 8.1 | Relative abundance of plasma protein biomarkers in all patients with familial 
hypercholesterolemia.
Analysis of protein biomarkers as indicators of CAD
Table 2 shows the results of the OC regression analysis for the level of each protein and 
also for the total number of proteins that could be detected. Crude HRs were generally 
lower than the adjusted HR, which reflects the increase in risk of coronary atherosclerosis 
and CAD with increasing age and with smoking. Two p values are shown in the table, 
the first tests the null hypothesis that the HR across the groups is equal (HR=1) and 
the second tests the null hypothesis that the change in the HR is the same for each 
transition from FH to FH + Ca to FH + CAD. Overall, it is clear that all of the peptides were 
significantly associated with progression of CAD, independently of age and smoking 
exposure, using a critical p value adjusted for multiple comparisons.
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Table 8.2a | Univariate CAD HR models for group by each peptide
Peptide Hazard ratio 95% CI for HR p1
HR=1
p2
HR=For each 
group
LRG1 0.054 0.017 0.170 <0.001 0.302
ITIH3 0.213 0.094 0.481 <0.001 0.054
C4B 0.005 0.000 0.050 <0.001 0.020
C1QB 0.069 0.021 0.230 <0.001 0.334
CD14 0.149 0.049 0.458 0.001 0.145
HRG 0.132 0.048 0.365 <0.001 0.001
Peptides detected 0.054 0.017 0.170 <0.001 0.302
Table 8.2b | Multivariable CAD HR models for each peptide adjusted for age and smoking status
LRG1 0.102 0.028 0.377 0.001 0.003
ITIH3 0.292 0.123 0.692 0.005 0.111
C4B 0.027 0.002 0.416 0.010 <0.001
C1QB 0.142 0.034 0.601 0.008 0.027
CD14 0.222 0.058 0.850 0.028 0.199
HRG 0.262 0.086 0.794 0.018 <0.001
Peptides detected 0.102 0.028 0.377 0.001 0.003
Results are presented as hazard ratios (HR) with 95% Confidence Intervals (95% CI) using continuation ratio 
regression model before and after adjustment for age and smoking. All of p1 were statistically significant after 
correction for multiple comparisons.
LRG1 – leucine-rich alpha-2-glycoprotein, ITIH3 – inter-alpha-trypsin inhibitor heavy chain H3, C4B – 
Complement C4-B, C1QB – Complement C1q subcomponent subunit B, CD14 – Monocyte differentiation 
antigen, HRG – histidine-rich glycoprotein
However, the analysis also showed that it was the absence of the proteins that was the 
strongest indicator and this is demonstrated in Table 3 where it can be seen that for all 
proteins, other than CD14, there are few patients in the FH only group who don’t show 
the protein and there are few in the FH + CAD group who do show the protein.
Results of the association between the amount of protein and other CAD severity 
markers are shown in Table 4. It is clear that the proteins are not associated with clinical 
indicators of CAD severity. A tobit truncated regression analysis demonstrated a significant 
negative association with the Framingham points score for C4B (coefficient=-11.4, 
p=0.031), C1QB (coefficient=-6.99, p=0.011) and HRG (coefficient=-4.83, p=0.033) in the 
FH and FH + Ca patients (the only patients for which this was appropriate). 
128 |      Chapter 8
Table 8.2a | Univariate CAD HR models for group by each peptide
Peptide Hazard ratio 95% CI for HR p1
HR=1
p2
HR=For each 
group
LRG1 0.054 0.017 0.170 <0.001 0.302
ITIH3 0.213 0.094 0.481 <0.001 0.054
C4B 0.005 0.000 0.050 <0.001 0.020
C1QB 0.069 0.021 0.230 <0.001 0.334
CD14 0.149 0.049 0.458 0.001 0.145
HRG 0.132 0.048 0.365 <0.001 0.001
Peptides detected 0.054 0.017 0.170 <0.001 0.302
Table 8.2b | Multivariable CAD HR models for each peptide adjusted for age and smoking status
LRG1 0.102 0.028 0.377 0.001 0.003
ITIH3 0.292 0.123 0.692 0.005 0.111
C4B 0.027 0.002 0.416 0.010 <0.001
C1QB 0.142 0.034 0.601 0.008 0.027
CD14 0.222 0.058 0.850 0.028 0.199
HRG 0.262 0.086 0.794 0.018 <0.001
Peptides detected 0.102 0.028 0.377 0.001 0.003
Results are presented as hazard ratios (HR) with 95% Confidence Intervals (95% CI) using continuation ratio 
regression model before and after adjustment for age and smoking. All of p1 were statistically significant after 
correction for multiple comparisons.
LRG1 – leucine-rich alpha-2-glycoprotein, ITIH3 – inter-alpha-trypsin inhibitor heavy chain H3, C4B – 
Complement C4-B, C1QB – Complement C1q subcomponent subunit B, CD14 – Monocyte differentiation 
antigen, HRG – histidine-rich glycoprotein
However, the analysis also showed that it was the absence of the proteins that was the 
strongest indicator and this is demonstrated in Table 3 where it can be seen that for all 
proteins, other than CD14, there are few patients in the FH only group who don’t show 
the protein and there are few in the FH + CAD group who do show the protein.
Results of the association between the amount of protein and other CAD severity 
markers are shown in Table 4. It is clear that the proteins are not associated with clinical 
indicators of CAD severity. A tobit truncated regression analysis demonstrated a significant 
negative association with the Framingham points score for C4B (coefficient=-11.4, 
p=0.031), C1QB (coefficient=-6.99, p=0.011) and HRG (coefficient=-4.83, p=0.033) in the 
FH and FH + Ca patients (the only patients for which this was appropriate). 
        
8129|Novel protein biomarker predictors of CAD in FH
Table 8.3 | Associations between protein biomarkers and CAD severity in FH patients.
lRG1 ITIH3 C4B C1QB Cd14 HRG
Disease severity score rho
p
-0.078
0.636
0.140
0.395
-0.028
0.868
-0.117
0.479
-0.180
0.274
-0.060
0.717
CAD severity score rho
p
-0.094
0.569
0.122
0.460
-0.025
0.879
-0.137
0.405
-0.181
0.269
-0.084
0.610
SIS score rho
p
-0.107
0.519
0.125
0.447
-0.066
0.692
-0.172
0.296
-0.189
0.248
-0.100
0.544
CAD extent 05 rho
p
-0.146
0.377
0.037
0.821
0.014
0.934
-0.146
0.377
-0.125
0.447
-0.026
0.874
CAD extent 04 rho
p
-0.144
0.381
0.038
0.819
0.015
0.928
-0.143
0.384
-0.125
0.447
-0.026
0.877
Univariate analysis of the association between peptides and CAD severity., LRG1 :Leucine-rich alpha-2-
glycoprotein, ITIH3 :Inter-alpha-trypsin inhibitor heavy chain H3, C4B :Complement C4-B, C1QB :Complement 
C1q subcomponent subunit B, CD14 :Monocyte differentiation antigen, HRG :Histidine-rich glycoprotein, Rho: 
Spearmans’s rho rank-order correlation coefficient, p: Significance for the H0 test that rho=0.
A logistic regression analysis comparing these three proteins and the Framingham score 
indicates that for C4B and C1QB, the Framingham score is superior as an indicator of 
arterial calcification. With HRG we found a significant interaction with the Framingham 
score so that together the two measures provide enhanced discrimination between 
asymptomatic FH patients and those with calcification (HRG: p=0.011, Framingham: 
p=0.007 and interaction: p=0.014, AUC=0.858).
Figure 8.2 | Proportion of patients within each disease severity group with any of the indicator 
proteins detected. 
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As might be expected, there are significant associations between treatment and disease 
progression for both RR-lowering drugs (p<0.001) and blood thinners (p<0.001) (Table 
6). Both treatments are also associated with each other and they show a significant 
association with the proteins of interest in this study. In addition, the RR-lowering drugs 
but not the blood thinners show significant interactions with LRG1, ITIH3, C4B and C1QB 
but not with CD14 or HRG (Table 5).
An analysis of the AUROC for FH + CAD for each protein, comparing the protein 
as measured with the protein ‘detectable’ vs. ‘not detectable’ showed there was little 
difference between the two (Table 5). This analysis includes the AUROC for the total 
number of peptides detected and whether any of the peptides were detected. The most 
accurate indicator of CAD is HRG (as measured) with an AUROC of 0.922 (0.862, 0.983), 
but there were a number of other proteins that were very similar (see Figure 2). 
Figure 8.3 Area under the ROC (AUROC), estimating the predictive accuracy of each protein with 
CAD progression. 
AUC: Area under the curve; C1QB: Complement C1q subcomponent subunit B; C4B: Complement C4-B; CAD: 
Coronary artery disease; CD14: Monocyte differentiation antigen; CI: Confidence interval; HRG: Histidine-rich 
glycoprotein; ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3; LRG1: Leucine-rich alpha-2-glycoprotein.
130 |      Chapter 8
As might be expected, there are significant associations between treatment and disease 
progression for both RR-lowering drugs (p<0.001) and blood thinners (p<0.001) (Table 
6). Both treatments are also associated with each other and they show a significant 
association with the proteins of interest in this study. In addition, the RR-lowering drugs 
but not the blood thinners show significant interactions with LRG1, ITIH3, C4B and C1QB 
but not with CD14 or HRG (Table 5).
An analysis of the AUROC for FH + CAD for each protein, comparing the protein 
as measured with the protein ‘detectable’ vs. ‘not detectable’ showed there was little 
difference between the two (Table 5). This analysis includes the AUROC for the total 
number of peptides detected and whether any of the peptides were detected. The most 
accurate indicator of CAD is HRG (as measured) with an AUROC of 0.922 (0.862, 0.983), 
but there were a number of other proteins that were very similar (see Figure 2). 
Figure 8.3 Area under the ROC (AUROC), estimating the predictive accuracy of each protein with 
CAD progression. 
AUC: Area under the curve; C1QB: Complement C1q subcomponent subunit B; C4B: Complement C4-B; CAD: 
Coronary artery disease; CD14: Monocyte differentiation antigen; CI: Confidence interval; HRG: Histidine-rich 
glycoprotein; ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3; LRG1: Leucine-rich alpha-2-glycoprotein.
        
8131|Novel protein biomarker predictors of CAD in FH
Table 8.4 | Tests comparing ROC AUC
Predictor of CVd AuC 95% CI for AuC s.e.
lCl uCl
LRG1 (as measured) 0.911 0.838 0.984 0.037
LRG1 (zero vs. more than zero) 0.911 0.839 0.983 0.037
ITIH3 (as measured) 0.784 0.693 0.875 0.046
ITIH3 (zero vs. more than zero) 0.783 0.691 0.874 0.047
C4B (as measured) 0.918 0.857 0.979 0.031
C4B (zero vs. more than zero) 0.898 0.823 0.974 0.039
C1QB (as measured) 0.905 0.823 0.986 0.041
C1QB (zero vs. more than zero) 0.911 0.839 0.983 0.037
CD14 (as measured) 0.654 0.580 0.727 0.037
CD14 (zero vs. more than zero) 0.654 0.580 0.727 0.037
HRG (as measured) 0.922 0.862 0.983 0.031
HRG (zero vs. more than zero) 0.911 0.839 0.983 0.037
Total peptides detected 0.912 0.840 0.983 0.037
Any peptides detected 0.911 0.839 0.983 0.037
Predictive accuracy of proteins with disease severity using area under the ROC (receiver operating curve), to 
compare peptides with each other.
AUC: Area under curve, LCL: Lower confidence level, UCL: Upper confidence level, s.e.: Standard error, LRG1: 
Leucine-rich alpha-2-glycoprotein, ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3, C4B: Complement C4-B
C1QB: Complement C1q subcomponent subunit B, CD14: Monocyte differentiation antigen, HRG: Histidine-
rich glycoprotein
Overall ROC analysis revealed LRG1, C4B and C1QB were excellent indicators of CAD in 
patients with FH (AUROC > 0.9), with ITIH3 only a relatively good indicator. In addition, 
the total number of proteins detected and whether any of them were detected was also 
excellent. For indication of either coronary atherosclerosis or CAD; LRG1, C4B, C1QB and 
HRG were relatively good (Figure 3). Although C1QB is a possible indicator, none of the 
protein biomarkers were considered to be good for indicating coronary atherosclerosis 
alone. When the AUC is adjusted for the use of RR-lowering drugs, bootstrapped 
estimates of the AUC showed that CD14 and ITIF3 are not accurate indicators of CAD 
when adjusted for the presence of RR-lowering drugs, but HRG (AUC=0.920, 0.846-0.974) 
and C4B (0.916, 0.837-0.961) are excellent indicators of CAD and are little influenced by 
RR-lowering drugs.
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Table 8.5 | Associations between protein biomarkers, treatment and disease progression
HR lCl95% uCl95% P
2 AuC for CAd (CI)
RR lowering drugs alone 5.04 2.18 11.7 <0.001 0.783 (0.668-0.897)
Blood thinner drugs alone <0.001
LRG1
   RR lowering drugs
   Protein/drug interaction
ITIH3
   RR lowering drugs
   Protein/drug interaction
0.188
18.9
0.005
0.555
11.1
0.044
0.053
2.12
0.0001
0.207
2.86
0.005
0.668
168
0.221
1.48
43.0
0.405
0.01
0.008
0.006
0.241
<0.001
0.006
0.907(0.818-0.960)
0.783 (0.682-0.899)
0.778 (0.688-0.868)
0.783 (0.682-0.899)
C4B
   RR lowering drugs
   Protein/drug interaction
0.027
9.34
0.000
0.002
2.04
0.0001
0.464
43.0
0.001
0.013
0.004
0.001
0.916 (0.837-0.961)
0.783 (0.645-0.884)
C1QB
   RR lowering drugs
   Protein/drug interaction
0.135
13.1
0.000
0.03
2.18
0.0001
0.608
79.1
0.048
0.009
0.005
0.001
0.902 (0.815-0.974)
0.783 (0.657-0.884)
CD14
   RR lowering drugs
   Protein/drug interaction
0.258
4.73
0.522
0.072
1.87
0.028
0.923
12.0
9.70
0.037
0.001
0.663
0.658 (0.605-0.763)
0.783 (0.682-0.896)
HRG
   RR lowering drugs
0.235
5.51
0.063
1.78
0.879
17.1
0.031
0.003
0.920 (0.846-0.974)
0.783 (0.668-0.884)
   Protein/drug interaction 0.316 0.033 3.001 0.316
P: p value for likelihood ratio test that HR=0, LRG1: Leucine-rich alpha-2-glycoprotein, ITIH3: Inter-alpha-
trypsin inhibitor heavy chain H3, C4B: Complement C4-B, C1QB: Complement C1q subcomponent subunit B, 
CD14: Monocyte differentiation antigen, HRG: Histidine-rich glycoprotein
dISCuSSIOn
Using highly sensitive proteomic techniques, the present study has revealed six plasma 
proteins that were significantly associated with coronary artery disease progression 
in statin-treated FH patients. This is the first study to describe such an association and 
the findings may represent a novel tool for predicting the development of CAD or the 
residual CAD risk, independent of classical risk factors and clinical indicators, in this 
high-risk population.
Atherosclerotic cardiovascular disease (CVD) is a leading cause of morbidity and 
mortality globally.30 A recent study has shown that proteomic profiling identified 
both single and multiple marker protein panels that were associated with new-
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onset atherosclerotic CVD in participants from the Framingham Heart Study. These 
included many novel protein biomarkers, which when viewed as a panel of aggregate 
proteins, improved myocardial infarction and atherosclerotic risk prediction above and 
beyond established risk factors.30 In the present study, we have highlighted six protein 
biomarkers as potential predictors of CAD risk in our statin-treated FH population. Since 
FH is already associated with an extremely elevated risk of developing CAD,7 albeit one 
with significant inter-individual variation,9-11 this represents an exciting new finding. This 
finding could potentially provide a tool for identifying those at high risk of developing 
CAD, which would then allow for personalised treatment to prevent early CAD events. 
This is particularly important given that intervention strategies at the preclinical stage 
are more likely to confer benefit. Interestingly, while all six peptides were associated with 
disease progression (from no atherosclerotic burden, to presence of severe coronary 
atherosclerosis, up to symptomatic coronary event), it was the absence of these proteins 
that suggested the highest risk, independent of age or smoking. 
Of the six proteins found, the strongest association with CAD appeared to be HRG, 
followed by LRG1, C4B and C1BQ. ITIH3 appeared to have little association with disease 
progression. Our analysis suggests that the association with LRG1, C4B and C1BQ may 
be an artefact because of the application of risk reduction therapy but this does not 
appear to be the case for HRG. HRG, or histidine-rich glycoprotein, is a serum protein 
belonging to the cystatin superfamily, which plays a regulatory role in hemostasis 
and innate immunity.31 A previous study in mice has shown that the Hrg-/-	 mice had 
higher anti-thrombin activity, shorter pro-thrombin time and reduced bleeding time, 
compared to their heterozygous and wild type counterparts. These findings suggest 
that HRG plays a role as both an anticoagulant and anti-fibrinolytic modifier, and may 
also regulate platelet function. As a result, the authors suggest that an absence of 
HRG could trigger monocyte proliferation to compensate for a decrease in phagocyte 
activation. Coupled with the suggestion that HRG binds several components of the 
coagulation and fibrinolysis cascades,31 this implies that its absence could also play a 
role in the development of atherosclerosis in humans. In agreement with this is our 
finding of significantly reduced levels of HRG in the FH + CAD group compared to the 
asymptomatic FH group. Indeed, only one patient in the FH + CAD group had detectable 
levels of HRG, while all but one had detectable levels in the FH group. Within the FH 
+ Ca group, 40% had detectable levels of HRG, suggesting that either a reduction in 
circulating HRG occurs with disease progression or there’s a possible ‘switching off” of 
HRG production leading to the development of atherosclerosis.
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Figure 8.4 | Area under the receiver operating characteristic curve, estimating the predictive 
accuracy of each protein with coronary artery calcium or coronary artery disease.
AUC: Area under the curve; C1QB: Complement C1q subcomponent subunit B; C4B: Complement 
C4-B; CAD: Coronary artery disease; CD14: Monocyte differentiation antigen;  CI: Confidence 
interval; HRG: Histidine-rich glycoprotein; ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3; 
LRG1: Leucine-rich alpha-2-glycoprotein.
LRG1, or leucine-rich α-2 glycoprotein is a highly conserved member of the leucine-
rich repeat family of proteins, many of which have been found to play a role in protein-
protein interaction, signalling and cell adhesion.32 LRG1 has been shown to increase 
proliferation in cultured endothelial cells and is up-regulated and pro-angiogenic in 
mouse models of retinal disease.33 A recent human study has found elevation of LRG1 
is associated with arterial stiffness, endothelial dysfunction and peripheral vascular 
disease in patients with type 2 diabetes.34 In the present study however, we saw 
almost a complete absence of LRG1 in the FH + CAD group when compared to the 
asymptomatic groups. Again, only one patient in the FH + CAD group had detectable 
levels of LRG1. The reason for this discrepancy between the previous animal and human 
studies and our study is unclear. It is possible that an initial elevation of LRG1 promotes 
arterial stiffening and endothelial dysfunction, both early hallmarks of atherosclerosis, 
but then decreases as the disease establishes and progresses. The findings from the 
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Framingham Heart Study support this, as LRG1 was only found to be predictive of new-
onset atherosclerosis, and not myocardial infarction.30
Inflammation plays a key role in both the development and progression of 
atherosclerosis, with initial modification of LDL resulting in its preferential uptake in the 
intimal layer of the arterial wall, resulting in an immediate innate immune response, 
which ultimately leads to the development of fatty lesions and atherosclerotic 
plaques.35 Children with FH have been shown to have an inflammatory imbalance, 
which may contribute to the accelerated atherosclerosis development.36 Furthermore, 
oxidative modification of LDL has been shown to be related to inflammatory gene 
expression and subsequent atherosclerosis development in both children and young 
adults with FH.37 Complement C4-B (C4B) and Complement C1q subcomponent subunit 
B (C1BQ) are part of the complement system, which plays a role in our innate defence. 
As oxidatively modified LDL promotes inflammation, the innate immune system is the 
Figure 8.5 | Area under the receiver operating characteristic curve, estimating the predictive 
accuracy of each protein with coronary artery calcium.
AUC: Area under the curve; C1QB: Complement C1q subcomponent subunit B; C4B: Complement 
C4-B; CAD: Coronary artery disease; CD14: Monocyte differentiation antigen; CI: Confidence 
interval; HRG: Histidine-rich glycoprotein; ITIH3: Inter-alpha-trypsin inhibitor heavy chain H3; 
LRG1: Leucine-rich alpha-2-glycoprotein.
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initial process for neutralising and eliminating these toxic particles.35 The complement 
system is also thought to contribute to endothelial dysfunction, and is activated in 
early fatty streaks and late stages of atherosclerosis.38 In the present study, we have 
shown that both C4B and C1BQ are excellent predictors of CAD. However, once again 
it was the absence of both of these proteins in the FH + CAD group compared to the 
FH group that was predictive. While inflammation plays a key role in atherosclerosis, 
it is also possible that chronic exposure to stressors and inflammatory markers in the 
arterial wall may lead to a loss of immune homeostasis. As such, both C4B and C1BQ 
may play a role in the early, subclinical stages of CAD (the asymptomatic groups) when 
atherosclerosis is first developing, but are absent in the FH + CAD group where disease 
is established. Supporting this is the suggestion that the complement system has a dual 
role in atherosclerosis, including the removal of debris as well as amplification of the 
inflammatory response. Furthermore, some components of the complement system, 
including C1Q appear to have a protective effect.38 Clearly the role of the complement 
system in the development of atherosclerosis is complex and the role of these proteins 
in disease progression warrants further investigation.
CD14, or monocyte differentiation antigen, is a protein expressed in monocytes 
and macrophages and also involved in inflammation.39 A recent study has shown that 
CD14 may be a potential marker of CAD where urinary CD14 levels were significantly 
higher in patients with angiographic CAD compared with controls.39 Interestingly, we 
saw no detectable amounts of circulating CD14 in >75% of our participants, including 
none of the patients in the FH + CAD group. This is in contrast to the previous study, 
however it should be noted that we did not perform CD14 analysis on urine within our 
study population. In the previous study, the authors noted no significant differences 
in plasma CD14 between their two groups. Furthermore, while their CAD group had 
angiographically proven CAD, they had not had a previous coronary event.39
The lack of association between any of the protein biomarkers and classical risk factors 
of CAD is interesting. Furthermore, while most of the proteins were excellent to good 
predictors of CAD, they were less robust as predictors of coronary atherosclerosis. The 
reason for this is unclear. However, it may be in part due to the fact that one or more 
proteins play different roles at different stages of the development of atherosclerosis. 
Our findings suggest that the proteins identified as potential biomarkers may be more 
relevant at the preclinical stage of disease development, which is where they would 
have the greatest clinical utility. Future studies examining healthy control populations 
as well as protein levels and disease progression in FH patients are needed to tease out 
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these relationships. Furthermore, it is worth considering that while FH is characterised 
by advanced atherosclerosis and CAD, it is a genetically distinct disease. It is therefore 
possible that there are additional underlying factors, unique to FH and its associated 
mutations, which manifest differently to a patient with CAD not associated with FH.
While it is too early in this investigation to conclude that a predictive relationship exists 
between the loss of these peptides and disease progression, the results suggest there 
are grounds to support such a hypothesis. Firstly, a statistical association exists between 
a number of related proteins and disease. Secondly, there is a clear lack of significant 
association between the severity of CAD and the potential biomarkers (Table 4). This 
supports a hypothesis of prediction of the change in state rather than progression of 
severity of the condition per	se. Thirdly, the significant association of age and smoking 
also support the hypothesis that these potential markers may be able to predict the 
change in disease status since age is a surrogate marker of elapsed time for each patient 
and smoking is a well established predictor of CAD. It is clear that a prospective study of 
asymptomatic FH patients to investigate CAD progression is warranted.
There are several limitations associated with the present study that must be 
acknowledged. These include; the cross-sectional study design and inclusion of a highly 
selected population with a relatively small sample size. Furthermore, we did not test 
against other biomarkers, including genetic ones. This is particularly important given 
the need for novel strategies to identify CAD risk in asymptomatic adults, which add to 
the prognostic value provided by standard risk factors. While alternate strategies that 
go beyond measuring traditional risk factors are needed, they must also be better than 
existing non-invasive strategies (imaging for carotid intimal medial thickness and coronary 
artery calcium) and have a wide variability, which does not correlate with traditional risk 
factors. The strengths of the present study, however, include the well characterised treated 
patient groups and the extreme selection of CAD endpoints at a relatively young age. 
In conclusion, the present study has identified six protein biomarkers that are 
associated with atherosclerotic disease progression and subsequent coronary events 
in treated patients with FH. As these are a group of individuals already at elevated 
risk of developing CAD, this offers a novel tool for more accurate prediction of risk 
and therefore commencement of early aggressive therapy to prevent future coronary 
events. Although the present study is hypothesis generating due to its cross-sectional 
design and needs to be tested in larger populations with prospective follow-up, this 
may be possible through international collaborations that utilise the power of well-
characterised registry data. 
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9145|Summary and Discussion
SuMMARy 
Since the introduction of statin therapy as cholesterol-lowering medication in the 1990s, 
the life expectancy of patients with familial hypercholesterolemia (FH) has improved 
significantly. However, despite the wide-spread use of statins among FH patients, some 
still do develop CVD (1). The aim of this thesis was to develop an approach to identify 
the residual cardiovascular disease (CVD) risk in statin-treated FH patients. Therefore, 
in part 1 I investigated the value of applying imaging techniques such as carotid 
ultrasonography and computed tomography coronary angiography (CTCA) (chapter 2,3 
and 4), and in part 2 measurement of non-traditional and traditional risk factors such as 
lipoprotein (a) [Lp(a)] levels in statin treated FH patients (chapter 5, 6) to distinguish who 
are high-risk FH patients and who not. In Chapter 7 I discussed the different treatment 
options of high Lp(a) levels. In Chapter 8 I concluded by using a proteomics technique 
to identify novel proteins that are associated with cardiovascular disease and coronary 
calcification in statin treated FH patients.
Part 1: Cardiovascular imaging and residual cardiovascular risk in FH patients.
Subclinical atherosclerosis can be measured by carotid ultrasonography. As it is a non-
invasive measurement and relatively easy to measure it is often used in clinical studies 
to determine cardiovascular risk.
First, in chapter 2 I showed that the carotid ultrasonography technique that was used 
in our studies, is reliable and reproducible by performing an intra- and inter-observer 
validation between a traditional and semi-automatic ultrasound device. 
Subsequently, I studied in chapter 3 whether carotid imaging results by ultrasonography, 
reflected by the prevalence of carotid plaques and carotid intima-media-thickness 
(C-IMT), are suitable for determining residual risk. Can we distinguish FH patients who 
use long-term statin treatment from non-FH subjects? Therefore, I compared carotid 
plaque prevalence and C-IMT between FH patients using long-term statin treatment 
and healthy non-FH controls. I showed that these outcomes were similar between the 
groups. In a subset of FH patients of whom a CTCA was available, I showed that carotid 
plaques presence was associated with coronary calcification determined by CTCA , 
implying that not C-IMT but carotid plaques could be of interest to determine residual 
risk in statin-treated FH patients. 
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Patients with homozygous FH patients have a high prevalence of aortic valve disease 
(AoVC)  and this is, in addition to coronary artery disease (CAD), the major cause of 
premature death in this group. On the other hand, whether AoVC is more common 
in heterozygous FH patients (heFH) compared to non-FH individuals is unknown. In 
chapter 4 I show that AoVC is more prevalent in asymptomatic FH patients than in 
non-FH controls. Among heFH patients, the prevalence of AoVC was highest in FH 
patients with a LDL-receptor negative mutation with the highest untreated LDL-C 
levels compared to FH patients with a LDL-receptor defective mutation. This suggests a 
causal role of LDL-C in the early onset of aortic valve pathology. Therefore, I established 
that the health of heFH patients is threatened beyond “classical” atherosclerotic CVD 
through the accelerated development of AoVC. While statin therapy can significantly 
diminish the risk of CVD, statins do not affect the course of AoVC and stenosis once this 
is established. This study implies: 1) to start with statin therapy at a young age not only 
to prevent CVD but also to prevent AVC; 2) that regularly screening heFH patients for 
AoVC might be needed.
Part 2: Non-traditional risk factors and residual cardiovascular risk in FH 
patients.
Lp(a) is a genetically determined atherogenic lipoprotein which is currently not part 
of the traditional lipid panel. Lp(a) is not only an independent risk factor for CVD, but 
has also been associated with aortic valve stenosis with SNPs in the LPA	gene as well 
as plasma Lp(a) levels (2). In Chapter 5 I show that Lp(a) levels are associated with 
AoVC determined by CTCA in asymptomatic FH patients. In Chapter 6 I investigated 
whether Lp(a) levels were associated with atherosclerosis depicted as C-IMT and carotid 
plaques measured by carotid ultrasonography in statin-treated HeFH patients. I found 
no association between Lp(a) levels and carotid ultrasonography outcomes. In Chapter 
7 I discuss the latest developments in the treatment of Lp(a). Both statins, the most 
widely used lipid lowering agents, and lifestyle intervention have no effect on Lp(a) 
levels. The new protein subtilisin/kexin type 9 inhibitors lower Lp(a) by 30-50%, but 
also lower LDL-C. It is unknown whether specifically lowering of Lp(a) can reduce CVD 
risk. However, recently an antisense oligonucleotide directed to apolipoprotein (a) has 
been developed which can specifically lower Lp(a) levels up to 90%. Trials with this new 
drug shall reveal whether reduction of Lp(a) levels can decrease CVD risk. In Chapter 8 
I identified six novel proteins associated with atherosclerosis and CVD events in heFH 
patients. For this purpose I used the isobaric tag for relative and absolute quantification 
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(iTRAQ) proteomics technique in 60 specifically selected heFH patients, and discovered 
plasma proteins previously not related to atherosclerosis. These proteins were, as 
expected, part of the coagulation pathway, the inflammation pathway, and the lipid 
metabolism pathway. Further research is required to confirm the importance of these 
proteins and if they are suitable as biomarkers or even potentially targets for novel 
therapeutic interventions to reduce CVD risk. 
dISCuSSIOn
The introduction of statin treatment has had great impact in the survival of FH patients 
by increasing the life expectancy similar to that of the general population. However, 
some FH patients still develop CVD despite statin treatment. In this thesis I investigated 
the role of cardiovascular imaging and non-traditional risk factors to discriminate 
between FH patients who are at high risk of developing CVD despite long-term statin 
treatment and those with low risk of CVD. Furthermore, I investigated the prevalence of 
aortic valve calcifications (AoVC) in FH patients, since this is another entity of CVD which 
has not been studied extensively yet.
Emerging lipid-lowering medication in FH patients
Identifying FH patients with high residual risk is very relevant in light of the development 
of novel therapeutic agents. The most promising, and recently approved therapeutic 
agents are proprotein convertase substillin/kexin type 9 (PCSK-9) inhibitors. The proposed 
mechanism of the PCSK-9 protein is binding to the LDL-receptor and subsequently 
degradation of the LDL-receptor after internalisation in the cell. When PCSK-9 cannot 
bind to the LDL-receptor, the receptor will be recycled and re-emerge on the cell surface 
where it can bind a new LDL-cholesterol particle. PCSK-9 inhibition with monoclonal 
anti-bodies lowers circulating PCSK-9 and prevents LDL-receptor degradation. These 
monoclonal anti-bodies have been shown to greatly reduce LDL-Cholesterol levels, also 
in addition to maximum statin therapy, and seem to be well tolerated (3-6). The PCSK-
9 inhibitors Alirocumab and Evolocumab have been recently approved by both the 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as an 
“adjunct to diet and maximally tolerated statin therapy for the treatment of adults with 
heFH or clinical atherosclerotic cardiovascular disease, who require additional lowering 
of LDL [low-density lipoprotein]-cholesterol (7). Additionally, the first CVD outcome 
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“adjunct to diet and maximally tolerated statin therapy for the treatment of adults with 
heFH or clinical atherosclerotic cardiovascular disease, who require additional lowering 
of LDL [low-density lipoprotein]-cholesterol (7). Additionally, the first CVD outcome 
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study (FOURIER) showed a reduction of CVD events when the PCSK9 inhibitor was 
used on top of high dose statin therapy (8). This new therapy grands new possibilities 
in lowering LDL-C and subsequently CVD risk reduction. However, the costs of these 
novel agents are high. In the Unites States the launched list price of Alirocumab and 
Evolocumab were $14,600 and $14,100 per patient per year respectively (9). Recently 
Schulman et al. questioned the cost effectiveness of these drugs in hyperlipidaemia 
patients (9). Since the costs are so high and the absolute CVD risk prevention in these 
statin treated patients will probably be quite low, the economic benefits seem to be 
limited. Although, these were: 1) not the formal economic evaluations; 2) the exact 
reduction in CVD events is currently unknown, and 3) the price will probably be reduced 
when available in the Netherlands. Given the high costs of these agents it certainly 
emphasizes the benefit of determining residual risk not only from a health perspective 
but also in reducing healthcare costs. 
Cardiovascular imaging
In the general population C-IMT and the presence of carotid artery plaques in particular, 
are significant predictors of CVD (10-13). Because of this association in the general 
population many studies including drug trials, have used C-IMT as a surrogate marker 
for atherosclerotic disease to determine the effectiveness of novel agents (14-16). An 
important factor to consider when investigating and comparing carotid ultrasonography 
outcomes in multicentre studies and meta-analysis is the use of different devices, 
measurement techniques, measurement software and inter-observer variability might 
yield very different results. I showed in chapter 2 that the outcomes between the 
devices and different observers used for the studies in this thesis was within acceptable 
range. One of the landmark trials using C-IMT as endpoint was the ENHANCE trial which 
randomized FH patients using simvastatin to addition of placebo or ezetimibe. This 
trial showed that the addition of ezetimibe in these patients did not result in difference 
in changes in C-IMT between the 2 groups. Later the IMPROVED trial showed that the 
addition of ezetimibe compared to placebo on top of statin therapy led to a decrease in 
CVD events. A proposed explanation for the lack of effect of ezetimibe in the ENHANCE 
trial was that the statin-treated FH patients included in this trial had normalized C-IMT 
values at baseline. In chapter 3 I showed indeed a normalization in C-IMT values in 
statin treated FH patients compared to healthy controls.
Interestingly plaque presence, measured by ultrasonography, was associated with the 
severity of coronary atherosclerosis as depicted by CTCA in a subgroup of statin-treated 
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FH patients for whom CTCA results were available. This suggests that carotid plaque 
presence might distinguish low residual CVD risk FH patients from those with high 
residual risk. In our study the prevalence of carotid plaques was 31% in asymptomatic 
statin-treated FH patients at the age of 46±15 years, with 95% of carotid plaques 
present in those of 40 years or older. In a study in asymptomatic FH patients older than 
40 years it was concluded that carotid plaques, measured by ultrasonography, were not 
significantly associated with coronary calcifications on CTCA (17). An explanation of this 
lacking association was the high prevalence of carotid plaques (93%) in this study. The 
results presented in that study and Chapter 3 emphasize the importance of studying the 
correlation between ultrasonography findings and coronary calcifications in subjects 
younger than 40 years (17). Currently CT coronary angiography scans, are usually not 
performed below the age of 40 years in asymptomatic individuals due to radiation 
exposure and the associated elevated long-term risk of cancer. With improvement 
in CT scanning techniques radiation exposure will further reduced, and in the future 
these studies might be possible in younger individuals. These studies might lead to a 
screening program among FH patients below the age of 40 years to identify those FH 
patients with the highest residual CVD risk.
 Another imaging finding reported in this thesis is the presence of AoVC measured by 
CTCA as was used in Chapter 4 and Chapter 5. I concluded that AoVC is more prevalent 
and severer in statin-treated heFH than in controls, and that the severity of AoVC was 
associated with higher untreated LDL-C levels which is related to LDL-receptor negative 
mutations as compared to carriers of LDL-receptor- defective mutations. This suggests a 
causal role of LDL-C in the development of AoVC. However previous clinical trials such as 
the SALTIRE, ASTRONOMER, and SEAS showed that statins cannot delay the progression 
of aortic valve sclerosis towards aortic valve stenosis (18-20). An explanation might 
be that the initiation and progression of AoVC are two different entities with separate 
pathophysiological mechanisms. The initiation of AoVC seems to be effected by the 
classical risk factors of atherosclerosis, including as LDL-C. These risk factors might 
be responsible for the differentiation of interstitial aortic valve cells to an osteogenic 
phenotype. These osteogenic cells cause the progressing of calcification of the valve 
and cannot be delayed by statins. This theory emphasizes the need of early LDL-C 
reduction in FH patients, to prevent early differentiation towards osteogenic cells and 
thereby progression to AoVC. Routine screening for aortic valve pathology by cardiac 
ultrasound, which is currently advised by guidelines for homozygous FH patients, 
could be considered in patients with heterozygous FH, especially in those with an LDL-
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receptor negative mutation or those who started with statin therapy in adulthood. 
Additionally, more research is needed to evaluate whether novel therapeutic agents 
like PSCK-9 inhibitors can inhibit the progression towards aortic valve stenosis. 
Novel biomarkers
In chapter 5 I show that plasma Lp(a) levels were independently associated with AoVC but 
not with coronary atherosclerosis in asymptomatic heterozygous FH patients. A possible 
explanation for the lack of association of Lp(a) levels with coronary atherosclerosis is 
that statins reduce coronary atherosclerosis so effectively that additional risk factors 
like Lp(a) no longer play a role. If Lp(a) is important in the initiation of AoVC like LDL-C, 
it is likely that the effect of high Lp(a) levels on AoVC also remains detectable. Currently, 
elevated Lp(a) levels cannot be specifically treated (as discussed in Chapter 7) and risk 
reduction in patients with high L(a) levels (>0,5 g/l) should be achieved by optimizing 
other risk factors such as blood pressure, BMI and LDL-C. PCSK-9 inhibitors, do not only 
lower LDL-C, but also lower Lp(a) levels by 30% (3). The mechanism of Lp(a) lowering 
of these agents is currently unknown and it unclear whether this effect ads to CVD risk 
reduction on top of the LDL-C lowering properties. Whether specific Lp(a) lowering can 
reduce CVD events and stop progression of aortic valve stenosis should be evaluated in 
future studies, that will be made possible by the specific antisense Lp(a) agents that are 
currently being developed (21). 
In chapter 8 I chose another approach in risk prediction in FH patients by using the 
iTRAQ proteomic technique to identify possible proteins that are associated with 
subclinical atherosclerosis or atherosclerotic cardiac events. I found six novel proteins 
whose levels were negatively associated with atherosclerotic disease progression 
and subsequent coronary events in patients. These six proteins; leucine-rich alpha-2-
glycoprotein (LRG1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), complement 
C4-B (C4B), complement C1q subcomponent subunit B (C1QB), monocyte differentiation 
antigen (CD14) and histidine-rich glycoprotein (HRG) appear to mainly have functions 
in the coagulation pathway, arterial compliance, and inflammation. These pathways are 
historically involved in the development of CVD risk and therefore these results seem 
promising. This study was conducted in FH patients and therefore it is possible that 
there are additional underlying factors, unique to FH and its associated mutations, 
which manifest differently to a patient with CAD not associated with FH. However, it 
seems worth investigating whether the levels of these novel discovered proteins differ 
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between patients with CVD and healthy controls in the general population. The exact 
role of these novel proteins also needs to be further investigated. They might be suitable 
in predicting CVD risk as markers or might even be causal in CVD disease progression. 
Future perspectives
Over a third of statin-treated FH patients still develop CVD events, it is relevant and 
important to identify these patients to intensify treatment, for example by initiating 
PCSK-9 inhibitor therapy (1). Optimal risk prediction among FH patients should be used 
to differentiate between those who are likely to remain asymptomatic using statin 
treatment and those who will develop CVD events or who have experienced a CVD event 
and are at an increased risk of experiencing subsequent CVD events despite maximum 
lipid lowering therapy. It is essential to, at least to attempt, to make this differentiation 
because of the high costs of the PCSK-9 inhibitors. To identify these patients at risk I 
showed that the asymptomatic statin-treated FH patients who have carotid plaques 
also have more coronary atherosclerosis whereas in these patients C-IMT is unlikely to 
add to further risk prediction. Whether carotid ultrasonography outcomes are related to 
CVD events in statin-treated patients is thus far unknown and should be clarified in the 
future. Moreover I showed that AoVC prevalence is high in heFH patients. Since statins 
do not reduce AoVC once established, but are associated with a reduction in mortality 
in FH patients, aortic valve disease might become a growing health threat for the aging 
FH patients. Further research is needed to clarify whether starting statins at a young age 
reduces the risk of developing AoVC. It is also important to study whether the current 
aging heFH patient would benefit from routinely cardiac ultrasound monitoring for 
valve diseases as is advised by guidelines for hoFH patients. 
I showed that circulating Lp(a) levels in statin treated patients are associated with 
AoVC. Future studies will tell if specific lowering of Lp(a) levels can lower the occurrence 
of CVD events. Because of the association of Lp(a) levels with AoVC, it will be interesting 
to find out if reducing Lp(a) levels will also slow down aortic valve disease progression. 
Finally, I found that lower protein levels of leucine-rich alpha-2-glycoprotein 
(LRG1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), complement C4-B (C4B), 
complement C1q subcomponent subunit B (C1QB), monocyte differentiation antigen 
(CD14) and histidine-rich glycoprotein (HRG) were associated with a higher abundance 
of subclinical atherosclerosis and previous CVD events in heFH patients. Whether these 
proteins can be used as potential biomarkers or are causally related to CVD outcome 
needs to be further investigated. 
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What was already known 
•	 Carotid plaques are a better cardiovascular disease (CVD) risk predictor than 
carotid intima-media thickness (C-IMT) in the general population (13,22,23)
•	 Carotid plaque progression and C-IMT are reduced by high dose statin treatment 
(24,25)
•	 Premature aortic valve disease is highly present in patients with homozygous 
Familial Hypercholesterolemia (FH) (26-28)
•	 Lipoprotein (a) is an independent risk factor of CVD and Aortic valve calcification 
(AoVC) (2,29,30)
What this thesis adds
•	 The prevalence of carotid plaques and the C-IMT are similar in long-term statin-
treated FH patients and healthy controls (Chapter 3)
•	 The prevalence and extent of AoVC are increased in statin-treated heterozygous 
FH patients compared to controls (Chapter 4)
•	 The dose response relation found in the prevalence of AoVC in non-FH patients, 
compared to FH patients with LDLR-defective mutations compared to FH 
patients with LDLR-negative mutations which reflects increasing LDL-C levels, 
suggests a causal role for cholesterol in the initiation of AoVC (chapter 4)
•	 Lp(a) levels are independently associated with AoVC in statin-treated FH 
patients (Chapter 5)
•	 Possible residual risk of Lp(a) is not detected via carotid ultrasonography 
outcomes (C-IMT and carotid plaque) in FH patients (Chapter 6)
•	 Novel plasma proteins: leucine-rich alpha-2-glycoprotein (LRG1), inter-alpha-
trypsin inhibitor heavy chain H3 (ITIH3), complement C4-B (C4B), complement 
C1q subcomponent subunit B (C1QB), monocyte differentiation antigen (CD14) 
and histidine-rich glycoprotein (HRG) associated with previous CVD events and 
coronary atherosclerosis in FH patients (Chapter 8)
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Proposed research
•	 The predictive value of carotid plaques and intima media thickness on CVD 
events in long-term statin-treated FH patients
•	 Prevalence of clinical relevant aortic valve pathology in aging heterozygous FH 
patients
•	 Cost-effectiveness of routine cardiac ultrasound in the aging heterozygous FH 
patient to detect aortic valve pathology
•	 Value of specific Lp(a) lowering medication for CVD prevention and to prevent 
progression of aortic valve sclerosis to clinical aortic valve stenosis
•	 Further investigation of the value of novel proteins: “leucine-rich alpha-2-
glycoprotein (LRG1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), 
complement C4-B (C4B), complement C1q subcomponent subunit B (C1QB), 
monocyte differentiation antigen (CD14) and histidine-rich glycoprotein 
(HRG)” as suitable biomarkers or CVD risk factors in FH and non-FH patients, 
and to study the potential mechanisms by which these proteins contribute in 
atherosclerotic disease.
OVeRAll COnCluSIOn OF THe THeSIS
In conclusion I found that imaging carotid ultrasonography outcomes were similar 
between asymptomatic statin-treated familial hypercholesterolemia (FH) patients 
and healthy controls, and that carotid plaque presence was associated with coronary 
calcification in these FH patients. I also showed that the prevalence and extent of aortic 
valve calcification (AoVC) was twice as high in heterozygous FH patients compared to 
non-FH controls, and that this effect is strongest in those with a LDL-receptor negative 
mutation and highest untreated LDL-cholesterol levels. This suggest a causal relationship 
between AoVC and LDL-cholesterol. Additionally, AoVC is also independently associated 
with plasma Lipoprotein (a) [Lp(a)] levels, but I did not see an effect of Lp(a) on carotid 
ultrasonography outcomes in asymptomatic statin-treated FH patients. Finally, I 
found that the absence of plasma protein levels of leucine-rich alpha-2-glycoprotein 
(LRG1), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), complement C4-B (C4B), 
complement C1q subcomponent subunit B (C1QB), monocyte differentiation antigen 
(CD14) and histidine-rich glycoprotein (HRG) proteins were associated with subclinical 
atherosclerosis and previous CVD events in heterozygous FH patients. 
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nedeRlAndSe SAMenVATTInG
Sinds de introductie van statines als cholesterolverlagende medicatie in de jaren 
negentig, is de levensverwachting van patiënten met familiare hypercholesterolemie 
(FH) aanzienlijk verbeterd. Ondanks het gebruik van statines, ontwikkelen sommige FH-
patiënten toch nog steeds hart- en vaatziekten (HVZ) (1). Het doel in dit proefschrift 
was om het resterende, oftewel residuale, risico op HVZ te identificeren in FH 
patienten die worden behandeld met lipidenverlagende medicatie zoals statines. 
In Deel 1 heb ik onderzocht wat de bijdrage is van beeldvormende technieken zoals 
echografie van de carotiden (hoofdstuk2,3), en coronaire angiografie (CTCA) hoofdstuk 
4) in het bepalen van het risico op HVZ bij FH patiënten die worden behandeld met 
lipidenverlagende medicatie. In Deel 2 onderzocht ik of niet-traditionele risicofactoren 
zoals het atherosclerose veroorzakende lipoproteïne (a) [Lp (a)] (hoofdstuk 5, 6, 7) en 
“proteomics”, een techniek waarmee grootschalig eiwitten en hun biologische functie 
kunnen worden bestudeerd, (hoofstuk 8) de diagnostiek en behandeling van FH 
patiënten kunnen verbeteren. 
Deel 1: Cardiovasculaire beeldvorming en resterend hart- en vaatrisico bij 
FH-patiënten.
Subklinische atherosclerose kan worden gemeten door middel van een echo van de 
halsslagaders ofwel carotiden. Met deze meting kan de afstand tussen de binnenste 
laag (intima) en middelste laag (media) worden gemeten, de “intima-media thickness” 
afgkort IMT. Tevens kan worden bepaald of er atherosclerotisch plaques aanwezig zijn in 
de carotiden. Omdat het een niet-invasieve meting is die relatief makkelijk te verrichten 
is en in een korte tijd te meten, wordt de halsslagader echo vaak gebruikt in klinische 
studies om cardiovasculaire risico’s te bepalen.
In hoofdstuk 2 heb ik aangetoond dat het echoapparaat dat ik in dit proefschrift 
beschreven onderzoeken heb gebruikt voor echografie van de carotiden, betrouwbaar 
en reproduceerbaar is. Dit heb ik gedaan door middel van het bepalen van de variatie 
tussen verschillende metingen van dezelfde patiënt door 1 onderzoeker op hetzelfde 
echoapparaat te meten (intra-observer variatie). Daarnaast werd de variatie tussen 
metingen van dezelfde patiënt tussen twee verschillende onderzoekers op hetzelfde 
echoapparaat gemeten (inter-observer variatie). En ten slotte heb ik onderzocht of 
er een verschil was in metingen van dezelfde patiënt door dezelfde onderzoeker met 
verschillende echoapparaten; een traditioneel echografie apparaat en het moderne 
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echoapparaat wat wij gebruikten in onze onderzoeken (inter-device variatie). De 
belangrijkste bevindingen waren dat de intra-observer, inter-observer en intra-device 
variatie klein was en dat de resultaten van het door ons gebruikte echoapparaat 
reproduceerbaar en daarmee betrouwbaar zijn.
Vervolgens heb ik in hoofdstuk 3 onderzocht of beeldvorming van de carotiden 
middels echografie, door het meten van de aanwezigheid van carotis plaques en de IMT 
van de carotiden (C-IMT), geschikt is om in met lipidenverlagende medicatie behandelde 
FH patiënten te bepalen welke patiënten een hoger risico op HVZ hebben. Dit heb ik 
gedaan door de echografie uitslagen van FH-patiënten die langdurig behandeld werden 
met lipidenverlagende medicatie te vergelijken met gezonde controles. Hieruit bleek dat 
de er geen verschil bestond tussen de groep FH patiënten en de gezonde controles in 
de C-IMT en percentage mensen met carotis plaques. In een aantal van de FH patiënten 
was er tevens een CTCA beschikbaar. De uitslagen van de echografie resultaten en de 
CTCA lieten zien dat de aanwezigheid van carotis plaques, maar niet C-IMT verband, hield 
met de hoeveelheid coronair calcificatie op CTCA. Deze uitkomsten impliceren dat 1) de 
behandeling met lipidenverlagende medicatie in FH patiënten zo succesvol is dat er qua 
halsslagader echo geen verschil meer is tussen gezonde mensen zonder FH en 2) dat van 
de halsslagader metingen niet C-IMT maar plaques in de carotiden van belang kunnen 
zijn om het resterende risico in statine-behandelde FH patiënten te bepalen.
Bijna alle patiënten met homozygote FH ontwikkelen versneld aortaklepsclerose 
(AoVC) en dit is naast coronarialijden de belangrijkste oorzaak van voortijdige dood 
in deze groep. Bij heterozygote FH-patiënten (heFH) is het echter niet bekend of AoVC 
vaker voorkomt in vergelijking met niet-FH-patiënten. In hoofdstuk 4 laten we zien dat 
AoVC meer voorkomt bij asymptomatische FH patiënten dan in controles die geen FH 
hebben. Bij heFH patiënten was de prevalentie van AoVC het hoogst bij FH patiënten 
met een LDL-receptor negatieve mutatie  (zonder LDL-receptor restfunctie) die de 
hoogste onbehandelde LDL-C waardes hebben in vergelijking met FH patiënten met 
een LDL-receptor defecte mutatie die nog enige LDL-receptor restfunctie hebben. Dit 
suggereert een causale rol van LDL-C bij het ontstaan van aortaklep verkalking. Hiermee 
heb ik vastgesteld dat de gezondheid van heFH-patiënten niet alleen bedreigd wordt 
door ‘klassieke’ atherosclerotische HVZ maar ook zeker door de versnelde ontwikkeling 
van AoVC. Klinisch is dit belangrijk omdat statine therapie het risico op HVZ aanzienlijk 
kan verminderen, maar geen effect meer lijkt te hebben als er al AoVC is opgetreden 
en dit zich verder kan ontwikkelen naar aortaklep stenose, wat een levensbedreigende 
aandoening kan zijn. Deze resultaten geven aan 1) het beter is om op jonge leeftijd al te 
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starten met lipidenverlagende medicatie, niet alleen ter preventie van atherosclerotische 
HVZ, maar ook om AoVC te voorkomen; 2) dat regelmatige screening van oudere heFH 
patiënten voor AoVC nuttig zou kunnen zijn.
Deel 2: Niet-traditionele risicofactoren en onverklaard cardiovasculair risico 
bij FH patiënten
Lp (a) is een genetisch bepaald atherogeen lipoproteïne. Lp (a) is niet alleen een 
onafhankelijke risicofactor voor HVZ, maar SNP’s in het LPA gen en plasma Lp (a) waardes 
(2), zijn ook geassocieerd met aortaklep stenose. Lp(a) is een niet traditionele risicofactor 
omdat het momenteel geen deel uitmaakt van het traditionele lipidenpanel wat 
bestaat uit totaal cholesterol, HDL-C, LDL-C, triglyceriden en in sommige klinieken apoB 
bepaling. In hoofdstuk 5 laat ik zien dat in asymptomatische FH patiënten plasma Lp(a) 
concentraties geassocieerd zijn met AoVC bepaald door CTCA. In hoofdstuk 6 onderzocht 
ik in HeFH-patiënten die behandeld werden met lipidenverlagende medicatie of plasma 
Lp (a) concentraties geassocieerd waren met atherosclerose weergegeven als C-IMT en 
carotis plaques gemeten door middel van halsslagaderechografie. In deze studie werd 
geen associatie aangetoond tussen plasma Lp(a) waardes en de uitkomsten van de 
echografie. In hoofdstuk 7 bespreek ik de nieuwste ontwikkelingen in de behandeling 
van Lp (a). Zowel leefstijl interventie  en statines, de meest gebruikte lipidenverlagende 
medicatie, hebben geen effect op plasma Lp (a) concentratie. De nieuwe proteïne 
subtilisine / kexine type 9 (PCSK-9) remmers verlagen Lp (a) concentraties met 30-50%, 
maar verlagen ook het LDL-C. Ondanks dat PCSK-9 remmers het risico op HVZ verlagen 
is het onbekend of specifieke verlaging van de Lp (a) waardes het risico op HVZ kan 
verminderen. Onlangs is er een antisense oligonucleotide gericht op apolipoproteïne 
(a) ontwikkeld die specifiek Lp (a) concentraties tot 90% kan verlagen. Studies met dit 
nieuwe geneesmiddel zullen aantonen of verlaging van Lp (a) concentraties het risico 
op HVZ kan verminderen. In hoofdstuk 8 identificeerden ik zes nieuwe eiwitten in die 
verband houden met atherosclerose en HVZ in HeFH-patiënten. Hiervoor gebruikten 
we de isobarische tag voor relatieve en absolute kwantificering (iTRAQ) proteomics 
techniek in 60 specifiek geselecteerde heFH patiënten. In deze groep ontdekte ik 
plasmaeiwitten die eerder niet gerelateerd waren aan atherosclerose. Deze eiwitten 
waren, zoals verwacht, onderdeel van stollings- ontstekings- en lipide metabolisme. 
Verder onderzoek is nodig om het belang van deze eiwitten te bevestigen en om uit 
te zoeken of ze geschikt zijn als biomarkers of zelfs potentiële doelen voor nieuwe 
therapeutische interventies om het risico op HVZ te verminderen.
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dAnKWOORd
En dan ten slotte het meest gelezen en minst aangepaste gedeelte van dit proefschrift. 
Ik wil iedereen in het algemeen bedanken die heeft meegeholpen met het tot stand 
brengen van dit boekwerk. Er zijn zo veel mensen te bedanken dat ik vrees niet iedereen 
te kunnen noemen, maar ook als je naam hieronder niet apart genoemd staat toch heel 
veel dank voor alle hulp!
Ten eerste mijn promotor, prof. dr. E.J.G. Sijbrands. Beste Eric, dank voor alle steun en 
hulp maar met name voor je enthousiasme tijdens mijn promotietraject. Ik ben blij dat 
je me ondanks mijn grootste tekortkoming, het niet kunnen verdragen van koffie, me 
altijd hebt geholpen. En uiteraard met het mogelijk maken van het fantastische project 
in Australië. Heel veel dank! 
Dan mijn twee co-promotoren: dr. J.E. Roeters van Lennep en dr. M.T. Mulder. Jeanine, 
zonder jouw enorme drive en enthousiasme had dit proefschrift er vast een stuk 
minder florissant uitgezien. De mogelijkheid om je altijd te kunnen benaderen, maar 
ook de gezonde druk voor vooruitgang hebben me enorm geholpen en geïnspireerd. 
En ondanks dat ik je eerste PhD student was, enorm veel lof! Monique, graag wil ik je 
bedanken voor je hulp, vooral als het gaat om de lab technische kant en je hulp bij 
het maken van figuren. Zonder jouw hulp had mijn proefwerk nooit tot stand kunnen 
komen.
Verder wil ik ook de leden van mijn kleine commissie, Prof.dr.ir. H. Boersma; Prof.
dr. J.L.C.M. van Saase en Prof.dr. J.W. Jukema, bedanken voor de bereidheid om mijn 
proefschrift te lezen en te beoordelen. 
Mijn paranimfen, Gijs en Reyhana. Gijs, gedurende de opleiding hebben we ontzettend 
veel lol gehad en gestudeerd. Ik ben blij dat je me op de dag van mijn verdediging naast 
me staat en ik hoop dat het je ook binnenkort gaat lukken om je promotietraject af te 
ronden. 
Reyhana, allereerst wil ik je bedanken dat je me hebt gewezen op de vacature voor 
dit promotietraject. Toen ik bij Eric en Jeanine op gesprek was geweest wist ik zeker 
dat deze plek precies was wat ik zocht. Verder hebben we ruim 3 jaar samengewerkt 
en kon ik altijd bij je terecht om samen over onze resultaten na te denken en eventueel 
nieuwe ideeën te onderzoeken. Aan het einde hebben we toch hele mooie projecten 
afgeleverd. Ik hoop dat je jouw proefschrift ook snel af kan ronden, naast de drukte van 
de opleiding en de kleine thuis!
A
163|Nederlandse samenvatting  |  Dankwoord  |  Curriculum Vitae  |  List of Publications  |  ECTS portfolio
dAnKWOORd
En dan ten slotte het meest gelezen en minst aangepaste gedeelte van dit proefschrift. 
Ik wil iedereen in het algemeen bedanken die heeft meegeholpen met het tot stand 
brengen van dit boekwerk. Er zijn zo veel mensen te bedanken dat ik vrees niet iedereen 
te kunnen noemen, maar ook als je naam hieronder niet apart genoemd staat toch heel 
veel dank voor alle hulp!
Ten eerste mijn promotor, prof. dr. E.J.G. Sijbrands. Beste Eric, dank voor alle steun en 
hulp maar met name voor je enthousiasme tijdens mijn promotietraject. Ik ben blij dat 
je me ondanks mijn grootste tekortkoming, het niet kunnen verdragen van koffie, me 
altijd hebt geholpen. En uiteraard met het mogelijk maken van het fantastische project 
in Australië. Heel veel dank! 
Dan mijn twee co-promotoren: dr. J.E. Roeters van Lennep en dr. M.T. Mulder. Jeanine, 
zonder jouw enorme drive en enthousiasme had dit proefschrift er vast een stuk 
minder florissant uitgezien. De mogelijkheid om je altijd te kunnen benaderen, maar 
ook de gezonde druk voor vooruitgang hebben me enorm geholpen en geïnspireerd. 
En ondanks dat ik je eerste PhD student was, enorm veel lof! Monique, graag wil ik je 
bedanken voor je hulp, vooral als het gaat om de lab technische kant en je hulp bij 
het maken van figuren. Zonder jouw hulp had mijn proefwerk nooit tot stand kunnen 
komen.
Verder wil ik ook de leden van mijn kleine commissie, Prof.dr.ir. H. Boersma; Prof.
dr. J.L.C.M. van Saase en Prof.dr. J.W. Jukema, bedanken voor de bereidheid om mijn 
proefschrift te lezen en te beoordelen. 
Mijn paranimfen, Gijs en Reyhana. Gijs, gedurende de opleiding hebben we ontzettend 
veel lol gehad en gestudeerd. Ik ben blij dat je me op de dag van mijn verdediging naast 
me staat en ik hoop dat het je ook binnenkort gaat lukken om je promotietraject af te 
ronden. 
Reyhana, allereerst wil ik je bedanken dat je me hebt gewezen op de vacature voor 
dit promotietraject. Toen ik bij Eric en Jeanine op gesprek was geweest wist ik zeker 
dat deze plek precies was wat ik zocht. Verder hebben we ruim 3 jaar samengewerkt 
en kon ik altijd bij je terecht om samen over onze resultaten na te denken en eventueel 
nieuwe ideeën te onderzoeken. Aan het einde hebben we toch hele mooie projecten 
afgeleverd. Ik hoop dat je jouw proefschrift ook snel af kan ronden, naast de drukte van 
de opleiding en de kleine thuis!
        
164 |      Appendices
Onmisbaar voor mijn proefschrift is ook de hulp van Edith Padberg geweest. Edith, 
echt ontzettend veel dank voor het regelen van alle afspraken en op het einde het 
uiteindelijk toch voor elkaar te krijgen om de promotiecommissie op één dag bij elkaar 
te krijgen. En uiteraard voor alle moeite die je afgelopen jaren hebt gedaan om alles in 
goede banen te lijden.
Graag wil ik ook Adrie Verhoeven en Edith Friesema noemen. Adrie, toen ik begon 
kende ik je met name vanuit de geneeskunde opleiding, maar je bent echt onmisbaar 
geweest als co-auteur en met je hulp bij posters en presentaties. Ook nog veel dank dat 
ik kon helpen bij onderwijs geven heb hier zelf ook veel van geleerd. Edith, graag wil ik 
je bedanken voor je hulp en dat ik altijd bij je aan kon kloppen voor vragen. 
Ook wil ik graag kort Erna Egelie nog bedanken voor haar werk als secretaresse van 
de COEUR. Erna, veel dank voor het op orde houden van ieders studiepunten en dat je 
van je pensioen mag genieten!
Dan mijn kamergenoot in het laatste jaar. Rochus, toen jij begon met je promotietraject 
was er eindelijk weer een Y chromosoom bij de promovendi beland. Ondanks, dat we 
soms wat afgeleid raakten met schaken/muziek etc. hebben we ook veel nuttige dingen 
samen gedaan onder andere de presentaties en quiz voor de JMS studenten. Ook wil 
ik je bedanken voor het contact dat ik heb overgehouden aan vrienden waar jij al veel 
langer mee om ging. Met name Pelle en Tip wie ik regelmatig spreek en een potje dota 
mee speel. Pelle en Tip ook jullie bedankt voor alle lol, maar ook het brainstormen over 
medisch inhoudelijke problemen! Tip, veel succes met het afronden van je promotie in 
Nijmegen en Pelle dat je het naar je zin mag hebben in het SFG als SEH arts. 
Graag wil ik ook de andere promovendi bedanken; Thijs, Stijn, Sjaam, Arthur, Mahdi, 
Stephanie, Khatera, Lodi, David, Koen, Kimberly, Jeroen, Kirsten, Mardin, Sandra. Dank 
voor jullie hulp, gezelligheid en toevoegingen op wetenschappelijk gebied!
Ook onmisbaar voor elk onderzoek zijn de analisten. Graag wil ik alle analisten in ons 
lab bedanken waaronder in het bijzonder Leonie en Jeanette. Graag wil ik jullie speciaal 
bedanken voor het afdraaien en organiseren voor de ongelooflijke hoeveelheid bloed 
die van controle patiënten is afgenomen. En uiteraard voor alle metingen die nodig zij 
geweest voor de database en uiteindelijk alle data voor de studies. Evelien Jäger, Evelien 
graag wil ik je bedanken met het alfabetiseren en structureren van mijn informed consent 
formulieren en het elektronisch registreren hiervan. Het was een enorme klus maar je hebt 
het fantastisch gedaan! Verder ook veel dank voor alle overige hulp en de gezelligheid!
Zonder wie mijn proefschrift ook nooit zo compleet had kunnen zijn is Martijne 
Duvekot. Martijne, ik ben enorm blij dat je gekozen hebt om je master onderzoek bij ons 
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te komen doen. De hoeveelheid werk die je hebt verzet met het maken van de echo’s 
en het invoeren van de CVG database zijn echt van ongelooflijke waarde geweest. De 
waarde is alleen al heel duidelijk aangezien je op 3 stukken uit dit proefschrift tweede 
auteur bent. Ik hoop dat het je lukt om snel in opleiding te komen voor de Neurologie 
en wens je veel succes in je verdere carrière.
Hanny Dussault, Hanny jouw waarde voor de polikliniek is enorm en met name ook 
voor de patiënten. De stambomen die je maakt en de families die je oproept zijn de 
spil waarop de poli draait en waar de preventie uiteindelijk om draait. Verder wil ik je 
bedanken voor de verhalen vol enthousiasme over je kinderen en hoe je geniet van je 
honden. Een waar voorbeeld waar prioriteiten horen te liggen! 
Annette Galema, Annette inmiddels ben je al gepromoveerd, proficiat! In het begin 
van mijn traject heb je me enorm geholpen bij de logistiek van de poli en bij het bepalen 
van het beleid voor de mensen met FH op de poli. Daarvoor heel veel dank
Verder ook veel dank aan alle medewerkers van de polikliniek Interne geneeskunde 
voor jullie ondersteuning en hulp.
Het cardiovasculair researchteam Sint-Fransciscus Gasthuis. Anho Liem, Anho graag 
wil ik jou en natuurlijk de research verpleegkundigen Marja, Ingrid Margreet en Irene 
bedanken voor jullie samenwerking met de PCSK-9 trials. Al met al hebben we een 
mooie groep patiënten bij jullie kunnen includeren in de studies. Daarvoor dank en 
uiteraard ook voor de gezelligheid.  
Gerald Watts, Gerald thank you for giving me the opportunity to work on the 
proteomics project in the Royal Perth Hospital, and also showing and emphasising the 
importance of clinical work. I really enjoyed the clinical rounds, the outpatient clinic and 
the meetings with the general practitioners on improving FH care in Western Australia.
Natalie Ward, Natalie it was a real pleasure working with you in Perth and you were 
great as a supervisor. I am really proud of the proteomics project, and wish you all the 
best in your further work. 
I also want to thank all the other people I have met during my project in Perth. Danie, 
Esther, Dick, Michael, Helen , many thanks all for the wonderful time. 
Damon and Katja Bell, Damon it was great meeting you in Perth, and I cannot thank 
you enough for all the help from you and Katja showing us around Perth and Subi. The 
most memorable part has to be the purple bike! Noa really loved playing with your 
kids and we were thrilled to be invited to your daughter’s birthday with a classic Aussie 
Barbie! Once more many thanks also from Marjan.
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Familie Schoonderwoerd; Henri, Gonnie, Marcel en Erik; dertien jaar geleden alweer 
kwam ik binnengewandeld als het vriendje van Marjan. Jullie als schoonfamilie hebben 
me altijd behandeld als een van jullie, bedankt daarvoor. Inmiddels hoor ik nu echt wel 
bij het meubilair en zijn we al vaak samen op vakantie geweest. Jullie zijn echt mijn 
tweede familie geworden en ik ben dan ook heel blij dat jullie er tijdens mijn promotie 
bij zijn.
Familie Bos; Peter Bos, Pa, graag wil ik je bedanken omdat ik altijd bij je terecht kan 
voor hulp en dat de deur altijd open staat. Vind het fijn om te zien hoe trots je altijd op 
al je kinderen bent en ben ontzettend blij dat je er bij bent. 
Sylvester, Sanne, Kay, Liam, Brent, Anouk, Menno, Tess en Lynn. Ook al zien we elkaar 
soms een tijd niet door onze drukke levens, het is altijd goed en gezellig als we bij elkaar 
zijn. Vindt het ook ontzettend fijn dat jullie er op deze dag bij zijn. 
Berth en Conny, Berth, 21 jaar geleden kwam je bij mij en mama wonen , ik was eerst 
uiteraard wat sceptisch maar ben uiteindelijk ontzettend blij dat het zo is gelopen. 
Mama, graag wil ik je enorm bedanken voor alle liefde die je me altijd hebt gegeven 
en dat je vanaf dat ik een klein manneke was al bezig was om alles voor mij mogelijk 
te maken in het leven. Jullie zeiden al vroeg dat ik geneeskunde moest gaan studeren, 
maar het duurde even voordat het landde. Laten we het op mijn eigenwijze inslag 
houden. Ik ben in ieder geval ontzettend dankbaar dat jullie altijd in mij hebben gelooft 
en dat jullie het voor mij mogelijk hebben gemaakt dat ik kon studeren. Ik ben blij dat 
jullie bij mijn promotie zijn en trots dat jullie me hebben gemaakt tot de man die ik 
vandaag de dag ben.  
Noa en Thijs, mijn lieve kinderen. Op het moment dat ik dit schrijf kunnen jullie nog 
niet lezen, maar oh wat geniet ik van jullie. Noa, het liefste meisje van de wereld, alweer 
vijf jaar en op de basisschool. Grote meid, het gaat me eigenlijk nu al allemaal veel 
te snel. Ik vond het ongelooflijk leuk dat je mee was naar Australië en ook al zal je je 
het later niet allemaal meer herinneren je had het echt geweldig naar je zin. Gelukkig 
hebben we de foto’s nog. Thijs, twee jaar en al lekker aan het brabbelen, en vooral “nee” 
zeggen. Elke avond thuiskomen met een volmondig “papa!!!” is heerlijk en ik ben trost 
dat jij mijn zoontje bent! 
Marjan, lieve lieve Marjan. Als laatst en ook als meest wil ik jou bedanken. Ook voor 
jou is mijn promotietijd een hectische, maar ook mooie tijd geweest. Eerst samen in 
Heerjansdam, waar Noa werd geboren, om daarna, met een kleine Noa van 1,5, de 
wereld over vliegen om 3 maanden lang in een ver land met me mee te gaan. Dan daar 
zwanger blijken te zijn van onze kleine prins Thijs. Om vervolgens bij terugkomst in 
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het laatste jaar van mijn promotie samen een huis te kopen, van top tot teen te verven, 
net op tijd voor de geboorte van onze prachtige zoon. Als laatst wil ik zeggen dat je 
een geweldige vrouw bent, een fantastische partner en moeder en daarom ontzettend 
bedankt dat je me altijd steunt ook in deze tropenjaren en dat we nog heel lang van 
elkaar mogen genieten.
A
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Personalia
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First Name Sven
Work address ‘s Gravendijkwal 230 
Zip code 3015 CE
City Rotterdam
Nationality Dutch
Year of birth 1987
E-mail address s.bos@erasmusmc.nl   /   svenbos87@hotmail.com
Training
Sept – 2012 Medical degree at Erasmus MC in Rotterdam
2006 – 2012 Medicine at Erasmus Universiteit in Rotterdam
2006 – 2007 Propedeuse Erasmus Universiteit in Rotterdam for Medicine.
1999 – 2006 Athenaeum with profile Nature en techniques + Nature and Health 
at the Walburg College in Zwijndrecht. Graduated in 2006.
Work experience
2012 – December 2015 M.D. researcher vascular internal medicine (Phd-student)
01-01-2016 – present Specialist registrar Internal Medicine, Albert Schweitzer zieken-
huis Dordrecht
Experience Medical Trials
Sub-investigator in randomized controlled trials:
•	 FOURIER  (PCSK-9 inhibitors, monoclonal antibodies)
•	 TAUSSIG (PCSK-9 inhibitors, monoclonal antibodies)
•	 Odyssey choice-II (PCSK-9 inhibitors, monoclonal antibodies)
•	 SPIRE  (PCSK-9 inhibitors, monoclonal antibodies) 
•	 GAUSS-3 (PCSK-9 inhibitors, monoclonal antibodies)
Study Coördinator on site:
•	 Lomitapide registry (MTP inhibitor)
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and associated risk factors in a case-control study 
J	Am	Coll	Cardiol	2015;66:2687–95
Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic 
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Summary of PhD training and teaching activities
Name PhD student: S. Bos 
Promoter:  prof. dr. E.J.G. Sijbrands
Institution:  Erasmus MC  
Co-promotors:  dr. J.E. Roeters van Lennep, dr. M.T. Mulder
Research school:  COEUR   
General Courses ECTS
BROK (good clinical practice) + exam 1,8
Statistical course (ESP01) en (ESP03) 2,0
Biomedical English writing (By David Alexander) 3,0
General Seminars
Human Smooth Muscle Cell Heterogeneity-from bedside to CALM(odulin) 0,1
Lecture LP(a) latest developments 0,1
Lecture wine ponyphenols and Health 0,1
Lecture The HDL story (so far) Jay Heinecke 0,1
Attending the PhD day 2013 0,1
Speaker at patients information evening FH 2013 and 2015 (novel therapies) 2,0
Netherlands Lipid Conference + presentation 1,0
Attending the PhD day 2014 0,1
COEUR courses / seminars 
COEUR seminar: 
The cardiovascular system in women: a relation with female hormones 0,4
Clinical cardiovascular epidemiology (COEUR course) 1,5
Peripheral and intracranial obstructive vascular disease (COEUR-course) 1,5
COEUR seminar:
Glucose metabolism and vascular disease. 0,4
COEUR seminiar: Translational Electrophysiology 0,4
COUER PhD day + oral presentation 2013 0,5
Cardiovascular Pharmacology (COEUR course) 1,5
COEUR Research seminar Gender differences in CVD 0,4
COEUR seminar: Coronary and Cranial Thrombosis 0,4
COEUR course cardiovascular medicine 1,5
COUER debate on cardiovascular controversies 0,4
COEUR course molecular medicine 1,5
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Conferences 
Wetenschapsdagen antwerpen 2013 and 2014 + Poster presentations 1,8
Annual Scandinavian Atherosclerosis Socieity Meeting 
(Denmark) 2013 + poster presentation 1,5
ESC annual meeting in Amsterdam, 2013 + poster 1,8 
Annual Scandinavian Atherosclerosis Socieity Meeting 
(Denmark) + poster presentation 2014 1,5
EAS 2014 (Madrid)  + poster presentation 1,5
ESC annual meeting in Barcelona 2014 + poster presentation 1,8
Annual Scandinavian Atherosclerosis Socieity Meeting 
(Denmark) + poster presentation 1,5
International society of atherosclerosis meeting, 
Amsterdam, 2015, 1 moderated poster session, 2 additional posters 3,0
Teaching activities
Onderwijs vet, koolhydraat en aminozuur metabolisme (
Met Adrie Verhoeven) 2013 en 2015 0,6
Onderwijs: klinisch redeneren (Master studenten geneeskunde) 0,3
Teaching intima media thickness measurements (45 weeks, 4 students) 1,25
Part of lab-day committee 2014 0,25
Junior Med school students, presentation + quiz 2013 and 2015 0,6
Peer reviewer of a manuscript for Atherosclerosis 0,1
Medical trial Meetings
FOURIER investigator’s meeting Woerden 2013 + 2015 0,6
AMGEN hyperlipidemia Acadamy Berlin  0,6
Total eCTS   39.8
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